EAU Guidelines on Prostate Cancer. Part 1: Screening, D Curative Intentâ€”Update 2013

European Urology

65, 124-137

DOI: 10.1016/j.eururo.2013.09.046

Citation Report

#	Article	IF	Citations
1	Advantages of caudal block over intrarectal local anesthesia plus periprostatic nerve block for transrectal ultrasound guided prostate biopsy. Pakistan Journal of Medical Sciences, 1969, 32, 978-82.	0.3	8
2	Prostate Biopsies Should Be Performed According to a Standard of Care. European Urology, 2013, 63, 528-529.	0.9	9
3	Prostate cancer with metastases to the kidney: a rare manifestation of a common disease. BMJ Case Reports, 2013, 2013, bcr2012008388-bcr2012008388.	0.2	9
4	Comparison in the follow-up of two patients with persistent elevated PSA and negative prostate biopsy. Urologia, 2014, 81, 21-24.	0.3	0
5	Laparoscopic radical prostatectomy with bladder neck preservation: positive surgical margin and urinary continence status. Wideochirurgia I Inne Techniki Maloinwazyjne, 2014, 3, 362-370.	0.3	10
6	Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard Â®) Tj ETQq1 1 0.784314 rgBT /Overlock 10 non-interventional study. Archives of Medical Science, 2014, 3, 477-483.	0.4	22
8	Prostate cancer: a review of active surveillance. Research and Reports in Urology, 2014, 6, 107.	0.6	12
9	Robotâ€assisted versus other types of radical prostatectomy: Populationâ€based safety and cost comparison in Japan, 2012â€“2013. Cancer Science, 2014, 105, 1421-1426.	1.7	26
10	External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer. BJU International, 2014, 114, E113-E119.	1.3	10
11	A Novel Practical Trocar Placement Technique for Extraperitoneal Laparoscopic and Robotic-Assisted Laparoscopic Radical Prostatectomy in Patients with Lower Midline Abdominal Incisions. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2014, 24, 417-421.	0.5	4
13	Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. British Journal of Cancer, 2014, 111, 1201-1212.	2.9	123
14	Feasibility study of a randomised controlled trial to compare (deferred) androgen deprivation therapy and cryotherapy in men with localised radiation-recurrent prostate cancer. British Journal of Cancer, 2014, 111, 424-429.	2.9	15
15	Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ, The, 2014, 348, g1502-g1502.	3.0	204
16	Intensified Adjuvant Treatment of Prostate Carcinoma: Feasibility Analysis of a Phase I/II Trial. BioMed Research International, 2014, 2014, 1-8.	0.9	2
17	Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature. Korean Journal of Urology, 2014, 55, 436.	1.2	25
19	Multiparametric MRI followed by targeted prostate biopsy for men with suspected prostate cancer: a clinical decision analysis. BMJ Open, 2014, 4, e004895-e004895.	0.8	23
20	Locally advanced and high risk prostate cancer: The best indication for initial radical prostatectomy?. Asian Journal of Urology, 2014, 1, 40-45.	0.5	11
21	Robotic and minimal access surgery: technology and surgical outcomes of radical prostatectomy for prostate cancer. Expert Review of Anticancer Therapy, 2014, 14, 1317-1321.	1.1	7

#	Article	IF	Citations
22	Benefits and Risks of Prostate Cancer Screening. Oncology Research and Treatment, 2014, 37, 29-37.	0.8	12
24	Pain After Hernia Repair with Simultaneous Extraperitoneal Laparoscopic Radical Prostatectomy. Journal of Endourology, 2014, 28, 1143-1148.	1.1	6
25	Survival, Continence and Potency (SCP) recovery after radical retropubic prostatectomy: A long-term combined evaluation of surgical outcomes. European Journal of Surgical Oncology, 2014, 40, 1716-1723.	0.5	19
26	Is Radiocholine PET/CT Already Clinically Useful in Patients with Prostate Cancer?. Journal of Nuclear Medicine, 2014, 55, 1401-1403.	2.8	15
27	MRI en active surveillance voor laagrisicoprostaatkanker. Tijdschrift Voor Urologie, 2014, 4, 185-191.	0.1	0
28	Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy. EJNMMI Research, 2014, 4, 58.	1.1	28
29	Biopsy strategies for selecting patients for focal therapy for prostate cancer. Current Opinion in Urology, 2014, 24, 209-217.	0.9	14
30	Individualized Prostate-specific Antigen Threshold Values to Avoid Overdiagnosis of Prostate Cancer and Reduce Unnecessary Biopsy in Elderly Men. Japanese Journal of Clinical Oncology, 2014, 44, 852-859.	0.6	1
31	Clinicopathologic Differences Between Prostate Cancers Detected During Initial and Repeat Transrectal Ultrasound-Guided Biopsy in Korea. Korean Journal of Urology, 2014, 55, 718.	1.2	3
32	The Real Practice of Antibiotic Prophylaxis for Prostate Biopsy in Korea Where the Prevalence of Quinolone-ResistantEscherichia coliIs High. Korean Journal of Urology, 2014, 55, 593.	1.2	6
33	Pulmonary Metastases After Low-Dose-Rate Brachytherapy for Localized Prostate Cancer. Korean Journal of Urology, 2014, 55, 309.	1.2	3
34	InformaciÃ³n obligatoria que debe conocer un paciente con cÃ¡ncer de prÃ³stata candidato a vigilancia activa. Actas UrolÃ³gicas EspaÃ±olas, 2014, 38, 559-565.	0.3	28
35	Forgive Them for They Know What Not They Do! The Importance of the Extent of Pelvic Lymph Node Dissection at Radical Prostatectomy. European Urology, 2014, 66, 644-645.	0.9	0
36	The Roles of Multiparametric Magnetic Resonance Imaging, PCA3 and Prostate Health Indexâ€"Which is the Best Predictor of Prostate Cancer after a Negative Biopsy?. Journal of Urology, 2014, 192, 60-66.	0.2	68
37	The Politics of Prostate Cancer Screening. Urologic Clinics of North America, 2014, 41, 249-255.	0.8	12
38	Contrast-enhanced Transrectal Ultrasonography for Detection and Localization of Prostate Index Tumor: Correlation With Radical Prostatectomy Findings. Urology, 2014, 84, 138-143.	0.5	14
39	Fascial Layers in Nerve Sparing Robot-Assisted Radical Prostatectomy. Urology Practice, 2014, 1, 86-91.	0.2	1
40	Prostate Cancer Screening. Primary Care - Clinics in Office Practice, 2014, 41, 355-370.	0.7	7

#	Article	IF	Citations
41	Underestimated role of MRI in EAU guidelines on prostate cancer. Magnetic Resonance Imaging, 2014, 32, 402-403.	1.0	1
42	Novel Tools to Improve Patient Selection and Monitoring on Active Surveillance for Low-risk Prostate Cancer: A Systematic Review. European Urology, 2014, 65, 1023-1031.	0.9	118
43	The Effects of Androgen Deprivation Therapy on Cardiac Function and Heart Failure: Implications for Management of Prostate Cancer. Clinical Genitourinary Cancer, 2014, 12, 399-407.	0.9	21
44	How to Minimize Lymphoceles and Treat Clinically Symptomatic Lymphoceles After Radical Prostatectomy. Current Urology Reports, 2014, 15, 445.	1.0	38
45	Reducing Prostate Cancer Deaths: Unsupported Speculation About the Androgen Deprivation Hypothesis. European Urology, 2014, 66, 973-974.	0.9	2
46	Obligatory information that a patient diagnosed of prostate cancer and candidate for an active surveillance protocol must know. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2014, 38, 559-565.	0.2	12
47	Sentinel Node Biopsy for Prostate Cancer: A Useless Surgical Exercise?. European Urology, 2014, 66, 999-1000.	0.9	0
49	Models of Assessment of Comparative Outcomes of Robot-Assisted Surgery. Urologic Clinics of North America, 2014, 41, 597-606.	0.8	6
50	Prostate-specific antigen screening, why have the guidelines changed?. Expert Review of Anticancer Therapy, 2014, 14, 1277-1281.	1.1	9
52	Limitations of Assessing Value in Robotic Surgery for Prostate Cancer: What Data Should Patients and Physicians Use to Make the Best Decision?. Journal of Clinical Oncology, 2014, 32, 1394-1395.	0.8	5
53	Testing of a Novel Easy-to-use Mortality Index in a Radical Prostatectomy Cohort. Urology, 2014, 84, 307-313.	0.5	3
54	Re: Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer. European Urology, 2014, 66, 596.	0.9	0
55	How to Optimize Patient Selection for Robot-Assisted Radical Prostatectomy: Functional Outcome Analyses from a Tertiary Referral Center. Journal of Endourology, 2014, 28, 792-800.	1.1	22
59	Comparison of image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies. World Journal of Urology, 2014, 32, 847-858.	1.2	122
60	Application of the 2013 American Urological Association early detection of prostate cancer guideline: Who will we miss?. World Journal of Urology, 2014, 32, 959-964.	1.2	13
61	Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1849-1861.	1.2	31
62	A Competing Risk Analysis of Cancer-Specific Mortality of Initial Treatment with Radical Prostatectomy versus Radiation Therapy in Clinically Localized High-Risk Prostate Cancer. Annals of Surgical Oncology, 2014, 21, 4026-4033.	0.7	30
63	Impact of Patient Navigation on Timely Cancer Care: The Patient Navigation Research Program. Journal of the National Cancer Institute, 2014, 106, dju115.	3.0	204

#	Article	IF	Citations
64	Role of 3.0ÂT multiparametric MRI in local staging in prostate cancer and clinical implications for radiation oncology. Clinical and Translational Oncology, 2014, 16, 993-999.	1.2	18
65	Septic complications and hospital admissions after transrectal ultrasound-guided prostate biopsy: incidence rates and outcomes in 913 consecutive biopsies. International Urology and Nephrology, 2014, 46, 2335-2336.	0.6	6
66	Will Focal Therapy Remain Only an Attractive Illusion for the Primary Treatment of Prostate Cancer?. Journal of Clinical Oncology, 2014, 32, 1299-1301.	0.8	31
67	Evolution and Immediate Future of US Screening Guidelines. Urologic Clinics of North America, 2014, 41, 229-235.	0.8	3
68	Re: Early Detection of Prostate Cancer: AUA Guideline. European Urology, 2014, 65, 1218.	0.9	3
69	Survival of Men with Prostate Cancer Undergoing Radical Prostatectomy in Ontario. Journal of Urology, 2014, 192, 1385-1389.	0.2	12
70	The Robotic Approach Does Not Change the Current Paradigms of Pelvic Lymph Node Dissection for Prostate Cancer. European Urology, 2014, 65, 17-19.	0.9	0
71	Magnetic Resonance Imaging-Ultrasound Fusion Biopsy for Prediction of Final Prostate Pathology. Journal of Urology, 2014, 192, 1367-1373.	0.2	121
73	Radical retropubic and perineal prostatectomy for clinically localised prostate cancer in renal transplant recipients. Arab Journal of Urology Arab Association of Urology, 2014, 12, 142-148.	0.7	18
74	The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: Which markers matter and how should they be used?. World Journal of Urology, 2014, 32, 871-880.	1.2	8
75	Surgery or radiotherapy for prostate cancer?. BMJ, The, 2014, 348, g1580-g1580.	3.0	2
76	Radical prostatectomy: a focus on urinary continence. Clinical Practice (London, England), 2014, 11, 737-748.	0.1	0
77	Comparison of Two Prostate Cancer Risk Calculators that Include the Prostate Health Index. European Urology Focus, 2015, 1, 185-190.	1.6	23
78	Clinical Case Discussion: Intermediate-risk Prostate Cancer: The Case for Active Surveillance. European Urology Focus, 2015, 1, 208-209.	1.6	0
79	Impact of Early Diagnosis of Prostate Cancer on Survival Outcomes. European Urology Focus, 2015, 1, 137-146.	1.6	18
80	Screening for Prostate Cancer: Current Status and Future Directions. European Urology Focus, 2015, 1, 147-148.	1.6	1
81	Long-term Survival Outcomes for Men Who Provided Ejaculate Specimens for Prostate Cancer Research: Implications for Patient Management. European Urology Focus, 2015, 1, 200-206.	1.6	2
82	Repeat Prostate Biopsy: Rationale, Indications, and Strategies. European Urology Focus, 2015, 1, 127-136.	1.6	12

#	Article	IF	Citations
83	The ONCOTYROL Prostate Cancer Outcome and Policy Model. Medical Decision Making, 2015, 35, 758-772.	1.2	8
84	Intravenous Preload of Mesenchymal Stem Cells Rescues Erectile Function in a Rat Model of Cavernous Nerve Injury. Journal of Sexual Medicine, 2015, 12, 1713-1721.	0.3	21
85	Assessment and clinical factors associated with pain in patients undergoing transrectal prostate biopsy. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2015, 39, 414-419.	0.2	4
86	Active Surveillance for Prostate Cancer under the Patient Protection and Affordable Care Act. Urology Practice, 2015, 2, 154-159.	0.2	1
87	Contemporary practice and techniqueâ€related outcomes for radical prostatectomy in the <scp>UK</scp>: a report of national outcomes. BJU International, 2015, 115, 753-763.	1.3	24
88	Expectant management for men with early stage prostate cancer. Ca-A Cancer Journal for Clinicians, 2015, 65, 264-282.	157.7	59
89	Guideline of Guidelines: Imaging of Localized Prostate Cancer. BJU International, 2015, 116, 526-530.	1.3	25
90	Prostateâ€specific antigenâ€based prostate cancer screening: Past and future. International Journal of Urology, 2015, 22, 524-532.	0.5	59
91	Comparison between Ultrasound Guided Transperineal and Transrectal Prostate Biopsy: A Prospective, Randomized and Controlled Trial. Scientific Reports, 2015, 5, 16089.	1.6	59
92	Clinical Significance of Neoadjuvant Combined Androgen Blockade for More Than Six Months in Patients with Localized Prostate Cancer Treated with Prostate Brachytherapy. Urologia Internationalis, 2015, 95, 457-464.	0.6	5
93	Androgen receptor profiling predicts prostate cancer outcome. EMBO Molecular Medicine, 2015, 7, 1450-1464.	3.3	67
94	Advances in hormonal therapies for hormone naÃ¯ve and castration-resistant prostate cancers with or without previous chemotherapy. Experimental Hematology and Oncology, 2015, 5, 15.	2.0	10
95	What tumours should we treat with focal therapy based on risk category, grade, size and location?. Current Opinion in Urology, 2015, 25, 212-219.	0.9	10
96	MP83-20 DISCORDANCE BETWEEN LOCATION OF POSITIVE CORES IN BIOPSY AND LOCATION OF POSITIVE SURGICAL MARGIN FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 2015, 193, .	0.2	0
97	MP42-19 DECISION AIDS FOR LOCALIZED PROSTATE CANCER TREATMENT CHOICE: SYSTEMATIC REVIEW AND META-ANALYSIS. Journal of Urology, 2015, 193, .	0.2	1
98	Longâ€term outcomes of robotâ€assisted radical prostatectomy: Where do we stand?. BJU International, 2015, 116, 845-846.	1.3	0
99	Seed migration after transperineal interstitial prostate brachytherapy by using loose seeds: Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS) multi-institutional cohort study. Radiation Oncology, 2015, 10, 228.	1.2	17
100	Impact of a web-based treatment decision aid for early-stage prostate cancer on shared decision-making and health outcomes: study protocol for a randomized controlled trial. Trials, 2015, 16, 231.	0.7	22

#	Article	IF	Citations
101	Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy. SpringerPlus, 2015, 4, 789.	1.2	18
102	Importance of prostate volume in the stratification of patients with intermediateâ€risk prostate cancer. International Journal of Urology, 2015, 22, 555-561.	0.5	16
103	PCA3 and PSA gene activity correlates with the true tumor cell burden in prostate cancer lymph node metastases. Cancer Biomarkers, 2015, 15, 311-316.	0.8	5
104	Ultrasound modalities and quantification. Current Opinion in Urology, 2015, 25, 191-197.	0.9	13
105	Multiparametric Prostate Magnetic Resonance Imaging at 3 T. Journal of Computer Assisted Tomography, 2015, 39, 674-680.	0.5	13
106	Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection. Prostate, 2015, 75, 1484-1491.	1.2	21
107	Assessment of longâ€term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy. Cancer, 2015, 121, 4071-4079.	2.0	28
108	A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate. Prostate, 2015, 75, 1447-1453.	1.2	13
109	Impact of prostate volume on oncologic, perioperative, and functional outcomes after radical prostatectomy. Prostate, 2015, 75, 1436-1446.	1.2	17
110	Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram. BJU International, 2015, 116, 703-712.	1.3	11
111	Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nuclear Medicine Communications, 2015, 36, 582-587.	0.5	125
112	Patient and disease factors affecting the choice and adherence to active surveillance. Current Opinion in Urology, 2015, 25, 272-276.	0.9	28
113	Extended pelvic lymph node dissection in patients with prostate cancer previously treated with surgery for lower urinary tract symptoms. BJU International, 2015, 116, 366-372.	1.3	4
114	Discordance between location of positive cores in biopsy and location of positive surgical margin following radical prostatectomy. Korean Journal of Urology, 2015, 56, 710.	1.2	3
115	A novel combination of triple metachronous malignancies of the kidney, oropharynx and prostate: A case report. Oncology Letters, 2015, 10, 917-920.	0.8	6
116	L-amino acid transporter 1 may be a prognostic marker for local progression of prostatic cancer under expectant management. Cancer Biomarkers, 2015, 15, 365-374.	0.8	20
117	Comparison of biochemical recurrence in prostate cancer patients treated with radical prostatectomy or radiotherapy. Korean Journal of Urology, 2015, 56, 703.	1.2	4
118	The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment. Korean Journal of Urology, 2015, 56, 689.	1.2	2

#	Article	IF	Citations
119	Impact of beta-blockers on prostate cancer mortality: a meta-analysis of 16,825 patients. OncoTargets and Therapy, 2015, 8, 985.	1.0	46
120	Rationale and development of image-guided intensity-modulated radiotherapy post-prostatectomy: the present standard of care?. Cancer Management and Research, 2015, 7, 331.	0.9	7
121	Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists. Korean Journal of Urology, 2015, 56, 487.	1.2	31
122	Safety of 12 core transrectal ultrasound guided prostate biopsy in patients on aspirin. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 1096-1100.	0.7	4
123	Can magnetic resonance imaging solve the prostate cancer conundrum?. Medical Journal of Australia, 2015, 202, 410-411.	0.8	0
124	Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with 18F-Choline PET/CT in Prostate Cancer. Frontiers in Medicine, 2015, 2, 67.	1.2	6
125	Serum Fucosylated Prostate-specific Antigen (PSA) Improves the Differentiation of Aggressive from Non-aggressive Prostate Cancers. Theranostics, 2015, 5, 267-276.	4.6	59
126	Evaluation of Multiparametric Magnetic Resonance Imaging in Detection and Prediction of Prostate Cancer. PLoS ONE, 2015, 10, e0130207.	1.1	11
127	Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program. PLoS ONE, 2015, 10, e0134134.	1.1	15
128	Contrast-enhanced ultrasound aids in the detection of prostate rhabdomyosarcoma: A case report and literature review. Oncology Letters, 2015, 10, 1541-1544.	0.8	1
129	Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4â€“10â€‰ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score. BioMed Research International, 2015, 2015, 1-7.	0.9	10
130	Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study. Prostate Cancer, 2015, 2015, 1-8.	0.4	12
131	Atypical Small Acinar Proliferation: Repeat Biopsy and Detection of High Grade Prostate Cancer. Prostate Cancer, 2015, 2015, 1-5.	0.4	11
132	Salvage Pelvic Lymph Node Dissection in Recurrent Prostate Cancer: Surgical and Early Oncological Outcome. BioMed Research International, 2015, 2015, 1-6.	0.9	26
133	The Role of Androgen Receptor Expression in the Curative Treatment of Prostate Cancer with Radiotherapy: A Pilot Study. BioMed Research International, 2015, 2015, 1-8.	0.9	7
134	Effect of patient position on pain scales during transrectal ultrasound-guided prostate biopsy. Korean Journal of Urology, 2015, 56, 449.	1.2	3
136	Landmarks in erectile function recovery after radical prostatectomy. Nature Reviews Urology, 2015, 12, 289-297.	1.9	39
137	Multiparametric ultrasound in the detection of prostate cancer: a systematic review. World Journal of Urology, 2015, 33, 1651-1659.	1.2	91

#	Article	IF	Citations
138	Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. European Radiology, 2015, 25, 2840-2850.	2.3	322
139	Accuracy of Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies to Diagnose Clinically Significant Prostate Cancer in Enlarged Compared to Smaller Prostates. Journal of Urology, 2015, 194, 669-673.	0.2	61
140	Treatment of Incidental Prostate Cancer by Active Surveillance: Results of the HAROW Study. Urologia Internationalis, 2015, 95, 209-215.	0.6	8
141	Heterogeneity in D×³Amico classificationâ€“based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 329.e13-329.e19.	0.8	37
142	Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland. Strahlentherapie Und Onkologie, 2015, 191, 778-786.	1.0	18
143	1.5-T multiparametric MRI using PI-RADS: a region by region analysis to localize the index-tumor of prostate cancer in patients undergoing prostatectomy. Acta Radiologica, 2015, 56, 500-511.	0.5	33
144	Is it Safe to Omit Baseline Bone Scan for Newly Diagnosed Prostate Cancer Patients?. Urologia Internationalis, 2015, 94, 342-346.	0.6	7
145	Prediction of Significant Prostate Cancer at Prostate Biopsy and Per Core Detection Rate of Targeted and Systematic Biopsies Using Real-Time Shear Wave Elastography. Urologia Internationalis, 2015, 95, 189-196.	0.6	23
146	Prostate cancer diagnosis: the feasibility of needle-based optical coherence tomography. Journal of Medical Imaging, 2015, 2, 037501.	0.8	28
147	Intensified antineoplastic effect by combining an <scp>HDAC</scp>â€inhibitor, an <scp>mTOR</scp>â€inhibitor and low dosed interferon alpha in prostate cancer cells. Journal of Cellular and Molecular Medicine, 2015, 19, 1795-1804.	1.6	11
148	Retropubic Intracorporeal Placement of a Suburethral Autologous Sling During Robot-Assisted Radical Prostatectomy to Improve Early Urinary Continence Recovery: Preliminary Data. Journal of Endourology, 2015, 29, 1379-1385.	1.1	19
149	Systemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine. Oncology Research and Treatment, 2015, 38, 654-668.	0.8	4
150	Sentinel node biopsy in uro-oncology: A history of the development of a promising concept. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 486-493.	0.8	16
151	microRNAs in the Malignant Transformation Process. Advances in Experimental Medicine and Biology, 2015, 889, 1-21.	0.8	4
152	A Population-Based Study of Men With Low-Volume Low-Risk Prostate Cancer: Does African-American Race Predict for More Aggressive Disease?. Clinical Genitourinary Cancer, 2015, 13, e259-e264.	0.9	22
153	Intravenous paracetamol for relief of pain during transrectalâ€ultrasoundâ€guided biopsy of the prostate: A prospective, randomized, doubleâ€blind, placeboâ€controlled study. Kaohsiung Journal of Medical Sciences, 2015, 31, 572-579.	0.8	1
154	Cognitive factors influencing treatment decision-making in patients with localised prostate cancer: development of a standardised questionnaire. Acta Clinica Belgica, 2015, 70, 272-279.	0.5	5
155	Comparison study of distinguishing cancerous and normal prostate epithelial cells by confocal and polarization diffraction imaging. Journal of Biomedical Optics, 2015, 21, 071102.	1.4	17

#	Article	IF	Citations
156	Lymphoceles Post-Radical Retropubic Prostatectomy: A Retrospective Evaluation of Epidemiology, Risk Factors and Outcome. Urologia Internationalis, 2015, 95, 400-405.	0.6	18
158	Point: Surgery is the most cost-effective option for prostate cancer needing treatment. Brachytherapy, 2015, 14, 753-755.	0.2	0
159	Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: An external validation. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 384.e1-384.e8.	0.8	5
160	Evaluation of data quality in the National Prostate Cancer Register of Sweden. European Journal of Cancer, 2015, 51, 101-111.	1.3	83
161	Switching and withdrawing hormonal agents for castration-resistant prostate cancer. Nature Reviews Urology, 2015, 12, 37-47.	1.9	60
162	Advanced Imaging and Possible Focal Therapy for Prostate Cancer. Current Surgery Reports, 2015, 3, 1.	0.4	1
164	Permanent prostate brachytherapy and short-term androgen deprivation for intermediate-risk prostate cancer in Japanese men: Outcome and toxicity. Brachytherapy, 2015, 14, 118-123.	0.2	8
165	Surgery for high-risk prostate cancer and metastatic prostate cancer. Current Problems in Cancer, 2015, 39, 33-40.	1.0	3
166	Shear Wave Elastography for Localization of Prostate Cancer Lesions and Assessment of Elasticity Thresholds: Implications for Targeted Biopsies and Active Surveillance Protocols. Journal of Urology, 2015, 193, 794-800.	0.2	97
167	EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. European Urology, 2015, 67, 1099-1109.	0.9	735
168	Discordance rate between radiolabelled choline PET/CT and bone scintigraphy in detecting bone metastases in patients with prostate cancer: a meta-analysis. Clinical and Translational Imaging, 2015, 3, 133-140.	1.1	2
169	Cytoreductive Radical Prostatectomy in Patients with Prostate Cancer and Low Volume Skeletal Metastases: Results of a Feasibility and Case-Control Study. Journal of Urology, 2015, 193, 832-838.	0.2	225
170	Precise construction of oligonucleotideâ€“Fab fragment conjugate for homogeneous immunoassay using HaloTag technology. Analytical Biochemistry, 2015, 472, 37-44.	1.1	3
171	How Does Active Surveillance for Prostate Cancer Affect Quality of Life? A Systematic Review. European Urology, 2015, 67, 637-645.	0.9	105
172	Feasibility, safety, and efficacy of salvage radical prostatectomy after TookadÂ® Soluble focal treatment for localized prostate cancer. World Journal of Urology, 2015, 33, 965-971.	1.2	31
173	Imaging biomarkers in prostate cancer: role of PET/CT and MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 644-655.	3.3	57
174	Quantification of ¹⁸F-Fluorocholine Kinetics in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 365-371.	2.8	32
176	Assessment of BI-RADS Category 4 Lesions Detected with Screening Mammography and Screening US: Utility of MR Imaging. Radiology, 2015, 274, 343-351.	3.6	67

#	Article	IF	Citations
177	High-intensity focused ultrasound for the treatment of prostate cancer: A prospective trial with long-term follow-up. Scandinavian Journal of Urology, 2015, 49, 267-274.	0.6	20
178	Prostate Imaging Reporting and Data System and Likert Scoring System: Multiparametric MR Imaging Validation Study to Screen Patients for Initial Biopsy. Radiology, 2015, 275, 458-468.	3.6	97
179	Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer. Scientific Reports, 2015, 5, 7713.	1.6	41
180	Transrectal ultrasoundâ€guided biopsy sepsis and the rise in carbapenem antibiotic use. ANZ Journal of Surgery, 2015, 85, 931-935.	0.3	14
181	Impact of body mass index on outcomes of laparoscopic radical prostatectomy with long-term follow-up. Scandinavian Journal of Urology, 2015, 49, 70-76.	0.6	10
182	Prostate cancer antigen-3 (PCA3) and PCA3-based nomograms in the diagnosis of prostate cancer: an external validation of Hansenâ€™s nomogram on a Norwegian cohort. Scandinavian Journal of Urology, 2015, 49, 8-15.	0.6	8
183	Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project. World Journal of Urology, 2015, 33, 1503-1509.	1.2	108
184	Low circulating free and bioavailable testosterone levels as predictors of high-grade tumors in patients undergoing radical prostatectomy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 384.e21-384.e27.	0.8	29
185	A novel urinary long nonâ€coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy. Prostate, 2015, 75, 653-661.	1.2	40
186	Correlation of gleason scores with magnetic resonance diffusion tensor imaging in peripheral zone prostate cancer. Journal of Magnetic Resonance Imaging, 2015, 42, 460-467.	1.9	41
187	Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment?. European Urology, 2015, 68, 175-178.	0.9	74
188	Prostate cancer staging with extracapsular extension risk scoring using multiparametric MRI: a correlation with histopathology. European Radiology, 2015, 25, 1776-1785.	2.3	72
189	[11C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 877-884.	3.3	38
190	Radiotherapy before and after radical prostatectomy for high-risk and locally advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 226-234.	0.8	9
191	Significance of apoptotic and nonâ€apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancer. Prostate, 2015, 75, 637-645.	1.2	16
192	SÃntomas del tracto urinario inferior y funciÃ³n erÃ©ctil en pacientes con sospecha de cÃ¡ncer de prÃ³stata. Actas UrolÃ³gicas EspaÃ±olas, 2015, 39, 360-366.	0.3	1
195	Clinical application of sonoelastography in thyroid, prostate, kidney, pancreas, and deep venous thrombosis. Abdominal Imaging, 2015, 40, 709-722.	2.0	22
197	Influence of pathological factors on oncological outcomes after robot-assisted radical prostatectomy for localized prostate cancer: Results of a prospective study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 330.e1-330.e7.	0.8	14

#	Article	IF	Citations
198	Added Value of Multiparametric Ultrasonography in Magnetic Resonance Imaging and Ultrasonography Fusionâ€“guided Biopsy of the Prostate in Patients With Suspicion for Prostate Cancer. Urology, 2015, 86, 108-114.	0.5	34
199	Transrectal Ultrasound Guided Biopsy of the Prostate: Is the Information Accessible, Usable, Reliable and Readable?. Current Urology, 2015, 8, 32-37.	0.4	8
200	Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2015, 26, v69-v77.	0.6	346
201	High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success. Radiotherapy and Oncology, 2015, 115, 84-89.	0.3	49
202	Immediate Versus Delayed Radical Prostatectomy: Updated Outcomes Following Active Surveillance of Prostate Cancer. European Urology, 2015, 68, 458-463.	0.9	49
203	Performance of transrectal prostate biopsies in detecting tumours and implications for focal therapy. Scandinavian Journal of Urology, 2015, 49, 90-96.	0.6	6
204	Variation between specialist uropatholgists in reporting extraprostatic extension after radical prostatectomy. Journal of Clinical Pathology, 2015, 68, 465-472.	1.0	7
205	Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	97
206	Identification of Candidates for Active Surveillance: Should We Change the Current Paradigm?. Clinical Genitourinary Cancer, 2015, 13, 499-504.	0.9	5
207	Integrated prostate cancer centers might cause an overutilization of radiotherapy for low-risk prostate cancer: A comparison of treatment trends in the United States and Germany from 2004 to 2011. Radiotherapy and Oncology, 2015, 115, 90-95.	0.3	29
208	The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy. Journal of Cancer Research and Clinical Oncology, 2015, 141, 2061-2068.	1.2	48
209	Combination of Tramadol and Lidocaine for Pain Control During Transrectal Ultrasound-guided Prostate Biopsy: A Randomized Double-blinded Study. Urology, 2015, 85, 1247-1251.	0.5	4
210	Prospective Randomized Trial Comparing Magnetic Resonance Imaging (MRI)-guided In-bore Biopsy to MRI-ultrasound Fusion and Transrectal Ultrasound-guided Prostate Biopsy in Patients with Prior Negative Biopsies. European Urology, 2015, 68, 713-720.	0.9	155
211	The Utility and Limitations of Contrast-Enhanced Ultrasound for the Diagnosis and Treatment of Prostate Cancer. Sensors, 2015, 15, 4947-4957.	2.1	31
213	Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates. Journal of Urology, 2015, 193, 1519-1524.	0.2	90
214	Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 71.e21-71.e26.	0.8	26
215	What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 164.e1-164.e9.	0.8	35
216	ActualizaciÃ³n de los resultados de la rama espaÃ±ola del Estudio aleatorizado europeo de screening del cÃ¡ncer de prÃ³stata (ERSPC). Actas UrolÃ³gicas EspaÃ±olas, 2015, 39, 405-413.	0.3	19

#	Article	IF	Citations
217	Organ-Specific Cancer Metabolism and Its Potential for Therapy. Handbook of Experimental Pharmacology, 2015, 233, 321-353.	0.9	86
218	Evolution of the patient characteristics of candidates for radical prostatectomy and the results obtained with the technique. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2015, 39, 78-84.	0.2	1
219	Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. Journal of Urology, 2015, 194, 343-349.	0.2	109
220	Changes in Gleason score grading on serial follow-up biopsies in prostate cancer patients undergoing active surveillance. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2015, 39, 139-143.	0.2	4
221	Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer. European Urology, 2015, 68, 805-811.	0.9	58
222	11C-colina PET/TAC y RM multiparamÃ©trica en la recidiva bioquÃmica del cÃ¡ncer de prÃ³stata. Actas UrolÃ³gicas EspaÃ±olas, 2015, 39, 259-263.	0.3	11
223	Association between Surgeon and Hospital Characteristics and Lymph Node Counts From Radical Prostatectomy and Pelvic Lymph Node Dissection. Urology, 2015, 85, 890-895.	0.5	11
224	PET/CT in prostate cancer. Medecine Nucleaire, 2015, 39, 54-58.	0.2	2
225	Salvage Therapies for Radiorecurrent Prostate Cancer. Urology Practice, 2015, 2, 126-132.	0.2	0
226	Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 109.e23-109.e31.	0.8	63
227	Radical treatment of localised prostate cancer in the elderly. BJU International, 2015, 116, 847-852.	1.3	13
228	Multiparametric Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Targeted Biopsy of the Prostate: Preliminary Results of a Prospective Single-Centre Study. Urologia Internationalis, 2015, 94, 313-318.	0.6	24
229	18F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy. World Journal of Urology, 2015, 33, 1749-1752.	1.2	9
230	Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis. International Journal of Clinical Oncology, 2015, 20, 1018-1025.	1.0	19
231	Trends in initial management of prostate cancer in New Hampshire. Cancer Causes and Control, 2015, 26, 923-929.	0.8	23
232	Guidance on Patient Consultation. Current Evidence for Prostate-Specific Antigen Screening in Healthy Men and Treatment Options for Men with Proven Localised Prostate Cancer. Current Urology Reports, 2015, 16, 28.	1.0	1
233	Plasma proteasomal chymotrypsin-like activity correlates with prostate cancer progression. Tumor Biology, 2015, 36, 4115-4121.	0.8	4
234	Gleason Score at Diagnosis Predicts the Rate of Detection of ¹⁸F-Choline PET/CT Performed When Biochemical Evidence Indicates Recurrence of Prostate Cancer: Experience with 1,000 Patients. Journal of Nuclear Medicine, 2015, 56, 209-215.	2.8	69

#	Article	IF	Citations
235	Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience. Radiation Oncology, 2015, 10, 47.	1.2	22
236	Could Machine Learning Improve the Prediction of Pelvic Nodal Status of Prostate Cancer Patients? Preliminary Results of a Pilot Study. Cancer Investigation, 2015, 33, 232-240.	0.6	4
237	68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1284-1294.	3.3	234
238	Prostate Cancer: Diagnostic Performance of Real-time Shear-Wave Elastography. Radiology, 2015, 275, 280-289.	3.6	133
239	Psychometric evaluation of the EORTC QLQ-PR25 questionnaire in assessing health-related quality of life in prostate cancer survivors: a curateâ€™s egg. Quality of Life Research, 2015, 24, 2219-2230.	1.5	17
240	Life Expectancy and Treatment Choice for Men with High-risk Prostate Cancer. European Urology, 2015, 68, 59-60.	0.9	3
241	Correlation between the changes in the EPIC QOL scores and the dose-volume histogram parameters in high-dose-rate brachytherapy combined with hypofractionated external beam radiation therapy for prostate cancer. Japanese Journal of Clinical Oncology, 2015, 45, 81-87.	0.6	4
242	Regulation of vascular endothelial growth factor in prostate cancer. Endocrine-Related Cancer, 2015, 22, R107-R123.	1.6	47
243	Positive surgical margins after radical prostatectomy: What should we care about?. World Journal of Urology, 2015, 33, 1973-1978.	1.2	17
244	Decision aids for localized prostate cancer treatment choice: Systematic review and metaâ€anâ€alysis. Ca-A Cancer Journal for Clinicians, 2015, 65, 239-251.	157.7	115
245	Is further screening of men with baseline PSAâ€‰<â€‰1 ngÂml^{â^'1}worthwhile? The discussion continues-Results of the Swiss ERSPC (Aarau). International Journal of Cancer, 2015, 137, 553-559.	2.3	13
246	Does Preoperative Magnetic Resonance Imaging Reduce the Rate of Positive Surgical Margins at Radical Prostatectomy in a Randomised Clinical Trial?. European Urology, 2015, 68, 487-496.	0.9	57
247	Use of the Prostate Health Index for the Detection of Aggressive Prostate Cancer at Radical Prostatectomy. Urologia Internationalis, 2015, 95, 390-399.	0.6	9
248	Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy. Strahlentherapie Und Onkologie, 2015, 191, 801-809.	1.0	15
249	Ã‰valuation de la rÃ©ponse mÃ©tabolique en TEP/TDM Ã la F18-FCH aprÃ¨s un mois de traitement par acÃ©tate dâ€™abiratÃ©rone chez les patients prÃ©sentant un cancer de la prostate mÃ©tastatique rÃ©sistant Ã la castration. Medecine Nucleaire, 2015, 39, 386-395.	0.2	0
250	MRI factors to predict urinary incontinence after retropubic/laparoscopic radical prostatectomy. International Urology and Nephrology, 2015, 47, 1343-1349.	0.6	32
251	Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer. JAMA Oncology, 2015, 1, 1261.	3.4	94
252	Closed-Bore Interventional MRI: Percutaneous Biopsies and Ablations. American Journal of Roentgenology, 2015, 205, W400-W410.	1.0	22

#	Article	IF	Citations
253	Adherence of the indication to European Association of Urology guideline recommended pelvic lymph node dissection at a high-volume center: Differences between open and robot-assisted radical prostatectomy. European Journal of Surgical Oncology, 2015, 41, 1547-1553.	0.5	13
254	Computer-aided transrectal ultrasound: does prostate HistoScanningâ„¢ improve detection performance of prostate cancer in repeat biopsies?. BMC Urology, 2015, 15, 76.	0.6	5
255	Efficiency, Satisfaction, and Costs for Remote Video Visits Following Radical Prostatectomy: A Randomized Controlled Trial. European Urology, 2015, 68, 729-735.	0.9	203
256	Adjuvant vs. salvage radiotherapy for patients at high risk for recurrence after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 451-455.	0.8	4
257	Diagnostic Value of Different Systematic Prostate Biopsy Methods in the Detection of Prostate Cancer with Ultrasonographic Hypoechoic Lesions - A Comparative Study. Urologia Internationalis, 2015, 95, 183-188.	0.6	3
258	Initial prostate cancer diagnosis and disease stagingâ€"the role of choline-PETâ€"CT. Nature Reviews Urology, 2015, 12, 510-518.	1.9	34
259	Editorial Comment from <scp>D</scp>r <scp>C</scp>antiello and <scp>D</scp>r <scp>D</scp>amiano to Addition of intrarectal local analgesia to periprostatic nerve block improves pain control for transrectal ultrasonographyâ€guided prostate biopsy: A systematic review and metaâ€analysis. International Journal of Urology, 2015, 22, 69-69.	0.5	0
260	sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients. Journal of Experimental and Clinical Cancer Research, 2015, 34, 43.	3.5	27
261	Robot-assisted radical prostatectomy in prostate cancer. Future Oncology, 2015, 11, 2767-2773.	1.1	12
262	The role for surgeryin high-risk prostate cancer. Wiener Medizinische Wochenschrift, 2015, 165, 395-400.	0.5	2
263	Ethnicity and prostate cancer: the way to solve the screening problem?. BMC Medicine, 2015, 13, 179.	2.3	5
264	Adjuvant and salvage radiation therapy after prostatectomy: investigating beliefs and practices of radiation oncologists. British Journal of Radiology, 2015, 88, 20150587.	1.0	3
265	Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading. Prostate Cancer and Prostatic Diseases, 2015, 18, 382-387.	2.0	26
266	The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer. Current Oncology Reports, 2015, 17, 53.	1.8	7
267	Urinary tract symptoms and erectile function in patients at risk of prostate cancer. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2015, 39, 360-366.	0.2	0
268	Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance. Prostate Cancer and Prostatic Diseases, 2015, 18, 288-296.	2.0	70
269	11C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2015, 39, 259-263.	0.2	10
270	PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer. PET Clinics, 2015, 10, 487-494.	1.5	5

#	Article	IF	Citations
272	MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker. British Journal of Cancer, 2015, 113, 1055-1065.	2.9	107
273	Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study. Journal of the National Cancer Institute, 2015, 107, .	3.0	146
274	Update of the results of the Spanish branch of the European randomized study on screening for prostate cancer (ERSPC). Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2015, 39, 405-413.	0.2	6
275	Postoperative Leukocytosis After Robotic-Assisted Radical Prostatectomy Is Not Associated with Perioperative Outcome and Histopathological Findings. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2015, 25, 808-813.	0.5	0
276	Does Multimedia Education with 3D Animation Impact Quality and Duration of Urologistsâ€™ Interactions with their Prostate Cancer Patients?. Advances in Therapy, 2015, 32, 863-873.	1.3	2
277	Accuracy of MRI-Targeted in-Bore Prostate Biopsy According to the Gleason Score with Postprostatectomy Histopathologic Controlâ€"a Targeted Biopsy-Only Strategy with Limited Number of Cores. Academic Radiology, 2015, 22, 1409-1418.	1.3	16
278	EvaluaciÃ³n del dolor y factores asociados en pacientes sometidos a biopsia de prÃ³stata. Actas UrolÃ³gicas EspaÃ±olas, 2015, 39, 414-419.	0.3	12
279	Nodal Occult Metastases in Intermediate- and High-Risk Prostate Cancer Patients Detected Using Serial Section, Immunohistochemistry, andÂReal-Time Reverse Transcriptase Polymerase Chain Reaction: Prospective Evaluation With Matched-Pair Analysis. Clinical Genitourinary Cancer, 2015, 13, e55-e64.	0.9	14
281	Sentinel node approach in prostate cancer. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 358-371.	0.1	0
282	Sentinel node approach in prostate cancer. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 358-371.	0.0	3
284	Comparative Study of Autologous Stromal Vascular Fraction and Adipose-Derived Stem Cells for Erectile Function Recovery in a Rat Model of Cavernous Nerve Injury. Stem Cells Translational Medicine, 2015, 4, 351-358.	1.6	85
285	Evolving role of positron emission tomography (<scp>PET</scp>) in urological malignancy. BJU International, 2015, 116, 538-545.	1.3	4
286	Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy. World Journal of Urology, 2015, 33, 1165-1171.	1.2	20
287	Reply. Urology, 2015, 85, 90-91.	0.5	0
288	Editorial Comment. Urology, 2015, 85, 90.	0.5	1
289	Targeting human prostate cancer with ¹¹¹Inâ€labeled D2B IgG, F(abâ€²)₂ and Fab fragments in nude mice with PSMAâ€expressing xenografts. Contrast Media and Molecular Imaging, 2015, 10, 28-36.	0.4	33
290	Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 235-244.	0.8	27
291	Incidence of Prostate Cancer in Hypogonadal Men Receiving Testosterone Therapy: Observations from 5-Year Median Followup of 3 Registries. Journal of Urology, 2015, 193, 80-86.	0.2	79

#	Article	IF	Citations
292	Improved Outcomes with Advancements in High Intensity Focused Ultrasound Devices for the Treatment of Localized Prostate Cancer. Journal of Urology, 2015, 193, 103-110.	0.2	75
293	Comparative Analysis of Transperineal Template Saturation Prostate Biopsy Versus Magnetic Resonance Imaging Targeted Biopsy with Magnetic Resonance Imaging-Ultrasound Fusion Guidance. Journal of Urology, 2015, 193, 87-94.	0.2	196
294	Apparent diffusion coefficient ratio correlates significantly with prostate cancer gleason score at final pathology. Journal of Magnetic Resonance Imaging, 2015, 42, 446-453.	1.9	84
295	Stage pT0 after radical prostatectomy: a diagnostic dilemma. World Journal of Urology, 2015, 33, 1291-1296.	1.2	11
296	Long-term Outcomes of Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer: Results of a Single-institution Series with a Minimum Follow-up of 5 Years. European Urology, 2015, 67, 299-309.	0.9	211
297	More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. European Urology, 2015, 67, 212-219.	0.9	178
298	EvoluciÃ³n de las caracterÃsticas del paciente candidato a prostatectomÃa radical y de los resultados obtenidos con la tÃ©cnica. Actas UrolÃ³gicas EspaÃ±olas, 2015, 39, 78-84.	0.3	5
299	Retropubic, laparoscopic and mini-laparoscopic radical prostatectomy: a prospective assessment of patient scar satisfaction. World Journal of Urology, 2015, 33, 1181-1187.	1.2	11
300	Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. Strahlentherapie Und Onkologie, 2015, 191, 310-320.	1.0	91
301	Cambios en el grado de Gleason en las biopsias de seguimiento de pacientes con cÃ¡ncer de prÃ³stata en programa de vigilancia activa. Actas UrolÃ³gicas EspaÃ±olas, 2015, 39, 139-143.	0.3	4
302	A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification. Clinica Chimica Acta, 2015, 439, 42-49.	0.5	14
303	Prosbiotate: A Multicenter, Prospective Analysis of Infectious Complications after Prostate Biopsy. Journal of Urology, 2015, 193, 145-150.	0.2	69
304	Infectious Complications after Prostate Biopsy: A Prospective Multicenter Prostate Biopsy Study. Urogenital Tract Infection, 2016, 11, 17.	0.1	1
305	Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy. Research and Reports in Urology, 2016, Volume 8, 225-231.	0.6	6
306	Prostate Cancer Risk in Relation to CYP3A4 and CYP3A5 Genotypes in the Bangladeshi Population. Dhaka University Journal of Pharmaceutical Sciences, 2016, 14, 179-185.	0.1	1
307	Predicting Gleason score using the initial serum total prostate-specific antigen in Black men with symptomatic prostate adenocarcinoma in Nigeria. Clinical Interventions in Aging, 2016, Volume 11, 961-966.	1.3	2
308	Updates of prostate cancer staging: Prostate-specific membrane antigen. Investigative and Clinical Urology, 2016, 57, S147.	1.0	6
309	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e235-e245.	1.8	26

#	Article	IF	Citations
310	Current status of active surveillance in prostate cancer. Investigative and Clinical Urology, 2016, 57, 14.	1.0	22
311	Preparation of [177Lu]PSMA-617 Using Carrier Added (CA) 177Lu for Radionuclide Therapy of Prostate Cancer. Journal of Nuclear Medicine & Radiation Therapy, 2016, 7, .	0.2	6
312	Feasibility of planned mini-laparotomy and adhesiolysis at the time of robotic-assisted radical prostatectomy in patients with prior major abdominal surgery. Canadian Urological Association Journal, 2016, 10, 125.	0.3	3
313	Association between 17q25.3-rs6465657 polymorphism and prostate cancer susceptibility: a meta-analysis based on 19 studies. OncoTargets and Therapy, 2016, Volume 9, 4491-4503.	1.0	4
314	Radical Prostatectomy in Korean Men Aged 75-Years or Older: Safety and Efficacy in Comparison with Patients Aged 65â€“69 Years. Journal of Korean Medical Science, 2016, 31, 957.	1.1	10
315	Urinary Continence after Robot-Assisted Laparoscopic Radical Prostatectomy: The Impact of Intravesical Prostatic Protrusion. Yonsei Medical Journal, 2016, 57, 1145.	0.9	20
316	High Grade Prostatic Intraepithelial Neoplasia and Atypical Glands. , 2016, , 49-62.		0
317	Evolving Recommendations on Prostate Cancer Screening. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e80-e87.	1.8	8
318	Non-invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles. Oncotarget, 2016, 7, 22566-22578.	0.8	113
319	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e235-e245.	1.8	16
320	Quantitative and Qualitative Analysis of Circulating Cell-Free DNA Can Be Used as an Adjuvant Tool for Prostate Cancer Screening: A Meta-Analysis. Disease Markers, 2016, 2016, 1-12.	0.6	21
321	Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?. BioMed Research International, 2016, 2016, 1-14.	0.9	44
322	Diagnostic Accuracy of Robot-Guided, Software Based Transperineal MRI/TRUS Fusion Biopsy of the Prostate in a High Risk Population of Previously Biopsy Negative Men. BioMed Research International, 2016, 2016, 1-6.	0.9	19
323	Radiotherapy and Hormone Treatment in Prostate Cancer. Deutsches Ärzteblatt International, 2016, 113, 235-41.	0.6	9
324	Clinical Application of High-intensity Focused Ultrasound in Cancer Therapy. Journal of Cancer, 2016, 7, 225-231.	1.2	121
325	Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy. Investigative and Clinical Urology, 2016, 57, S155.	1.0	4
326	Polymorphisms of eNOS, catalase, and myeloperoxidase genes in prostate cancer in Turkish men: preliminary results. Genetics and Molecular Research, 2016, 15, .	0.3	10
327	Postprostatectomy Erectile Dysfunction: A Review. World Journal of Men?s Health, 2016, 34, 73.	1.7	54

#	Article	IF	Citations
328	Robot assisted lymphadenectomy in urology: pelvic, retroperitoneal and inguinal. Minerva Urology and Nephrology, 2016, 69, 38-55.	1.3	12
329	Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization. International Journal of Molecular Sciences, 2016, 17, 102.	1.8	298
330	Gaps between Evidence and Practice in Postoperative Radiotherapy for Prostate Cancer: Focus on Toxicities and the Effects on Health-Related Quality of Life. Frontiers in Oncology, 2016, 6, 70.	1.3	10
331	Tissue Microstructure Is Linked to MRI Parameters and Metabolite Levels in Prostate Cancer. Frontiers in Oncology, 2016, 6, 146.	1.3	10
332	Metabolic Imaging in Prostate Cancer: Where We Are. Frontiers in Oncology, 2016, 6, 225.	1.3	21
333	Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers. International Journal of Molecular Sciences, 2016, 17, 1784.	1.8	93
334	Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer. International Journal of Molecular Sciences, 2016, 17, 1879.	1.8	4
335	Single punch, double biopsy. SpringerPlus, 2016, 5, 1456.	1.2	1
336	MR Spectroscopy in Prostate Cancer: New Algorithms to Optimize Metabolite Quantification. PLoS ONE, 2016, 11, e0165730.	1.1	7
337	Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes. Theranostics, 2016, 6, 1190-1204.	4.6	104
338	⁶⁸Ga-HBED-CC-PSMA PET/CT Versus Histopathology In Primary Localized Prostate Cancer: A Voxel-Wise Comparison. Theranostics, 2016, 6, 1619-1628.	4.6	89
339	Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeutics. Theranostics, 2016, 6, 1085-1095.	4.6	60
340	Urethral strictures after radiation therapy for prostate cancer. Investigative and Clinical Urology, 2016, 57, 309.	1.0	15
341	Radical Retropubic Prostatectomy. , 2016, , 265-273.		0
342	Optimizing safety and accuracy of prostate biopsy. Current Opinion in Urology, 2016, 26, 472-480.	0.9	14
343	Adult weight gain and risk of prostate cancer: A doseâ€"response metaâ€analysis of observational studies. International Journal of Cancer, 2016, 138, 866-874.	2.3	15
344	Prostate cancer characteristics and outcome in renal transplant recipients: results from a contemporary single center study. Clinical Transplantation, 2016, 30, 964-971.	0.8	28
345	Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. International Journal of Urology, 2016, 23, 241-246.	0.5	2

#	Article	IF	Citations
346	Prostate-specific membrane antigen positron emission tomography in prostate cancer. Current Opinion in Oncology, 2016, 28, 216-221.	1.1	45
347	PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castrationâ€resistant prostate cancerâ€like cells. Prostate, 2016, 76, 273-285.	1.2	20
349	Sampling of the anterior apical region results in increased cancer detection and upgrading in transrectal repeat saturation biopsy of the prostate. BJU International, 2016, 117, 592-597.	1.3	21
350	Impact of stage migration and practice changes on highâ€risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades. BJU International, 2016, 117, 740-747.	1.3	28
351	Prognostic value of Caveolinâ€1 in patients treated with radical prostatectomy: a multicentric validation study. BJU International, 2016, 118, 243-249.	1.3	14
352	Detection of prostate cancer index lesions with multiparametric magnetic resonance imaging (mpâ€<scp>MRI</scp>) using wholeâ€mount histological sections as the reference standard. BJU International, 2016, 118, 84-94.	1.3	63
353	Active surveillance in localized prostate cancer: comparison of incidental tumours (T1a/b) and tumours diagnosed by core needle biopsy (T1c/T2a): results from the HAROW study. BJU International, 2016, 118, 258-263.	1.3	10
354	Management of localized and advanced prostate cancer in Canada: A lifetime cost and qualityâ€adjusted lifeâ€year analysis. Cancer, 2016, 122, 1085-1096.	2.0	21
355	Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection. International Journal of Cancer, 2016, 138, 2221-2230.	2.3	11
356	Dynamic contrastâ€enhanced ultrasound parametric imaging for the detection of prostate cancer. BJU International, 2016, 117, 598-603.	1.3	43
357	PET/MRI and prostate cancer. Clinical and Translational Imaging, 2016, 4, 473-485.	1.1	13
358	Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France. Joint Bone Spine, 2016, 83, 501-509.	0.8	39
359	Evaluation of apparent diffusion coefficient and MR volumetry as independent associative factors for extraâ€prostatic extension (EPE) in prostatic carcinoma. Journal of Magnetic Resonance Imaging, 2016, 43, 726-736.	1.9	27
360	High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Lowâ€“Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients. Clinical Oncology, 2016, 28, e173-e178.	0.6	33
361	A positive Real-Time Elastography (RTE) combined with a Prostate Cancer Gene 3 (PCA3) score above 35 convey a high probability of intermediate- or high-risk prostate cancer in patient admitted for primary prostate biopsy. BMC Urology, 2016, 16, 39.	0.6	12
362	Significance of urethral fibrosis evaluated by preoperative magnetic resonance imaging as a predictor of continence status after robotâ€assisted radical prostatectomy. International Journal of Medical Robotics and Computer Assisted Surgery, 2016, 12, 496-501.	1.2	7
363	Bone Scan Index predicts outcome in patients with metastatic hormoneâ€sensitive prostate cancer. BJU International, 2016, 117, 748-753.	1.3	41
364	Do all men with pathological Gleason score 8â€“10 prostate cancer have poor outcomes? Results from the <scp>SEARCH</scp> database. BJU International, 2016, 118, 250-257.	1.3	12

#	Article	IF	Citations
365	Doseâ€dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU International, 2016, 118, 221-229.	1.3	22
366	Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: results from REDUCE. Prostate Cancer and Prostatic Diseases, 2016, 19, 202-208.	2.0	9
367	High resolution digital autoradiographic and dosimetric analysis of heterogeneous radioactivity distribution in xenografted prostate tumors. Medical Physics, 2016, 43, 6632-6643.	1.6	3
368	Prostate Cancer Patientsâ€"Negative Biopsy Controls Discrimination by Untargeted Metabolomics Analysis of Urine by LC-QTOF: Upstream Information on Other Omics. Scientific Reports, 2016, 6, 38243.	1.6	29
369	HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method. Oncology Letters, 2016, 12, 4651-4658.	0.8	19
370	Predictive factors of 18F-choline PET/CT positivity in patients with prostate cancer recurrence after radiation therapy: is the impact of PSA nadir underestimated?. EJNMMI Research, 2016, 6, 84.	1.1	5
371	Synthesis of IR-780 dye-conjugated abiraterone for prostate cancer imaging and therapy. International Journal of Oncology, 2016, 49, 1911-1920.	1.4	14
372	A Novel Pain Alternative for Patients with Anorectal Pathologies: The Comparison of Transperineal Prostatic Blockage Technique with Periprostatic Nerve Blockage and Rectal Gel Technique in Initial Transrectal Ultrasound-Guided Prostate Biopsy - A Prospective, Randomized Trial. Urologia Internationalis, 2016, 97, 416-420.	0.6	4
373	Editorial Comment to Does bilateral seminal vesicle invasion at radical prostatectomy predict worse prognosis than unilateral invasion among patients with <scp>pT</scp>3b prostate cancers?. International Journal of Urology, 2016, 23, 763-764.	0.5	0
374	Trends in prostate cancer in elderly in Denmark, 1980â€"2012. Acta OncolÃ³gica, 2016, 55, 74-78.	0.8	5
375	Can multiparametric MRI replace Roach equations in staging prostate cancer before external beam radiation therapy?. European Journal of Radiology, 2016, 85, 2231-2237.	1.2	1
376	Multiparametric dynamic contrast-enhanced ultrasound classification of prostate cancer. , 2016, , .		2
377	68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. Clinical Nuclear Medicine, 2016, 41, e473-e479.	0.7	86
378	Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1395-1401.	2.3	21
379	Radiolabeled choline PET/CT before salvage lymphadenectomy dissection. Nuclear Medicine Communications, 2016, 37, 1223-1231.	0.5	21
381	Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study. BMC Cancer, 2016, 16, 407.	1.1	24
383	Clinical impact of prostate biopsy undergrading in an academic and community setting. World Journal of Urology, 2016, 34, 1481-1490.	1.2	6
384	Non-surgically related causes of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2016, 19, 185-190.	2.0	14

#	Article	IF	Citations
385	Robotic Prostatectomy on the Web: A Cross-Sectional Qualitative Assessment. Clinical Genitourinary Cancer, 2016, 14, e355-e362.	0.9	13
386	Uso de contenedores individuales para las muestras obtenidas en biopsia prostÃ¡tica: Â¿ganamos en rendimiento diagnÃ³stico?. Actas UrolÃ³gicas EspaÃ±olas, 2016, 40, 224-228.	0.3	1
387	Excellent Erectile Function Recovery after Focal Therapy: Is This Enough?. European Urology, 2016, 69, 852-853.	0.9	3
388	Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy. BMC Cancer, 2016, 16, 329.	1.1	26
389	Activity, content, contributors, and influencers of the twitter discussion on urologic oncology. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 377-383.	0.8	44
390	Cratylia mollis lectin nanoelectrode for differential diagnostic of prostate cancer and benign prostatic hyperplasia based on label-free detection. Biosensors and Bioelectronics, 2016, 85, 171-177.	5.3	38
391	Atypical small acinar proliferation (ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review. Prostate Cancer and Prostatic Diseases, 2016, 19, 68-71.	2.0	24
392	Concurrent Androgen Deprivation with Radiotherapy: A Cautionary Tale of â€œDo As I Say, Not As I Doâ€?. European Urology, 2016, 70, 436-437.	0.9	0
394	Radiotherapy versus Prostatectomy: a Question of Survival or Survivorship? Addressing Ongoing Questions and Controversies in the Management of Localised Prostate Cancer in the UK. Clinical Oncology, 2016, 28, 479-481.	0.6	1
395	Validation of 3ÂT MRI including diffusion-weighted imaging for nodal staging of newly diagnosed intermediate- and high-risk prostate cancer. Clinical Radiology, 2016, 71, 328-334.	0.5	30
396	Re: Jesse D. Sammon, Firas Abdollah, Anthony Dâ€™Amico, et al. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. Eur Urol 2015;68:756â€“65.. European Urology, 2016, 69, e128.	0.9	0
397	Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21â€“30. European Urology, 2016, 70, e11-e12.	0.9	5
398	Staging of prostatic carcinoma at 1.5-T MRI: correlation of a simplified MRI exam with whole-mount radical prostatectomy specimens. British Journal of Radiology, 2016, 89, 20160101.	1.0	5
399	Diagnostic Difficulties With Atrophy, Atypical Adenomatous Hyperplasia, and Atypical Small Acinar Proliferation: A Systematic Review of Current Literature. Clinical Genitourinary Cancer, 2016, 14, 361-365.	0.9	6
400	Exponential apparent diffusion coefficient in evaluating prostate cancer at 3â€‰T: preliminary experience. British Journal of Radiology, 2016, 89, 20150470.	1.0	9
401	Urologic cancer in China. Japanese Journal of Clinical Oncology, 2016, 46, 497-501.	0.6	131
402	LinfadenectomÃa pÃ©lvica extendida en pacientes con cÃ¡ncer de prÃ³stata clÃnicamente localizado: estudio observacional prospectivo. Actas UrolÃ³gicas EspaÃ±olas, 2016, 40, 446-452.	0.3	2
403	Population-based screening for cancer: hope and hype. Nature Reviews Clinical Oncology, 2016, 13, 550-565.	12.5	98

#	Article	IF	Citations
404	Regulation of E3 ubiquitin ligase-1 (WWP1) by microRNA-452 inhibits cancer cell migration and invasion in prostate cancer. British Journal of Cancer, 2016, 114, 1135-1144.	2.9	53
405	Can the Free/Total PSA Ratio Predict the Gleason Score Before Prostate Biopsy?. Current Urology, 2016, 9, 24-27.	0.4	12
406	The Role of Pelvic Lymph Node Dissection During Radical Prostatectomy in Patients With Gleason 6 Intermediate-risk Prostate Cancer. Urology, 2016, 93, 141-146.	0.5	7
407	JOURNAL CLUB: Identification of Bone Metastasis With Routine Prostate MRI: A Study of Patients With Newly Diagnosed Prostate Cancer. American Journal of Roentgenology, 2016, 206, 1156-1163.	1.0	25
408	Prostate cancer radiation therapy: A physicianâ€™s perspective. Physica Medica, 2016, 32, 438-445.	0.4	22
410	3D Navigoâ„¢ versus TRUS-guided prostate biopsy in prostate cancer detection. World Journal of Urology, 2016, 34, 1255-1260.	1.2	7
411	Effects of tadalafil treatment combined with physical activity in patients with low onset hypogonadism: results from a not-randomized single arm phase 2 study. Aging Male, 2016, 19, 155-160.	0.9	16
412	Resultados oncolÃ³gicos en enfermedad N1 posterior a la prostatectomÃa radical. Revista Mexicana De Urologia, 2016, 76, 23-28.	0.0	0
413	Differentiation of prostatitis and prostate cancer using the Prostate Imagingâ€”Reporting and Data System (PI-RADS). European Journal of Radiology, 2016, 85, 1304-1311.	1.2	23
415	Multiparametric Prostate Magnetic Resonance Imaging and Cognitively Targeted Transperineal Biopsy in Patients With Previous Abdominoperineal Resection and Suspicion of Prostate Cancer. Urology, 2016, 96, 8-14.	0.5	9
417	Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer. Cancer Immunology Research, 2016, 4, 881-892.	1.6	57
418	PSMA PET and Radionuclide Therapy in Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 522-535.	2.5	82
419	PET/CT com Fluorocolinaâ€F18 no estadiamento inicial do carcinoma da prÃ³stata. Acta UrolÃ³gica Portuguesa, 2016, 33, 87-97.	0.1	1
420	In-bore transrectal MRI-guided prostate biopsies: Are there risk factors for complications?. European Journal of Radiology, 2016, 85, 2169-2173.	1.2	5
421	Recognition and Management of Ectopic Ureterocele During Robotic Assisted Laparoscopic Radical Prostatectomy. Urology Case Reports, 2016, 8, 15-17.	0.1	1
422	Reply to Re: The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening. Urology, 2016, 95, 224.	0.5	0
423	Extended pelvic lymphadenectomy in patients with clinically localized prostate cancer: A prospective observational study. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2016, 40, 446-452.	0.2	2
424	Non-invasive actionable biomarkers for metastatic prostate cancer. Asian Journal of Urology, 2016, 3, 170-176.	0.5	8

#	Article	IF	Citations
425	Internal Hernia Underneath an Elongated External Iliac Artery: AÂComplication After Extended Pelvic Lymphadenectomy and Robotic-assisted Laparoscopic Prostatectomy. Urology Case Reports, 2016, 8, 9-11.	0.1	20
426	Impact of positive surgical margin on biochemical recurrence following radical prostatectomy in locally advanced prostate cancer. Kaohsiung Journal of Medical Sciences, 2016, 32, 514-517.	0.8	7
427	MRI evaluation following partial HIFU therapy for localized prostate cancer: A single-center study. Progres En Urologie, 2016, 26, 517-523.	0.3	13
428	Single session of high-intensity focused ultrasound therapy for the management of organ-confined prostate cancer: A single-institute experience. Urological Science, 2016, 27, 226-229.	0.2	3
429	Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 530.e9-530.e14.	0.8	10
430	A novel approach to estimation of the time to biomarker threshold: applications to HIV. Pharmaceutical Statistics, 2016, 15, 541-549.	0.7	3
431	The use of ^{68Â}Gaâ€<scp>PSMA PET CT</scp> in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU International, 2016, 118, 49-55.	1.3	79
432	Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1177-1188.	1.5	38
433	Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide. Prostate International, 2016, 4, 118-124.	1.2	82
434	Evaluation of Prostate Cancer with ¹¹C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis. Journal of Nuclear Medicine, 2016, 57, 49S-54S.	2.8	25
435	What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 6S-12S.	2.8	12
436	Current perspectives of sentinel lymph node dissection at the time of radical surgery for prostate cancer. Cancer Treatment Reviews, 2016, 50, 228-239.	3.4	12
437	Primary care follow-up of radical prostatectomy patients: A regional New Zealand experience. Prostate International, 2016, 4, 136-139.	1.2	7
439	Impact of Periurethral Inflammation on Continence Status Early After Robot-Assisted Radical Prostatectomy. Journal of Endourology, 2016, 30, 1207-1213.	1.1	5
440	Pathological outcomes and agressiveness of low-risk prostate cancer in Northern African men. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2016, 40, 556-563.	0.2	0
441	PET imaging in prostate cancer, state of the art: a review of 18F-choline and 11C-choline PET/CT applications. Clinical and Translational Imaging, 2016, 4, 449-456.	1.1	1
442	Development of an explanatory model of sexual intimacy following treatment for localised prostate cancer: A systematic review and meta-synthesis of qualitative evidence. Social Science and Medicine, 2016, 163, 80-88.	1.8	19
443	Do androgen deprivation and the biologically equivalent dose matter in lowâ€doseâ€rate brachytherapy for intermediateâ€risk prostate cancer?. Cancer Medicine, 2016, 5, 2314-2322.	1.3	5

#	Article	IF	Citations
444	Could Magnetic Resonance Imaging Help to Identify the Presence of Prostate Cancer Before Initial Biopsy? The Development of Nomogram Predicting the Outcomes of Prostate Biopsy in the Chinese Population. Annals of Surgical Oncology, 2016, 23, 4284-4292.	0.7	20
445	Repeat Prostate-Specific Antigen Tests Before Prostate Biopsy Decisions. Journal of the National Cancer Institute, 2016, 108, djw165.	3.0	13
446	Predictors and rate of adjuvant radiation therapy following radical prostatectomy: A report from the <scp>P</scp>rostate <scp>C</scp>ancer <scp>R</scp>egistry. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 247-254.	0.9	14
447	Sequencing robot-assisted extended pelvic lymph node dissection prior to radical prostatectomy: a step-by-step guide to exposure and efficiency. BJU International, 2016, 117, 192-198.	1.3	7
448	Prostate cancer detection on transrectal ultrasonographyâ€guided random biopsy despite negative realâ€time magnetic resonance imaging/ultrasonography fusionâ€guided targeted biopsy: reasons for targeted biopsy failure. BJU International, 2016, 118, 35-43.	1.3	86
449	Patient specific modeling of palpationâ€based prostate cancer diagnosis: effects of pelvic cavity anatomy and intrabladder pressure. International Journal for Numerical Methods in Biomedical Engineering, 2016, 32, e02734.	1.0	5
450	Prostate cancer diagnosis by optical coherence tomography: First results from a needle based optical platform for tissue sampling. Journal of Biophotonics, 2016, 9, 490-498.	1.1	24
451	Index lesion characterization by ¹¹Câ€Choline PET/CT and Apparent Diffusion Coefficient parameters at 3 Tesla MRI in primary prostate carcinoma. Prostate, 2016, 76, 3-12.	1.2	9
452	Editorial Comment to Relationship between androgen deprivation therapy and communityâ€acquired respiratory infections in patients with prostate cancer. International Journal of Urology, 2016, 23, 312-312.	0.5	0
453	Concomitant transrectal ultrasound-guided biopsy and transurethral resection of prostate in patients with urinary retention and elevated serum prostate-specific antigen levels. Journal of the Chinese Medical Association, 2016, 79, 605-608.	0.6	1
454	Integrating Patient Preference into Treatment Decisions for Men with Prostate Cancer at the Point of Care. Journal of Urology, 2016, 196, 1640-1644.	0.2	46
455	Prostate-Specific Antigen Screening: Time to Change the Dominant Forces on the Pendulum. Journal of Clinical Oncology, 2016, 34, 3499-3501.	0.8	7
456	Label-Free Detection of AR-V7 mRNA in Prostate Cancer Using Yb₂Ti₂O₇â€"Based Electrolyte-Insulator-Semiconductor Biosensors. Journal of the Electrochemical Society, 2016, 163, B710-B717.	1.3	10
457	The very-high-risk prostate cancer: a contemporary update. Prostate Cancer and Prostatic Diseases, 2016, 19, 340-348.	2.0	29
458	Cessation of long-term adjuvant androgen deprivation therapy after radical prostatectomy: is it feasible?. Japanese Journal of Clinical Oncology, 2016, 46, 1143-1147.	0.6	1
459	Extreme hypofractionation for early prostate cancer: Biology meets technology. Cancer Treatment Reviews, 2016, 50, 48-60.	3.4	40
460	Predicting survival in nodeâ€positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multiâ€institutional database. International Journal of Urology, 2016, 23, 1000-1008.	0.5	8
461	Recovery of urinary continence after radical prostatectomy. Expert Review of Anticancer Therapy, 2016, 16, 1039-1052.	1.1	8

#	Article	IF	Citations
462	Efficacy of vacuum erectile devices (VEDs) after radical prostatectomy: the initial Irish experience of a dedicated VED clinic. International Journal of Impotence Research, 2016, 28, 205-208.	1.0	10
463	Impact of an endorectal coil for 1H-magnetic resonance spectroscopy of the prostate at 3.0T in comparison to 1.5T: Do we need an endorectal coil?. European Journal of Radiology, 2016, 85, 1432-1438.	1.2	4
464	Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center. Acta OncolÃ³gica, 2016, 55, 1456-1460.	0.8	10
465	Stratified analysis of 800 Asian patients after robotâ€assisted radical prostatectomy with a median 64 months of follow up. International Journal of Urology, 2016, 23, 765-774.	0.5	9
466	Beyond penile cancer, is there a role for sentinel node biopsy in urological malignancies?. Clinical and Translational Imaging, 2016, 4, 395-410.	1.1	11
467	Penile rehabilitation for post-prostatectomy erectile dysfunction. The Cochrane Library, 0, , .	1.5	12
468	Evaluation of predictors of unfavorable pathological features in men eligible for active surveillance using radical prostatectomy specimens: a multi-institutional study. Japanese Journal of Clinical Oncology, 2016, 46, 1-6.	0.6	6
469	Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells. Scientific Reports, 2016, 6, 34796.	1.6	40
470	Incorporating multiparametric MRI staging and the new histological Grade Group system improves risk-stratified detection of bone metastasis in prostate cancer. British Journal of Cancer, 2016, 115, 1285-1288.	2.9	12
471	Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ, The, 2016, 352, i851.	3.0	180
472	Rationale for local treatment in the management of metastatic prostate cancer. Current Opinion in Supportive and Palliative Care, 2016, 10, 266-272.	0.5	6
473	Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer. Medicine (United States), 2016, 95, e4326.	0.4	23
474	Lymph node dissection for renal cell carcinoma. Current Opinion in Urology, 2016, 26, 424-431.	0.9	11
475	Differences in Patient Characteristics Among Men Choosing Open or Robot-Assisted Radical Prostatectomy in Contemporary Practice at a European High-Volume Center. Urologia Internationalis, 2016, 97, 8-15.	0.6	5
476	Significance and outcome of nuclear anaplasia and mitotic index in prostatic adenocarcinomas. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 430.e9-430.e16.	0.8	0
477	Laparoscopic sentinel lymph node dissection in prostate cancer patients: the additional value depends on preoperative data. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1849-1856.	3.3	3
478	Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c-T2N0M0 prostate cancer. International Journal of Clinical Oncology, 2016, 21, 783-790.	1.0	11
479	Long-term quality of life among localised prostate cancer survivors: QALIPRO population-based study. European Journal of Cancer, 2016, 63, 143-153.	1.3	27

#	Article	IF	Citations
480	Integration of multiparametric MRI into active surveillance of prostate cancer. Future Oncology, 2016, 12, 2513-2529.	1.1	6
481	Descriptive Technique and Initial Results for Robotic Radical Perineal Prostatectomy. Urology, 2016, 94, 129-138.	0.5	51
482	Use of individual containers for prostate biopsy samples: Do we gain diagnostic performance?. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2016, 40, 224-228.	0.2	0
483	Prospective assessment of time-dependent changes in quality of life of Japanese patients with prostate cancer following robot-assisted radical prostatectomy. Journal of Robotic Surgery, 2016, 10, 201-207.	1.0	19
484	Resultados patolÃ³gicos y agresividad del cÃ¡ncer de prÃ³stata de bajo riesgo en los hombres del norte de Ã₹rica. Actas UrolÃ³gicas EspaÃ±olas, 2016, 40, 556-563.	0.3	0
485	Erectile Function Recovery After Nerve-Sparing Radical Prostatectomy for Prostate Cancer: Is Back to Baseline Status Enough for Patient Satisfaction?. Journal of Sexual Medicine, 2016, 13, 669-678.	0.3	15
486	Human Prostate Tissue-derived Extracellular Matrix as a Model of Prostate Microenvironment. European Urology Focus, 2016, 2, 400-408.	1.6	8
487	Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia. European Urology, 2016, 69, 831-833.	0.9	8
488	PD30-08 INTRAOPERATIVE FROZEN SECTION MONITORING DURING NERVE-SPARING RADICAL PROSTATECTOMY: EVALUATION OF PARTIAL SECONDARY RESECTION OF NEUROVASCULAR BUNDLES AND ITS EFFECT ON ONCOLOGIC AND FUNCTIONAL OUTCOME. Journal of Urology, 2016, 195, .	0.2	0
489	Australian patterns of prostate cancer care: Are they evolving?. Prostate International, 2016, 4, 20-24.	1.2	8
490	The most suitable guidelines for performing bone scans in prostate cancer staging â€“ One southern Taiwan medical center's results. Urological Science, 2016, 27, 208-211.	0.2	2
491	UHRF1 overexpression is involved in cell proliferation and biochemical recurrence in prostate cancer after radical prostatectomy. Journal of Experimental and Clinical Cancer Research, 2016, 35, 34.	3.5	28
492	Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2114-2121.	3.3	302
494	MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy. European Radiology, 2016, 26, 2252-2260.	2.3	55
495	Significance of erection hardness score as a diagnostic tool to assess erectile function recovery in Japanese men after robot-assisted radical prostatectomy. Journal of Robotic Surgery, 2016, 10, 221-226.	1.0	18
496	Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group. International Journal of Cancer, 2016, 138, 1388-1400.	2.3	216
497	Improving multivariable prostate cancer risk assessment using the Prostate Health Index. BJU International, 2016, 117, 409-417.	1.3	39
498	European Randomised Study of Screening for Prostate Cancer (<scp>ERSPC</scp>) risk calculators significantly outperform the Prostate Cancer Prevention Trial (<scp>PCPT</scp>) 2.0 in the prediction of prostate cancer: a multiâ€institutional study. BJU International, 2016, 118, 706-713.	1.3	60

#	Article	IF	Citations
499	Significant reduction in positive surgical margin rate after laparoscopic radical prostatectomy by application of the modified surgical margin recommendations of the 2009 International Society of Urological Pathology consensus. BJU International, 2016, 118, 750-757.	1.3	10
501	A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. European Urology, 2016, 69, 788-794.	0.9	140
502	Prostate Cancer Registries: Current Status and Future Directions. European Urology, 2016, 69, 998-1012.	0.9	56
503	Integrated analysis of the prostate cancer smallâ€nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. Molecular Oncology, 2016, 10, 693-703.	2.1	48
504	68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. European Urology, 2016, 70, 553-557.	0.9	248
505	The Role of Positron Emission Tomography With 68Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy. Urology, 2016, 95, 11-15.	0.5	20
506	Prostate cancer screening in Switzerland: 20-year trends and socioeconomic disparities. Preventive Medicine, 2016, 82, 83-91.	1.6	38
507	CaracterÃsticas de los casos incidentes de cÃ¡ncer de prÃ³stata en los Ãºltimos 5 aÃ±os en un hospital de tercer nivel en MÃ©xico. Revista Mexicana De Urologia, 2016, 76, 76-80.	0.0	3
508	The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort. Clinical and Translational Oncology, 2016, 18, 1026-1033.	1.2	2
509	Impact of multiparametric magnetic resonance imaging on risk group assessment of patients with prostate cancer addressed to external beam radiation therapy. European Journal of Radiology, 2016, 85, 764-770.	1.2	12
510	Nodal Clearance Rate and Long-Term Efficacy ofÂIndividualized Sentinel Nodeâ€“Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 263-271.	0.4	6
511	Limitations of Elastography Based Prostate Biopsy. Journal of Urology, 2016, 195, 1731-1736.	0.2	20
512	Reducing the Harm of Prostate Cancer Screening: Repeated Prostate-Specific Antigen Testing. Mayo Clinic Proceedings, 2016, 91, 17-22.	1.4	30
513	Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach. Journal of Cancer Research and Clinical Oncology, 2016, 142, 849-858.	1.2	19
514	Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans. European Urology, 2016, 69, 1129-1134.	0.9	54
515	Characteristics of Anteriorly Located Prostate Cancer and the Usefulness of Multiparametric Magnetic Resonance Imaging for Diagnosis. Journal of Urology, 2016, 196, 367-373.	0.2	25
516	Bladder Instillation Therapy With Hyaluronic Acid and Chondroitin Sulfate Improves Symptoms of Postradiation Cystitis: Prospective Pilot Study. Clinical Genitourinary Cancer, 2016, 14, 444-449.	0.9	27
517	T2- and diffusion-weighted magnetic resonance imaging at 3 T for the detection of prostate cancer with and without endorectal coil: An intraindividual comparison of image quality and diagnostic performance. European Journal of Radiology, 2016, 85, 1075-1084.	1.2	35

#	Article	IF	Citations
518	The implications of ageing and life expectancy in prostate cancer treatment. Nature Reviews Urology, 2016, 13, 289-295.	1.9	7
521	Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer. Radiotherapy and Oncology, 2016, 118, 141-147.	0.3	16
522	Radioimmunotherapy for Prostate Cancerâ€"Current Status and Future Possibilities. Seminars in Nuclear Medicine, 2016, 46, 165-179.	2.5	23
523	Can DW-MRI, with its ADC values, be a reliable predictor of biopsy outcome in patients with suspected prostate cancer?. Abdominal Radiology, 2016, 41, 926-933.	1.0	12
524	The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening. Urology, 2016, 91, 12-18.	0.5	54
525	Three-dimensional transrectal ultrasound guided high-dose-rate prostate brachytherapy: A comparison of needle segmentation accuracy with two-dimensional image guidance. Brachytherapy, 2016, 15, 231-239.	0.2	13
526	Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database. European Urology, 2016, 70, 837-845.	0.9	178
527	Multimodal hybrid imaging agents for sentinel node mapping as a means to (re)connect nuclear medicine to advances made in robot-assisted surgery. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1278-1287.	3.3	53
528	Intermittent androgen deprivation in prostate cancer cases with biochemical progression after radical prostatectomy: Are we ready to treat?. Critical Reviews in Oncology/Hematology, 2016, 99, 351-361.	2.0	2
529	Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F]fluorocyclobutanecarboxylic) Tj ETQq1 1 0.784314 rgBT /Overlo Oncology, 2016, 46, 152-162.	0.6	41
530	No Detrimental Effect of a Positive Family History on Long-Term Outcomes Following Radical Prostatectomy. Journal of Urology, 2016, 195, 343-348.	0.2	10
531	A prospective comparative analysis of the accuracy of HistoScanning and multiparametric magnetic resonance imaging in the localization of prostate cancer among men undergoing radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 3.e1-3.e8.	0.8	8
532	Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies?. International Urology and Nephrology, 2016, 48, 671-680.	0.6	13
533	New Clinical Indications for 18 F/ 11 C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. European Urology, 2016, 70, 161-175.	0.9	184
534	Developing a model for forecasting Gleason scoreÂâ‰¥7 in potential prostate cancer patients to reduce unnecessary prostate biopsies. International Urology and Nephrology, 2016, 48, 535-540.	0.6	11
536	Targeted MRI-guided prostate biopsy: are two biopsy cores per MRI-lesion required?. European Radiology, 2016, 26, 3858-3864.	2.3	21
537	Validation of contemporary guidelines for bone scintigraphy in prostate cancer staging: A prospective study in patients undergoing radical prostatectomy. Scandinavian Journal of Urology, 2016, 50, 29-32.	0.6	5
538	The Problem Is Not What to Do with Indolent and Harmless Prostate Cancerâ€"The Problem Is How to Avoid Finding These Cancers. European Urology, 2016, 70, 547-548.	0.9	18

#	Article	IF	Citations
539	Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy. Prostate Cancer and Prostatic Diseases, 2016, 19, 209-215.	2.0	20
541	The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival. Radiotherapy and Oncology, 2016, 118, 131-135.	0.3	16
542	Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study. Annals of Oncology, 2016, 27, 460-466.	0.6	13
543	Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 119.e11-119.e18.	0.8	14
544	Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 234.e13-234.e19.	0.8	15
545	Repeatability of Quantitative ¹⁸F-Fluoromethylcholine PET/CT Studies in Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 721-727.	2.8	22
546	Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2016, 70, 21-30.	0.9	222
547	Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry. Modern Pathology, 2016, 29, 157-165.	2.9	31
548	Combined Chemohormonal Strategy in Hormone-Sensitive Prostate Cancer: A Pooled Analysis of Randomized Studies. Clinical Genitourinary Cancer, 2016, 14, 203-209.	0.9	6
549	Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer. International Journal of Clinical Oncology, 2016, 21, 148-155.	1.0	14
550	Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. European Urology, 2016, 69, 592-598.	0.9	212
552	Orgasmic Dysfunction After Robot-assisted Versus Open Radical Prostatectomy. European Urology, 2016, 70, 223-226.	0.9	36
553	Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database. World Journal of Urology, 2016, 34, 517-523.	1.2	31
554	Prostatitis, other genitourinary infections and prostate cancer: results from a population-based caseâ€“control study. World Journal of Urology, 2016, 34, 425-430.	1.2	17
555	Extended versus limited pelvic lymph node dissection during bilateral nerve-sparing radical prostatectomy and its effect on continence and erectile function recovery: long-term results and trifecta rates of a comparative analysis. World Journal of Urology, 2016, 34, 811-820.	1.2	18
556	Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 41-45.	2.8	45
559	Should Prebiopsy Multiparametric Magnetic Resonance Imaging be Offered to All Biopsy-naÃ¯ve Men Undergoing Prostate Biopsy?. European Urology, 2016, 69, 426-427.	0.9	7
561	Pin1 promotes prostate cancer cell proliferation and migration through activation of Wnt/Î²-catenin signaling. Clinical and Translational Oncology, 2016, 18, 792-797.	1.2	25

#	Article	IF	Citations
562	Intraoperative frozen section monitoring during nerve-sparing radical prostatectomy: evaluation of partial secondary resection of neurovascular bundles and its effect on oncologic and functional outcome. World Journal of Urology, 2016, 34, 229-236.	1.2	12
563	The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer. Journal of Urology, 2016, 195, 1428-1435.	0.2	124
564	Erectile function after radical prostatectomy: Do patients return to baseline?. Scandinavian Journal of Urology, 2016, 50, 160-163.	0.6	7
565	Impact of magnetic resonance imaging-guided prostate biopsy in the supine position on the detection of significant prostate cancer in an inhomogeneous patient cohort. Scandinavian Journal of Urology, 2016, 50, 110-115.	0.6	4
566	Additional elastography-targeted biopsy improves the agreement between biopsy Gleason grade and Gleason grade at radical prostatectomy. World Journal of Urology, 2016, 34, 805-810.	1.2	7
567	Association between long-term erectile dysfunction and biochemical recurrence after permanent seed I125implant brachytherapy for prostate cancer. A longitudinal study of a single-institution. Aging Male, 2016, 19, 15-19.	0.9	5
568	The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy. World Journal of Urology, 2016, 34, 525-532.	1.2	93
569	â€œHit the primaryâ€• A paradigm shift in the treatment of metastatic prostate cancer?. Critical Reviews in Oncology/Hematology, 2016, 97, 231-237.	2.0	18
570	Relationship between non-suspicious MRI and insignificant prostate cancer: results from a monocentric study. World Journal of Urology, 2016, 34, 673-678.	1.2	14
571	Comparisons of Oncological and Functional Outcomes Between Primary Whole-Gland Cryoablation and High-Intensity Focused Ultrasound for Localized Prostate Cancer. Annals of Surgical Oncology, 2016, 23, 328-334.	0.7	24
572	Aptamerâ€“MIP hybrid receptor for highly sensitive electrochemical detection of prostate specific antigen. Biosensors and Bioelectronics, 2016, 75, 188-195.	5.3	231
573	Comparison of patient comfort between MR-guided in-bore and MRI/ultrasound fusion-guided prostate biopsies within a prospective randomized trial. World Journal of Urology, 2016, 34, 215-220.	1.2	23
574	Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. European Urology, 2016, 70, 233-245.	0.9	466
575	Laparoscopic versus Robotic-Assisted Radical Prostatectomy for the Treatment of Localised Prostate Cancer: A Systematic Review. Urologia Internationalis, 2016, 96, 373-378.	0.6	68
576	Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial. European Urology, 2016, 69, 419-425.	0.9	157
577	Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. European Urology, 2016, 69, 214-220.	0.9	126
578	Six-core versus twelve-core prostate biopsy: a retrospective study comparing accuracy, oncological outcomes and safety. Irish Journal of Medical Science, 2016, 185, 219-223.	0.8	4
579	Diffusionâ€weighted imaging predicts upgrading of Gleason score in biopsyâ€proven low grade prostate cancers. BJU International, 2017, 119, 57-66.	1.3	20

#	Article	IF	Citations
580	Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins. World Journal of Urology, 2017, 35, 199-206.	1.2	19
581	Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multiâ€institutional study. BJU International, 2017, 119, 234-238.	1.3	16
582	Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy. Journal of Robotic Surgery, 2017, 11, 37-45.	1.0	22
583	Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. European Urology, 2017, 71, 319-327.	0.9	74
584	Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer. European Urology, 2017, 71, 249-256.	0.9	73
585	Imaging of Prostate Cancer Using 18 F-Choline PET/Computed Tomography. PET Clinics, 2017, 12, 173-184.	1.5	6
586	Three-minute SPECT/CT is sufficient for the assessment of bone metastasis as add-on to planar bone scintigraphy: prospective head-to-head comparison to 11-min SPECT/CT. EJNMMI Research, 2017, 7, 1.	1.1	64
587	Glycoproteins functionalized natural and synthetic polymers for prospective biomedical applications: A review. International Journal of Biological Macromolecules, 2017, 98, 748-776.	3.6	40
588	Implementation of a Surgeon-Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical Prostatectomy. Journal of Urology, 2017, 197, 1245-1250.	0.2	16
589	How do patients choose between active surveillance, radical prostatectomy, and radiotherapy? The effect of a preference-sensitive decision aid on treatment decision making for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 37.e9-37.e17.	0.8	25
590	Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer. Clinical and Translational Oncology, 2017, 19, 651-657.	1.2	75
591	Patterns of Care for Prostate Cancer Patients: Predictors of Care, But For Whom?. European Urology, 2017, 71, 738-739.	0.9	0
592	Effect of age on biochemical recurrence after radical prostatectomy. Kaohsiung Journal of Medical Sciences, 2017, 33, 91-95.	0.8	6
594	Prebiopsy mp-MRI Can Help to Improve the Predictive Performance in Prostate Cancer: A Prospective Study in 1,478 Consecutive Patients. Clinical Cancer Research, 2017, 23, 3692-3699.	3.2	18
595	68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 941-949.	3.3	247
596	Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer. BMC Urology, 2017, 17, 12.	0.6	25
597	Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study. Prostate Cancer and Prostatic Diseases, 2017, 20, 197-202.	2.0	35
598	Imaging of Prostate Cancer Using 11 C-Choline PET/Computed Tomography. PET Clinics, 2017, 12, 137-143.	1.5	2

#	Article	IF	Citations
599	Individual and Population-Based Screening. , 2017, , 43-55.		0
600	The addition of a sagittal image fusion improves the prostate cancer detection in a sensor-based MRI /ultrasound fusion guided targeted biopsy. BMC Urology, 2017, 17, 7.	0.6	8
601	The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. European Urology, 2017, 72, 84-109.	0.9	348
602	Additional value of magnetic resonance-targeted biopsies to standard transrectal ultrasound-guided biopsies for detection of clinically significant prostate cancer. Scandinavian Journal of Urology, 2017, 51, 107-113.	0.6	5
603	Anatomical Retzius-space preservation is associated with lower incidence of postoperative inguinal hernia development after robot-assisted radical prostatectomy. Hernia: the Journal of Hernias and Abdominal Wall Surgery, 2017, 21, 555-561.	0.9	30
604	â€œIn-boreâ€•MRI-guided Prostate Biopsy Using an Endorectal Nonmagnetic Device: A Prospective Study of 70 Consecutive Patients. Clinical Genitourinary Cancer, 2017, 15, 417-427.	0.9	24
605	Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer. Quality of Life Research, 2017, 26, 1635-1645.	1.5	24
606	Gallium-68 Prostate-Specific Membrane Antigen PET Imaging. PET Clinics, 2017, 12, 219-234.	1.5	29
607	Detection Efficacy of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria. Journal of Nuclear Medicine, 2017, 58, 1081-1087.	2.8	66
609	PET/Computed Tomography for Radiation Therapy Planning of Prostate Cancer. PET Clinics, 2017, 12, 257-267.	1.5	4
610	Extended versus Standard Pelvic Lymph Node Dissection in Radical Prostatectomy on Oncological and Functional Outcomes: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2017, 24, 2047-2054.	0.7	39
611	Long-term cancer control outcomes of robot-assisted radical prostatectomy for prostate cancer treatment: a meta-analysis. International Urology and Nephrology, 2017, 49, 995-1005.	0.6	19
612	Cost-Effectiveness Comparison of Imaging-Guided Prostate Biopsy Techniques: Systematic Transrectal Ultrasound, Direct In-Bore MRI, and Image Fusion. American Journal of Roentgenology, 2017, 208, 1058-1063.	1.0	58
613	Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study. International Urology and Nephrology, 2017, 49, 811-816.	0.6	10
614	Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). Journal of Magnetic Resonance Imaging, 2017, 46, 1089-1095.	1.9	75
615	Radical Prostatectomy for Locally Advanced Prostate Cancersâ€”Review of Literature. Indian Journal of Surgical Oncology, 2017, 8, 175-180.	0.3	5
616	Collecte et prise en charge de certaines comorbiditÃ©s et facteurs de risque associÃ©s dans le cadre des rhumatismes inflammatoires chroniques dans la pratique quotidienne en France. Revue Du Rhumatisme (Edition Francaise), 2017, 84, 123-131.	0.0	0
617	Prevalence and Predicting Factors for Commonly Neglected Sexual Side Effects to External-Beam Radiation Therapy for Prostate Cancer. Journal of Sexual Medicine, 2017, 14, 558-565.	0.3	30

#	Article	IF	Citations
618	Optimization of 18 F-Choline PET/CT acquisition in prostate cancer: Preliminary results concerning the length of the acquisition. Medecine Nucleaire, 2017, 41, 15-20.	0.2	0
619	miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis. Cancer Letters, 2017, 395, 53-62.	3.2	80
620	Role of radical prostatectomy in metastatic prostate cancer: A review. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 125-134.	0.8	26
621	Incidence, grade and distribution of prostate cancer following transperineal template-guided mapping biopsy in patients with atypical small acinar proliferation. World Journal of Urology, 2017, 35, 1009-1013.	1.2	10
622	Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?. Cancer Treatment Reviews, 2017, 55, 173-180.	3.4	3
623	PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer. American Journal of Roentgenology, 2017, 209, W1-W9.	1.0	56
624	The application of a bluntâ€tip needle to suture the dorsal venous complex in robotâ€assisted laparoscopic radical prostatectomy. International Journal of Medical Robotics and Computer Assisted Surgery, 2017, 13, e1822.	1.2	2
625	Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy. European Urology, 2017, 72, 345-351.	0.9	16
626	Differences in Patient Characteristics among Men Choosing Open or Robot-Assisted Radical Prostatectomy in Contemporary Practice - Analysis of Surveillance, Epidemiology, and End Results Database. Urologia Internationalis, 2017, 98, 40-48.	0.6	15
627	PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1751-1776.	3.3	45
628	Late Genitourinary Toxicity Outcomes in 300 Prostate Cancer Patients Treated With Dose-escalated Image-guided Intensity-modulated Radiotherapy. Clinical Oncology, 2017, 29, 617-625.	0.6	13
629	Written information material and availability of sexual health care for men experiencing sexual dysfunction after prostate cancer treatment: An evaluation of Dutch urology and radiotherapy departments. European Journal of Cancer Care, 2017, 26, e12629.	0.7	10
630	The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information. International Journal of Clinical Practice, 2017, 71, e12943.	0.8	24
631	ACR Appropriateness Criteria Â® Prostate Cancerâ€"Pretreatment Detection, Surveillance, andÂStaging. Journal of the American College of Radiology, 2017, 14, S245-S257.	0.9	44
632	Comparative effectiveness of prostate cancer treatments for patient-centered outcomes. Medicine (United States), 2017, 96, e6790.	0.4	18
633	Transrectal ultrasound guided prostate biopsy in the era of increasing fluoroquinolone resistance: prophylaxis with single-dose ertapenem. World Journal of Urology, 2017, 35, 1681-1688.	1.2	14
634	Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy. Strahlentherapie Und Onkologie, 2017, 193, 692-699.	1.0	19
635	Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach. Prostate Cancer and Prostatic Diseases, 2017, 20, 311-317.	2.0	55

#	Article	IF	Citations
636	Atypical Small Acinar Proliferation and High-grade Prostatic Intraepithelial Neoplasia in the Era of Multiparametric Magnetic Resonance Imaging: A Contemporary Review. Urology, 2017, 107, 5-10.	0.5	7
637	Prospective comparison of the efficacy of caudal versus periprostatic nerve block, both with intrarectal local anesthesia, during transrectal ultrasonography-guided prostatic needle biopsy. Scandinavian Journal of Urology, 2017, 51, 245-250.	0.6	6
638	Newsworthiness vs scientific impact: are the most highly cited urology papers the most widely disseminated in the media?. BJU International, 2017, 120, 441-454.	1.3	42
639	Prostate cancer diagnosis: Efficacy of a simple electromagnetic MRI-TRUS fusion method to target biopsies. European Journal of Radiology, 2017, 86, 127-134.	1.2	12
640	Cell-cycle Progression-score Might Improve the Current Risk Assessment in Newly Diagnosed Prostate Cancer Patients. Urology, 2017, 102, 73-78.	0.5	19
641	Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. Practical Radiation Oncology, 2017, 7, e125-e133.	1.1	18
642	Diffusion-Weighted Genitourinary Imaging. Radiologic Clinics of North America, 2017, 55, 393-411.	0.9	7
643	The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis. Medical Oncology, 2017, 34, 1.	1.2	55
644	The Y-located proto-oncogene TSPY exacerbates and its X-homologue TSPX inhibits transactivation functions of androgen receptor and its constitutively active variants. Human Molecular Genetics, 2017, 26, 901-912.	1.4	22
645	The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. Nuclear Medicine Communications, 2017, 38, 149-155.	0.5	32
646	Clinical efficacy of transrectal ultrasound-guided prostate biopsy in men younger than 50 years old with an elevated prostate-specific antigen concentration (>4.0 ng/mL). Journal of the Chinese Medical Association, 2017, 80, 413-418.	0.6	2
647	Significantly altered expression of miR-511-3p and its target AKT3 has negative prognostic value in human prostate cancer. Biochimie, 2017, 140, 66-72.	1.3	19
648	Accuracy of shear wave elastography for the diagnosis of prostate cancer: A meta-analysis. Scientific Reports, 2017, 7, 1949.	1.6	41
649	Predictive Parameters Identifying Men Eligible for a Sole MRI/Ultrasound Fusion-Guided Targeted Biopsy without an Additional Systematic Biopsy. Urologia Internationalis, 2017, 98, 15-21.	0.6	6
650	Heterogeneous oncologic outcomes according to surgical pathology in high-risk prostate cancer: implications for better risk stratification and preoperative prediction of oncologic outcomes. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1871-1878.	1.2	1
651	Contemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer and Prostatic Diseases, 2017, 20, 283-288.	2.0	32
652	The Non-Coding Transcriptome of Prostate Cancer: Implications for Clinical Practice. Molecular Diagnosis and Therapy, 2017, 21, 385-400.	1.6	18
653	68Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review. Molecular and Clinical Oncology, 2017, 7, 67-72.	0.4	2

#	Article	IF	Citations
654	Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer. Current Urology Reports, 2017, 18, 55.	1.0	15
655	Vertebral and femoral bone mineral density and bone strength in prostate cancer patients assessed in phantomless PET/CT examinations. Bone, 2017, 101, 62-69.	1.4	28
656	Predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer. Cancer Science, 2017, 108, 663-670.	1.7	19
657	Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1463-1472.	3.3	51
658	Is suspicious upstaging on multiparametric magnetic resonance imaging useful in improving the reliability of Prostate Cancer Research International Active Surveillance (PRIAS) criteria? Use of the K-CaP registry. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 459.e7-459.e13.	0.8	5
659	The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling. Oncogenesis, 2017, 6, e342-e342.	2.1	68
660	A prospective randomized controlled trial for assessment of perineal hydrodissection technique for nervesparing robot assisted radical prostatectomy. International Journal of Medical Robotics and Computer Assisted Surgery, 2017, 13, e1835.	1.2	4
661	Acetonitrile extract of Salvia miltiorrhiza Radix exhibits growth-inhibitory effects on prostate cancer cells through the induction of cell cycle arrest and apoptosis. Oncology Letters, 2017, 13, 2921-2928.	0.8	9
662	Healthcare policy and urologic practice. Current Opinion in Urology, 2017, 27, 348-353.	0.9	1
663	Adenosine Signaling Pathways as Potential Therapeutic Targets in Prostate Cancer Disease. , 2017, , 93-107.		1
664	External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients. Prostate, 2017, 77, 928-933.	1.2	8
665	Prospective Evaluation of PI-RADSâ„¢ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System. Journal of Urology, 2017, 198, 583-590.	0.2	127
666	Prostate cancer before renal transplantation: A multicentre study. Progres En Urologie, 2017, 27, 166-175.	0.3	5
667	Role of 18 F-Choline PET/CT in guiding biopsy in patients with risen PSA levels and previous negative biopsy for prostate cancer. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2017, 36, 241-246.	0.0	3
668	Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes. Journal of Urology, 2017, 198, 335-344.	0.2	22
669	Overexpression of SOX18 promotes prostate cancer progression via the regulation of TCF1, c-Myc, cyclin D1 and MMP-7. Oncology Reports, 2017, 37, 1045-1051.	1.2	28
670	What does it cost Medicare to diagnose and treat men with localized prostate cancer in the first year?. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 152-159.	0.7	5
671	Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediateâ€risk localised prostate cancer â€“ results from a large contemporaneous cohort. BJU International, 2017, 120, E59-E63.	1.3	8

#	Article	IF	Citations
672	Nonâ€medical prescribing in prostate cancer care: a case study reflection. International Journal of Urological Nursing, 2017, 11, 106-117.	0.1	4
673	ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancerâ€"results from an international multicenter study. Prostate Cancer and Prostatic Diseases, 2017, 20, 271-275.	2.0	25
674	Risk stratification: a tool to predict the course of active surveillance for localized prostate cancer?. BJU International, 2017, 120, 212-218.	1.3	9
675	Potential of long nonâ€coding RNAs in cancer patients: From biomarkers to therapeutic targets. International Journal of Cancer, 2017, 140, 1955-1967.	2.3	417
676	Electrochemical bioassay development for ultrasensitive aptasensing of prostate specific antigen. Biosensors and Bioelectronics, 2017, 91, 284-292.	5.3	104
677	Lower use of prostate specific antigen testing by cigarette smokersâ€"Another possible explanation for the unfavorable prostate cancer (PCA) specific prognosis in smokers?. Cancer Epidemiology, 2017, 46, 34-35.	0.8	2
678	Beyond the Briganti nomogram: Individualisation of lymphadenectomy using selective sentinel node biopsy during radical prostatectomy for prostate cancer. Actas UrolÃ³gicas EspaÃ±olas (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4		
679	Active surveillance for low-risk prostate cancer in Austria: the online registry of the QualitÃtspartnerschaft Urologie (QuapU). Wiener Klinische Wochenschrift, 2017, 129, 375-379.	1.0	0
680	Salvage Lymph Node Dissection for Node-only Recurrence of Prostate Cancer: Ready for Prime Time?. European Urology, 2017, 71, 693-694.	0.9	9
681	Incremental value of high b value diffusion-weighted magnetic resonance imaging at 3-T for prediction of extracapsular extension in patients with prostate cancer: preliminary experience. Radiologia Medica, 2017, 122, 228-238.	4.7	9
682	Dosimetric feasibility of ablative dose escalated focal monotherapy with MRI-guided high-dose-rate (HDR) brachytherapy for prostate cancer. Radiotherapy and Oncology, 2017, 122, 103-108.	0.3	8
683	IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer. British Journal of Cancer, 2017, 117, 1600-1606.	2.9	35
684	Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis. Medical Oncology, 2017, 34, 190.	1.2	13
685	Cancers of the Endocrine System. , 2017, , 499-530.		1
686	Pathological Concordance between Prostate Biopsies and Radical Prostatectomy Using Transperineal Sector Mapping Biopsies: Validation and Comparison with Transrectal Biopsies. Urologia Internationalis, 2017, 99, 168-176.	0.6	17
687	A role of human beta defensinâ€1 in predicting prostatic adenocarcinoma in cases of falseâ€negative biopsy. Apmis, 2017, 125, 1063-1069.	0.9	5
688	Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2179-2188.	3.3	35
689	A urinary biomarkerâ€based risk score correlates with multiparametric MRI for prostate cancer detection. Prostate, 2017, 77, 1401-1407.	1.2	61

#	Article	IF	Citations
690	The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer. Nuclear Medicine Communications, 2017, 38, 956-963.	0.5	29
691	Long nonâ€coding RNAs and prostate cancer. Cancer Science, 2017, 108, 2107-2114.	1.7	107
692	Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer. World Journal of Urology, 2017, 35, 1849-1855.	1.2	35
693	Sub-differentiating equivocal PI-RADS-3 lesions in multiparametric magnetic resonance imaging of the prostate to improve cancer detection. European Journal of Radiology, 2017, 95, 307-313.	1.2	40
694	Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study. European Journal of Surgical Oncology, 2017, 43, 2193-2199.	0.5	9
696	Magnetic Resonance Imagingâ€"Based Prostate-Specific Antigen Density for Prediction of Gleason Score Upgrade in Patients With Low-Risk Prostate Cancer on Initial Biopsy. Journal of Computer Assisted Tomography, 2017, 41, 731-736.	0.5	6
697	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. Journal of Nuclear Medicine, 2017, 58, 67S-76S.	2.8	163
698	The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICAREÂ® Military Database. Journal of Urology, 2017, 198, 1295-1300.	0.2	10
699	Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients postâ€surgery. Prostate, 2017, 77, 1288-1300.	1.2	15
700	Variation in Locoregional Prostate Cancer Care and Treatment Trends at Commission on Cancer Designated Facilities: A National Cancer Data Base Analysis 2004 to 2013. Clinical Genitourinary Cancer, 2017, 15, e955-e968.	0.9	17
701	Role of 18 F-Choline PET/CT in guiding biopsy in patients with risen PSA levels and previous negative biopsy for prostate cancer. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2017, 36, 241-246.	0.1	0
704	Diagnosis of human prostate carcinoma cancer stem cells enriched from DU145 cell lines changes with microscopic texture analysis in radiation and hyperthermia treatment using run-length matrix. International Journal of Radiation Biology, 2017, 93, 1248-1256.	1.0	4
705	Identifying intermediate-risk candidates for active surveillance of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 605.e1-605.e8.	0.8	20
706	Drug-Eluting Biopsy Needle as a Novel Strategy for Antimicrobial Prophylaxis in Transrectal Prostate Biopsy. Technology in Cancer Research and Treatment, 2017, 16, 1038-1043.	0.8	3
707	Single-step homogeneous immunoassay for detecting prostate-specific antigen using dual-color light scattering of metal nanoparticles. Analyst, The, 2017, 142, 3484-3491.	1.7	13
708	Primary Treatment Choice Over Time and Relative Survival of Prostate Cancer Patients: Influence of Age, Grade, and Stage. Oncology Research and Treatment, 2017, 40, 484-489.	0.8	7
709	Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study. Urology, 2017, 108, 135-141.	0.5	10
710	Toxicity, Adverse Events, and Quality of Life Associated with the Treatment of Metastatic Castration-Resistant Prostate Cancer. Current Urology, 2017, 10, 169-173.	0.4	12

#	Article	IF	Citations
711	Can Anterior Prostatic Fat Harbor Prostate Cancer Metastasis? A Prospective Cohort Study. Current Urology, 2017, 10, 182-185.	0.4	6
712	Long-term outcomes of I-Stop TOMSâ„¢ male sling implantation for post-prostatectomy incontinence management. Progres En Urologie, 2017, 27, 1084-1090.	0.3	13
713	Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP). BMJ Open, 2017, 7, e015994.	0.8	11
714	The prostate cancer screening clinic in the Bahamas: a model for low- and middle-income countries. Cancer Causes and Control, 2017, 28, 1187-1193.	0.8	4
715	Multiparametric MRI Evaluation of Tumor Recurrence in the Posttreatment Prostate. Contemporary Diagnostic Radiology, 2017, 40, 1-5.	0.1	0
716	The Role of Local Therapy for Oligometastatic Prostate Cancer. Urologic Clinics of North America, 2017, 44, 623-633.	0.8	11
717	Label-Free MIP Sensors for Protein Biomarkers. Springer Series on Chemical Sensors and Biosensors, 2017, , 291-321.	0.5	4
718	Multiparametric dynamic contrast-enhanced ultrasound imaging of prostate cancer. European Radiology, 2017, 27, 3226-3234.	2.3	38
719	Quality of Working Life of cancer survivors: associations with health- and work-related variables. Supportive Care in Cancer, 2017, 25, 1475-1484.	1.0	25
720	Transrectal real-time tissue elastography targeted biopsy coupled with peak strain index improves the detection of clinically important prostate cancer. Oncology Letters, 2017, 14, 210-216.	0.8	8
721	Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution. International Journal of Clinical Oncology, 2017, 22, 1087-1093.	1.0	16
722	Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer, 2017, 17, 361.	1.1	67
723	Diabetes and beta-adrenergic blockage are risk factors for metastatic prostate cancer. World Journal of Surgical Oncology, 2017, 15, 50.	0.8	6
724	Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer â€“ focus on overall survival. Radiation Oncology, 2017, 12, 98.	1.2	19
725	Incremental diagnostic utility of systematic double-bed SPECT/CT for bone scintigraphy in initial staging of cancer patients. Cancer Imaging, 2017, 17, 16.	1.2	24
726	¹⁷⁷Lu-PSMA Radioligand Therapy for Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1196-1200.	2.8	159
727	Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2025-2038.	1.2	12
728	Optimal screening interval for men with low baseline prostate-specific antigen levels (â‰¤1.0Âng/mL) in a prostate cancer screening program. World Journal of Urology, 2017, 35, 579-586.	1.2	1

#	Article	IF	Citations
729	A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy. International Urology and Nephrology, 2017, 49, 61-67.	0.6	9
730	The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer. Prostate Cancer and Prostatic Diseases, 2017, 20, 85-92.	2.0	48
731	Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with <scp>pN</scp>1 prostate cancer treated with radical prostatectomy. BJU International, 2017, 119, 717-723.	1.3	39
732	The role of adjuvant radiotherapy in pathologically lymph nodeâ€positive prostate cancer. Cancer, 2017, 123, 512-520.	2.0	48
733	Impact of postoperative phosphodiesterase type 5 inhibitor treatment on lower urinary tract symptoms after robot-assisted radical prostatectomy: a longitudinal study. Scandinavian Journal of Urology, 2017, 51, 33-37.	0.6	7
735	First report of robot-assisted transperineal fusion versus off-target biopsy in patients undergoing repeat prostate biopsy. World Journal of Urology, 2017, 35, 1023-1029.	1.2	15
736	New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8â€“10 Prostate Cancer. European Urology, 2017, 71, 907-912.	0.9	44
737	European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical Significance. Urology, 2017, 102, 85-91.	0.5	16
738	Full Neurovascular Sparing Extraperitoneal Robotic Radical Prostatectomy: Our Experience with PERUSIA Technique. Journal of Endourology, 2017, 31, 32-37.	1.1	30
739	Association between radical prostatectomy and risk of herpes zoster. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 337-342.	1.3	3
740	PET imaging for lymph node dissection in prostate cancer. World Journal of Urology, 2017, 35, 507-515.	1.2	9
741	Dynamic contrast-enhanced MRI for automatic detection of foci ï»¿of residual or recurrent disease after prostatectomy. Strahlentherapie Und Onkologie, 2017, 193, 13-21.	1.0	4
742	Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer. World Journal of Urology, 2017, 35, 1031-1036.	1.2	14
743	A PET/MRI study towards finding the optimal [18F]Fluciclovine PET protocol for detection and characterisation of primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 695-703.	3.3	25
744	Comparing High-Intensity Focal Ultrasound Hemiablation to Robotic Radical Prostatectomy in the Management of Unilateral Prostate Cancer: A Matched-Pair Analysis. Journal of Endourology, 2017, 31, 14-19.	1.1	39
745	Performance of PI-RADS version 1 versus version 2 regarding the relation with histopathological results. World Journal of Urology, 2017, 35, 687-693.	1.2	51
746	Primary Gleason pattern upgrading in contemporary patients with D'Amico lowâ€risk prostate cancer: implications for future biomarkers and imaging modalities. BJU International, 2017, 119, 692-699.	1.3	16
747	Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk. World Journal of Urology, 2017, 35, 587-593.	1.2	29

#	Article	IF	Citations
748	Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis. Abdominal Radiology, 2017, 42, 271-277.	1.0	17
749	The influence of prostateâ€specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7â€“10 prostate cancer in a repeat biopsy setting. BJU International, 2017, 119, 724-730.	1.3	66
750	Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA. Clinical Nutrition, 2017, 36, 672-679.	2.3	65
751	The Impact of Repeat Prostate Biopsies on Oncologic, Pathological and Perioperative Outcomes after Radical Prostatectomy. Journal of Urology, 2017, 197, 103-108.	0.2	7
752	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2017, 71, 618-629.	0.9	2,497
753	Clinical Translation of a Dual Integrin Î±_vÎ²₃â€“ and Gastrin-Releasing Peptide Receptorâ€“Targeting PET Radiotracer, ⁶⁸Ga-BBN-RGD. Journal of Nuclear Medicine, 2017, 58, 228-234.	2.8	76
754	Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naÃ¯ve Patients with Suspected Prostate Cancer. European Urology, 2017, 72, 282-288.	0.9	168
755	MR-based prognostic nomogram for prostate cancer after radical prostatectomy. Journal of Magnetic Resonance Imaging, 2017, 45, 586-596.	1.9	21
756	Unexplained Bone Pain Is an Independent Risk Factor for Bone Metastases in Newly Diagnosed Prostate Cancer: A Prospective Study. Urology, 2017, 99, 148-154.	0.5	6
757	Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. European Urology, 2017, 71, 274-280.	0.9	11
758	MÃ¡s allÃ¡ del nomograma de Briganti: individualizaciÃ³n de la linfadenectomÃa utilizando la biopsia selectiva del ganglio centinela durante la prostatectomÃa radical por cÃ¡ncer de prÃ³stata. Actas UrolÃ³gicas EspaÃ±olas, 2017, 41, 23-31.	0.3	1
760	Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nature Reviews Urology, 2017, 14, 15-25.	1.9	210
761	Use of Age and Medical Comorbidity to Assess Long-term Other-cause Mortality Risk in a Cohort of Men Undergoing Prostate Biopsy at an Academic Medical Center. Urology, 2017, 100, 169-174.	0.5	0
762	Safety of selective nerve sparing in high risk prostate cancer during robot-assisted radical prostatectomy. Journal of Robotic Surgery, 2017, 11, 129-138.	1.0	29
763	Comparison of perioperative, functional, and oncologic outcomes between standard laparoscopic and robotic-assisted radical prostatectomy: a systemic review and meta-analysis. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 1045-1060.	1.3	52
764	Lymph Node Fluorescence During Robot-Assisted Radical Prostatectomy With Indocyanine Green: Prospective Dosing Analysis. Clinical Genitourinary Cancer, 2017, 15, e529-e534.	0.9	25
765	The effect of an online support group on patients×³ treatment decisions for localized prostate cancer: An online survey. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 37.e19-37.e28.	0.8	32
767	Patient reported functional outcomes following robotic-assisted (RARP), laparoscopic (LRP), and open radical prostatectomies (ORP). Irish Journal of Medical Science, 2017, 186, 835-840.	0.8	10

#	Article	IF	Citations
768	Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound imageâ€fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU International, 2017, 120, 631-638.	1.3	104
769	Psychological impact of serial prostate-specific antigen tests in Japanese men waiting for prostate biopsy. International Journal of Clinical Oncology, 2017, 22, 174-180.	1.0	4
770	Molecular Imaging and Precision Medicine in Prostate Cancer. PET Clinics, 2017, 12, 83-92.	1.5	9
771	Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study. Prostate Cancer and Prostatic Diseases, 2017, 20, 61-66.	2.0	30
772	Prostate cancer screening in Europe and Asia. Asian Journal of Urology, 2017, 4, 86-95.	0.5	48
773	Sentinel Node Procedure in Prostate Cancer: A Systematic Review to Assess Diagnostic Accuracy. European Urology, 2017, 71, 596-605.	0.9	98
774	Correlation of diffusion tensor imaging parameters and Gleason scores of prostate cancer. Experimental and Therapeutic Medicine, 2017, 15, 351-356.	0.8	7
775	Meta-analysis of studies comparing oncologic outcomes of radical prostatectomy and brachytherapy for localized prostate cancer. Therapeutic Advances in Urology, 2017, 9, 241-250.	0.9	7
776	Pelvic Lymph Node Dissection in Prostate Cancer: Indications, Extent and Tailored Approaches. Urologia, 2017, 84, 9-19.	0.3	25
778	Cytoreductive cryosurgery in patients with bone metastatic prostate cancer: A retrospective analysis. Kaohsiung Journal of Medical Sciences, 2017, 33, 609-615.	0.8	14
779	Retropubic, Laparoscopic, and Robot-Assisted Radical Prostatectomy: A Comparative Analysis of the Surgical Outcomes in a Single Regional Center. Current Urology, 2017, 11, 36-41.	0.4	27
780	Atypical Small Acinar Proliferation and High Grade Prostatic Intraepithelial Neoplasia: Should We Be Concerned? An Observational Cohort Study with a Minimum Follow-Up of 3 Years. Current Urology, 2017, 10, 199-205.	0.4	10
781	Pentafecta Rates of Three-Dimensional Laparoscopic Radical Prostatectomy: Our Experience after 150 Cases. Urologia, 2017, 84, 93-97.	0.3	7
782	Determinants of behavioral intentions to screen for prostate cancer in Omani men. Asia-Pacific Journal of Oncology Nursing, 2017, 4, 348-355.	0.7	8
783	Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications. Hormones, 2017, 16, 115-123.	0.9	15
784	Does T1- and diffusion-weighted magnetic resonance imaging give value-added than bone scintigraphy in the follow-up of vertebral metastasis of prostate cancer?. Investigative and Clinical Urology, 2017, 58, 324.	1.0	3
785	The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer. Investigative and Clinical Urology, 2017, 58, 307.	1.0	17
786	Assessment of Bone Metastases in Patients with Prostate Cancerâ€"A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT. Pharmaceuticals, 2017, 10, 68.	1.7	47

#	Article	IF	Citations
787	Androgen receptor splice variants and prostate cancer: From bench to bedside. Oncotarget, 2017, 8, 18550-18576.	0.8	100
788	Updated analysis of vitamin D receptor gene FokI polymorphism and prostate cancer susceptibility. Archives of Medical Science, 2017, 6, 1449-1458.	0.4	12
789	Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applicationsâ€"Focus on Prostate and Breast Cancer. International Journal of Molecular Sciences, 2017, 18, 1102.	1.8	59
790	Comparison of Functional Outcome after Extended versus Super-Extended Pelvic Lymph Node Dissection during Radical Prostatectomy in High-Risk Localized Prostate Cancer. Frontiers in Oncology, 2017, 7, 280.	1.3	9
791	Are the Pathological Characteristics of Prostate Cancer More Aggressive or More Indolent Depending upon the Patient Age?. BioMed Research International, 2017, 2017, 1-6.	0.9	14
792	The Influence of Serum Prostate-Specific Antigen on the Accuracy of Magnetic Resonance Imaging Targeted Biopsy versus Saturation Biopsy in Patients with Previous Negative Biopsy. BioMed Research International, 2017, 2017, 1-6.	0.9	3
793	Initial single-centre Canadian experience with 18F-fluoromethylcholine positron emission tomography-computed tomography (18F-FCH PET/ CT) for biochemical recurrence in prostate cancer patients initially treated with curative intent. Canadian Urological Association Journal, 2017, 11, 47.	0.3	9
794	Comparison of ⁶⁸Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics, 2017, 7, 228-237.	4.6	135
795	Abdominal Mass After Robotic Assisted Laparoscopic Prostatectomy: Spigelian Type Trocar Hernia. Current Urology, 2017, 10, 163-165.	0.4	5
796	Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer. Theranostics, 2017, 7, 1770-1780.	4.6	123
797	Menâ€™s perspectives of prostate cancer screening: A systematic review of qualitative studies. PLoS ONE, 2017, 12, e0188258.	1.1	46
798	Prospective evaluation of computer-assisted analysis of skeletal lesions for the staging of prostate cancer. BMC Medical Imaging, 2017, 17, 40.	1.4	6
799	Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologistsâ€™ recommendations for active treatment or active surveillance: a randomized clinical utility trial. BMC Urology, 2017, 17, 51.	0.6	9
800	The EEF1A2 gene expression as risk predictor in localized prostate cancer. BMC Urology, 2017, 17, 86.	0.6	18
801	Detection rate of prostate cancer following biopsy among the northern Han Chinese population: a single-center retrospective study of 1022 cases. World Journal of Surgical Oncology, 2017, 15, 165.	0.8	13
802	Application of ultrasound imaging biomarkers (HistoScanningâ„¢) improves staging reliability of prostate biopsies. BMC Research Notes, 2017, 10, 579.	0.6	1
803	Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. EJNMMI Research, 2017, 7, 77.	1.1	33
804	A population-based study of the clinical utility of 18Fâ€“choline PET/CT for primary metastasis staging of high-risk prostate cancer. European Journal of Hybrid Imaging, 2017, 1, .	0.6	2

#	Article	IF	Citations
805	Utility of preoperative 3 Tesla pelvic phased-array multiparametric magnetic resonance imaging in prediction of extracapsular extension and seminal vesicle invasion of prostate cancer and its impact on surgical margin status: Experience at a Canadian academic tertiary care centre. Canadian Urological Association Journal, 2017, 11, 174.	0.3	17
806	Lateral decubitus position vs. lithotomy position: which is the best way to minimize patientâ€™s pain perception during transrectal prostate biopsy?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 462-469.	0.7	5
807	Isolation and purification of novel peptides derived from Sepia ink: Effects on apoptosis of prostate cancer cell PC-3. Molecular Medicine Reports, 2017, 16, 4222-4228.	1.1	15
808	Is PSMA PET-CT Better than Bone Scan? When and Why. Journal of Nuclear Medicine & Radiation Therapy, 2017, 08, .	0.2	0
809	Albumin and Fibrinogen Combined Prognostic Grade Predicts Prognosis of Patients with Prostate Cancer. Journal of Cancer, 2017, 8, 3992-4001.	1.2	25
810	Effect of irreversible electroporation of prostate cancer on microcirculation: Imaging findings in contrast-enhanced T1-weighted 3D MRI. Clinical Hemorheology and Microcirculation, 2017, 67, 399-405.	0.9	6
811	Diffusion weighted imaging of the prostateâ€"principles, application, and advances. Translational Andrology and Urology, 2017, 6, 490-498.	0.6	25
812	Atypical small acinar proliferation and two or more cores of high-grade intraepithelial neoplasia on a previous prostate biopsy are significant predictors of cancer during a transperineal template-guided saturation biopsy aimed at sampling one core for each 1 mL of prostate volume. Research and Reports in Urology, 2017, Volume 9, 187-193.	0.6	8
813	Carbon nanomaterials sensitize prostate cancer cells to docetaxel and mitomycin C via induction of apoptosis and inhibition of proliferation. Beilstein Journal of Nanotechnology, 2017, 8, 1307-1317.	1.5	10
814	Eleven-year Management of Prostate Cancer Patients on Active Surveillance: What have We Learned?. Tumori, 2017, 103, 464-474.	0.6	20
815	Occupational Therapy in Oncology and Palliative Care. , 2017, , .		1
816	The impact of the 2005 International Society of Urological Pathology Gleason grading consensus on active surveillance for prostate cancer. Central European Journal of Urology, 2017, 70, 344-348.	0.2	2
817	The influence of previous robotic experience in the initial learning curve of laparoscopic radical prostatectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 871-879.	0.7	5
818	Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity scorematched cohort. Canadian Urological Association Journal, 2017, 11, 41.	0.3	11
819	Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer: a meta-analysis and trial sequential analysis. Oncotarget, 2017, 8, 23322-23336.	0.8	71
820	Effect of Comorbidity on Prostate Cancerâ€"Specific Mortality: A Prospective Observational Study. Journal of Clinical Oncology, 2017, 35, 3566-3574.	0.8	29
821	Diagnostic performance of 68Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with 18FEC PET/CT. Oncotarget, 2017, 8, 111073-111083.	0.8	39
822	Integrated 68Ga-HBED-CC-PSMAPET/MRI in patients with suspected recurrent prostate cancer. Nuklearmedizin - NuclearMedicine, 2017, 56, 73-81.	0.3	19

#	Article	IF	Citations
823	Impact of United States Preventive Services Task Force Recommendations on Utilization of Prostate-specific Antigen Screening in Medicare Beneficiaries. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1069-1075.	0.6	5
824	Surgeonâ€led prostate cancer lymph node staging: pathological outcomes stratified by robotâ€assisted dissection templates and patient selection. BJU International, 2018, 122, 66-75.	1.3	10
825	Factors contributing to treatment outcomes of postâ€prostatectomy incontinence surgery for the selection of the proper surgical procedure for individual patients: A singleâ€center experience. Neurourology and Urodynamics, 2018, 37, 1978-1987.	0.8	10
826	Indication to pelvic lymph nodes dissection for prostate cancer: the role of multiparametric magnetic resonance imaging when the risk of lymph nodes invasion according to Briganti updated nomogram is <5%. Prostate Cancer and Prostatic Diseases, 2018, 21, 85-91.	2.0	14
827	Advances in prostate-specific membrane antigen PET of prostate cancer. Current Opinion in Oncology, 2018, 30, 189-196.	1.1	24
828	Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts. Clinical Cancer Research, 2018, 24, 2408-2416.	3.2	19
829	Imageâ€guided surgery in cancer: A strategy to reduce incidence of positive surgical margins. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2018, 10, e1412.	6.6	60
830	Accordance of Online Health Information on Prostate Cancer with the European Association of Urology Guidelines. Urologia Internationalis, 2018, 100, 288-293.	0.6	5
831	Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance. Journal of Pathology, 2018, 245, 74-84.	2.1	18
832	Prostate cancer screening: Beliefs and practices of the Brazilian physicians with different specialties. Journal of Evaluation in Clinical Practice, 2018, 24, 508-513.	0.9	2
833	Prospective comparative study of ¹⁸F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer. Acta OncolÃ³gica, 2018, 57, 1063-1069.	0.8	9
834	Transition zone and anterior stromal prostate cancers: Evaluation of discriminant location criteria using multiparametric fusion-guided biopsy. Diagnostic and Interventional Imaging, 2018, 99, 403-411.	1.8	6
835	IDEAL 2a Phase II Study of Ultrafocal Brachytherapy for Low- and Intermediate-risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 903-911.	0.4	19
836	Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases. Medical Oncology, 2018, 35, 75.	1.2	19
837	Are There Extended Benefits with Extended Lymph Node Dissection During Radical Prostatectomy?. European Urology, 2018, 74, 138-139.	0.9	2
838	Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in nodeâ€positive prostate cancer patients: External validation on a multiâ€institutional database. International Journal of Urology, 2018, 25, 574-581.	0.5	8
839	Prazosin but Not Tamsulosin Sensitises PC-3 and LNCaP Prostate Cancer Cells to Docetaxel. Pharmacology, 2018, 102, 17-25.	0.9	10
840	Long noncoding RNA BDNF-AS is associated with clinical outcomes and has functional role in human prostate cancer. Biomedicine and Pharmacotherapy, 2018, 102, 1105-1110.	2.5	33

#	Article	IF	Citations
841	Efficacy and Safety of Tadalafil 5 mg Once Daily for the Treatment of Erectile Dysfunction After Robot-Assisted Laparoscopic Radical Prostatectomy: A 2-Year Follow-Up. Sexual Medicine, 2018, 6, 108-114.	0.9	15
842	Healthâ€related quality of life in active surveillance and radical prostatectomy for lowâ€risk prostate cancer: a prospective observational study (HAROW â€•Hormonal therapy, Active Surveillance, Radiation,) Tj ETQq1 1 0.784314 rgBT /Ov	1.3	14
843	Initial series of magnetic resonance imaging (MRI)-fusion targeted prostate biopsy using the first transperineal targeted platform available in the USA. BJU International, 2018, 122, 909-912.	1.3	7
844	Localised prostate cancer in elderly men aged 80â€“89Âyears, findings from a populationâ€based registry. BJU International, 2018, 121, 48-54.	1.3	17
845	SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer. Clinical Nuclear Medicine, 2018, 43, 225-231.	0.7	42
846	Impact of comorbidities at diagnosis on prostate cancer treatment and survival. Journal of Cancer Research and Clinical Oncology, 2018, 144, 707-715.	1.2	24
847	A review discussing fluciclovine (18F) PET/CT imaging in the detection of recurrent prostate cancer. Future Oncology, 2018, 14, 1101-1115.	1.1	8
848	A clinicianâ€centred programme for behaviour change in the optimal use of staging investigations for newly diagnosed prostate cancer. BJU International, 2018, 121, 22-27.	1.3	14
849	Antimicrobial lubricant reduces rectal bacteria at transrectal prostate biopsy: results from a prospective randomized trial. World Journal of Urology, 2018, 36, 871-876.	1.2	5
850	3-D Quantitative Dynamic Contrast Ultrasound for Prostate Cancer Localization. Ultrasound in Medicine and Biology, 2018, 44, 807-814.	0.7	11
851	Feasibility study of MR-guided transgluteal targeted in-bore biopsy for suspicious lesions of the prostate at 3 Tesla using a freehand approach. European Radiology, 2018, 28, 2690-2699.	2.3	7
852	Plumbagin Triggers ER Stress-Mediated Apoptosis in Prostate Cancer Cells via Induction of ROS. Cellular Physiology and Biochemistry, 2018, 45, 267-280.	1.1	43
853	Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncology, 2018, 4, e175230.	3.4	65
854	Intraindividual Comparison of ^{99m}Tc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand ^{99m}Tc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1373-1379.	2.8	31
855	Accuracy of multiparametric MR imaging with PI-RADS V2 assessment in detecting infiltration of the neurovascular bundles prior to prostatectomy. European Journal of Radiology, 2018, 98, 187-192.	1.2	9
856	Pathologic Outcomes of Candidates for Active Surveillance Undergoing Radical Prostatectomy: Results from a Contemporary Turkish Patient Cohort. Urologia Internationalis, 2018, 100, 43-49.	0.6	5
857	The CADMUS trial â€“ Multi-parametric ultrasound targeted biopsies compared to multi-parametric MRI targeted biopsies in the diagnosis of clinically significant prostate cancer. Contemporary Clinical Trials, 2018, 66, 86-92.	0.8	9
858	Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, and Urinary Retention. Medical Clinics of North America, 2018, 102, 301-311.	1.1	19

#	Article	IF	Citations
859	Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 158.e1-158.e6.	0.8	10
860	Effect of repeat prostate biopsies on functional outcomes after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 91.e17-91.e22.	0.8	4
861	Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors. Molecular Imaging and Biology, 2018, 20, 501-509.	1.3	67
862	Prostate cancer rates in patients with initially negative elastography-targeted biopsy vs. systematic biopsy. World Journal of Urology, 2018, 36, 623-628.	1.2	5
863	A Comparison of Prilocaine vs Prilocaineâ€‰+â€‰Bupivacaine in Periprostatic Block in Ambulatory Prostate Biopsies: A Single-Blind Randomized Controlled Study. Pain Medicine, 2018, 19, 2069-2076.	0.9	3
864	Stochastic Modeling of Temporal Enhanced Ultrasound: Impact of Temporal Properties on Prostate Cancer Characterization. IEEE Transactions on Biomedical Engineering, 2018, 65, 1798-1809.	2.5	4
865	18F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients. European Radiology, 2018, 28, 3151-3159.	2.3	59
866	68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1862-1872.	3.3	91
868	Return to work following robot-assisted laparoscopic and open retropubic radical prostatectomy: A single-center cohort study to compare duration of sick leave. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 309.e1-309.e6.	0.8	8
869	Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA). Medicine (United) Tj ETQq1 1 0.784314 rgBT /Ov		
870	The role of real-time elastography-targeted biopsy in the detection and diagnosis of prostate cancer. Medicine (United States), 2018, 97, e0220.	0.4	8
871	Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6. Clinical Genitourinary Cancer, 2018, 16, 281-287.	0.9	27
872	Clinical comparison of the efficacy of three different bowel preparation methods on the infectious complications following transrectal ultrasonographyâ€guided prostate biopsy in nursing practice. Journal of Clinical Nursing, 2018, 27, 2583-2589.	1.4	6
873	Comparison of nomograms predicting lymph node invasion in patients undergoing radical prostatectomy for prostate cancer. Irish Journal of Medical Science, 2018, 187, 33-37.	0.8	5
874	Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up. European Urology Focus, 2018, 4, 351-359.	1.6	32
875	Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study. Journal of Cancer Education, 2018, 33, 180-185.	0.6	14
876	Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer. European Urology, 2018, 73, 353-360.	0.9	105
877	Ultraâ€small superparamagnetic iron oxides for metastatic lymph node detection: back on the block. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2018, 10, e1471.	3.3	70

#	Article	IF	Citations
878	Ex vivo MRI evaluation of prostate cancer: Localization and margin status prediction of prostate cancer in fresh radical prostatectomy specimens. Journal of Magnetic Resonance Imaging, 2018, 47, 439-448.	1.9	8
879	Prostate Multiparametric Magnetic Resonance Imaging Program Implementation and Impact: Initial Clinical Experience in a Community Based Health System. Urology Practice, 2018, 5, 165-171.	0.2	3
880	Robotic-assisted Radical Prostatectomy for High-risk Cancer: Time for â€œSexta-fectaâ€• European Urology, 2018, 73, 224-225.	0.9	1
881	Impact of ⁶⁸Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management. Journal of Nuclear Medicine, 2018, 59, 89-92.	2.8	58
882	Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative Study-1). Prostate International, 2018, 6, 7-11.	1.2	7
883	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. European Urology, 2018, 73, 156-165.	0.9	55
884	Lymph node-positive prostate cancer after robotic prostatectomy and extended pelvic lymphadenectomy. Journal of Robotic Surgery, 2018, 12, 425-431.	1.0	6
885	Dynamic Patterns of Testosterone Levels in Individuals and Risk of Prostate Cancer among Hypogonadal Men: A Longitudinal Study. Journal of Urology, 2018, 199, 465-473.	0.2	11
886	Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsyâ€•naÃ¯ve men with suspicion of prostate cancer. BJU International, 2018, 122, 40-49.	1.3	108
887	Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy. Clinical Genitourinary Cancer, 2018, 16, 103-105.	0.9	4
888	Postoperative radiotherapy for prostate cancer: the sooner the better and potential to reduce toxicity even further. Radiologia Medica, 2018, 123, 63-70.	4.7	13
889	New Approach to Guide Target Prostate Biopsy: Technique and Initial Experience. Urology, 2018, 121, 198-199.	0.5	3
890	Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy. Nature Reviews Urology, 2018, 15, 55-66.	1.9	18
891	Radical prostatectomy for clinically localized prostate cancer in patients aged 75 years or older: comparison with primary androgen deprivation therapy. Aging Male, 2018, 21, 17-23.	0.9	8
892	Survival outcomes in elderly men undergoing radical prostatectomy in Australia. ANZ Journal of Surgery, 2018, 88, E189-E193.	0.3	1
893	Prostate cancer treatment in renal transplant recipients: a systematic review. BJU International, 2018, 121, 327-344.	1.3	26
894	Prospective randomised nonâ€•inferiority trial of pelvic drain placement vs no pelvic drain placement after robotâ€•assisted radical prostatectomy. BJU International, 2018, 121, 357-364.	1.3	31
895	A match-pair analysis of continence in intermediate and high-risk prostate cancer patients after robot-assisted radical prostatectomy: the role of urine loss ratio and predictive analysis. Prostate International, 2018, 6, 94-98.	1.2	7

#	Article	IF	Citations
896	Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy. World Journal of Urology, 2018, 36, 177-185.	1.2	17
897	The incidence of prostate cancer in Iran: a systematic review and meta-analysis. Prostate International, 2018, 6, 41-45.	1.2	37
898	EBONI: A Tool for Automated Quantification of Bone Metastasis Load in PSMA PET/CT. Journal of Nuclear Medicine, 2018, 59, 1070-1075.	2.8	22
899	Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy. Clinical Genitourinary Cancer, 2018, 16, e491-e496.	0.9	15
900	Review of the comparative effectiveness of radical prostatectomy, radiation therapy, or expectant management of localized prostate cancer in registry data. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 183-192.	0.8	19
901	Variation in Radiotherapy Referral and Treatment for High-risk Pathological Features after Radical Prostatectomy: Results from aÂPopulation-based Study. Clinical Oncology, 2018, 30, 47-56.	0.6	9
902	^{99m}Tcâ€MIPâ€1404â€SPECT/CT for the detection of PSMAâ€positive lesions in 225 patients with biochemical recurrence of prostate cancer. Prostate, 2018, 78, 54-63.	1.2	61
903	3D T2-weighted imaging to shorten multiparametric prostate MRI protocols. European Radiology, 2018, 28, 1634-1641.	2.3	29
904	Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 80.e17-80.e24.	0.8	10
905	Validation of Prostate Imaging-Reporting and Data System Version 2: A Retrospective Analysis. Current Problems in Diagnostic Radiology, 2018, 47, 404-409.	0.6	8
906	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. Journal of Nuclear Medicine, 2018, 59, 469-478.	2.8	372
907	Atypical small acinar proliferation at index prostate biopsy: rethinking the re-biopsy paradigm. International Urology and Nephrology, 2018, 50, 1-6.	0.6	8
908	Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients. Clinical Chemistry, 2018, 64, 297-306.	1.5	67
909	PET Using a GRPR Antagonist ⁶⁸Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients. Journal of Nuclear Medicine, 2018, 59, 922-928.	2.8	70
910	Prostate cancer detection among readers with different degree of experience using ultra-high b-value diffusion-weighted Imaging: Is a non-contrast protocol sufficient to detect significant cancer?. European Radiology, 2018, 28, 869-876.	2.3	20
911	Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT. European Radiology, 2018, 28, 610-619.	2.3	59
914	Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 355-362.	1.8	28
915	Quality of life in active surveillance and the associations with decision-makingâ€"a literature review. Translational Andrology and Urology, 2018, 7, 160-169.	0.6	8

#	Article	IF	Citations
916	Stopping screening, when and how?. Translational Andrology and Urology, 2018, 7, 46-53.	0.6	6
917	De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT). Implementation Science, 2018, 13, 144.	2.5	9
918	Prostate Cancer-Specific of DD3-driven oncolytic virus-harboring mK5 gene. Open Medicine (Poland), 2018, 14, 1-9.	0.6	4
919	Pattern of care of prostate cancer patients across the Martinique: results of a population-based study in the Caribbean. BMC Cancer, 2018, 18, 1130.	1.1	9
921	Clinical significance of multiparametric MRI and PSA density as predictors of residual tumor (pT0) following radical prostatectomy for T1a-T1b (incidental) prostate cancer. PLoS ONE, 2018, 13, e0210037.	1.1	12
922	Is cryosurgery a feasible local therapy for bone metastatic prostate cancer?. Singapore Medical Journal, 2018, 59, 584-589.	0.3	4
923	3.0-T multiparametric MRI modifies the template of endoscopic, conventional radical prostatectomy in all cancer risk categories. Archives of Medical Science, 2018, 14, 1381-1386.	0.4	5
924	The Evolving Role of Shear Wave Elastography in the Diagnosis and Treatment of Prostate Cancer. Ultrasound Quarterly, 2018, 34, 245-249.	0.3	14
926	Detection of CK19 mRNA Using One-step Nucleic Acid Amplification (OSNA) in Prostate Cancer: Preliminary Results. Journal of Cancer, 2018, 9, 4611-4617.	1.2	13
927	Current concepts in multiparametric magnetic resonance imaging for active surveillance of prostate cancer. Clinics, 2018, 73, e464s.	0.6	1
928	Evaluation of prostateâ€‘specific antigen density in the diagnosis of prostate cancer combined with magnetic resonance imaging before biopsy in men aged 70ï¿½years and older with elevated PSA. Molecular and Clinical Oncology, 2018, 9, 656-660.	0.4	8
929	Imaging as a Personalized Biomarker for Prostate Cancer Risk Stratification. Diagnostics, 2018, 8, 80.	1.3	3
930	Simultaneous 18F-fluciclovine Positron Emission Tomography and Magnetic Resonance Spectroscopic Imaging of Prostate Cancer. Frontiers in Oncology, 2018, 8, 516.	1.3	4
931	Quantitative Apparent Diffusion Coefficient Derived From Diffusion-Weighted Imaging Has the Potential to Avoid Unnecessary MRI-Guided Biopsies of mpMRI-Detected PI-RADS 4 and 5 Lesions. Investigative Radiology, 2018, 53, 736-741.	3.5	20
932	Advantages of systematic trunk SPECT/CT to planar bone scan (PBS) in more than 300 patients with breast or prostate cancer. Oncotarget, 2018, 9, 31744-31752.	0.8	16
934	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncology, The, 2018, 19, e534-e545.	5.1	98
935	Pelvic Lymph Node Dissection for Prostate Cancer and Nomograms. , 2018, , 317-330.		0
936	Health Services Research and Robotic Surgery. , 2018, , 235-252.		0

#	Article	IF	Citations
937	The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 500.e11-500.e19.	0.8	10
938	Multiparametric magnetic resonance imaging: Overview of the technique, clinical applications in prostate biopsy and future directions. Turkish Journal of Urology, 2018, 44, 93-102.	1.3	20
939	Clinical significance and predictors of oncologic outcome after radical prostatectomy for invisible prostate cancer on multiparametric MRI. BMC Cancer, 2018, 18, 1057.	1.1	10
941	Evaluation of Dispersion MRI for Improved Prostate Cancer Diagnosis in a Multicenter Study. American Journal of Roentgenology, 2018, 211, W242-W251.	1.0	7
942	Penile rehabilitation for postprostatectomy erectile dysfunction. The Cochrane Library, 2018, 10, CD012414.	1.5	30
943	Assessment of Treatment Response by 99mTc-MIP-1404 SPECT/CT. Clinical Nuclear Medicine, 2018, 43, e250-e258.	0.7	18
944	Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Translational Andrology and Urology, 2018, 7, 83-97.	0.6	99
945	Retzius-Sparing Approach for Robot-Assisted Laparoscopic Radical Prostatectomy. , 2018, , 299-316.		0
946	Risk of upgrading from prostate biopsy to radical prostatectomy pathology: Is magnetic resonance imaging-guided biopsy more accurate?. Journal of Cancer, 2018, 9, 3634-3639.	1.2	22
947	Targeted Prostate Biopsy and MR-Guided Therapy for Prostate Cancer. Advances in Experimental Medicine and Biology, 2018, 1096, 159-184.	0.8	2
948	Effects of age and comorbidity on survival vary according to risk grouping among patients with prostate cancer treated using radical prostatectomy. Medicine (United States), 2018, 97, e12766.	0.4	5
949	Reporting and Handling of Indeterminate Bone Scan Results in the Staging of Prostate Cancer: A Systematic Review. Diagnostics, 2018, 8, 9.	1.3	5
950	A Case Series of Patients Who Underwent Laparoscopic Extraperitoneal Radical Prostatectomy with the Simultaneous Implant of a Penile Prosthesis: Focus on Penile Length Preservation. World Journal of Men?s Health, 2018, 36, 132.	1.7	12
951	Imaging of distant metastases of prostate cancer. Medical Oncology, 2018, 35, 148.	1.2	16
952	Neoadjuvant chemohormonal therapy followed by robot-assisted and minimum incision endoscopic radical prostatectomy in patients with high-risk prostate cancer: comparison of perioperative and oncological outcomes at single institution. International Urology and Nephrology, 2018, 50, 1999-2005.	0.6	10
953	Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. American Journal of Men's Health, 2018, 12, 1807-1823.	0.7	303
954	Evidence-based Risk Stratification to Guide Hormone Therapy Use With Salvage Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 556-560.	0.4	6
955	Autoantibody against new gene expressed in prostate protein is traceable in prostate cancer patients. Biomarkers in Medicine, 2018, 12, 1125-1138.	0.6	11

#	Article	IF	Citations
956	Vascular endothelial growth factor suppresses dendritic cells function of human prostate cancer. OncoTargets and Therapy, 2018, Volume 11, 1267-1274.	1.0	19
957	Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges. Korean Journal of Radiology, 2018, 19, 819.	1.5	29
958	Application of Cu-64 NODAGA-PSMA PET in Prostate Cancer. Advances in Therapy, 2018, 35, 779-784.	1.3	16
959	Bombesin functionalized ⁶⁴Cu-copper sulfide nanoparticles for targeted imaging of orthotopic prostate cancer. Nanomedicine, 2018, 13, 1695-1705.	1.7	23
960	Prostate biopsy. Current Opinion in Urology, 2018, 28, 354-359.	0.9	16
961	Gallium-68 HBED-CC-PSMA Positron Emission Tomography/Magnetic Resonance Imaging for Prostate Fusion Biopsy. Clinical Genitourinary Cancer, 2018, 16, 245-247.	0.9	8
962	²²³Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. Tumori, 2018, 104, 128-136.	0.6	14
963	Exploring positive surgical margins after minimally invasive radical prostatectomy: Does body habitus really make a differenceÂ?. Progres En Urologie, 2018, 28, 434-441.	0.3	4
964	Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. European Urology Oncology, 2018, 1, 531-537.	2.6	106
965	The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation. British Journal of Cancer, 2018, 118, 1399-1405.	2.9	12
966	Tissue proteomics studies in the investigation of prostate cancer. Expert Review of Proteomics, 2018, 15, 593-611.	1.3	8
967	Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer. PLoS Genetics, 2018, 14, e1007355.	1.5	50
968	Health literacy and the health status of men with prostate cancer. Psycho-Oncology, 2018, 27, 2374-2381.	1.0	29
969	NMR-based metabolomics studies of human prostate cancer tissue. Metabolomics, 2018, 14, 88.	1.4	21
970	Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer. Oncology Letters, 2018, 15, 5149-5154.	0.8	11
971	Tailored postoperative treatment of prostate cancer: final results of a phase I/II trial. Prostate Cancer and Prostatic Diseases, 2018, 21, 564-572.	2.0	2
972	Optimal biopsy strategy for prostate cancer detection by performing a Bayesian network meta-analysis of randomized controlled trials. Journal of Cancer, 2018, 9, 2237-2248.	1.2	8
973	Porphyrin-grafted Lipid Microbubbles for the Enhanced Efficacy of Photodynamic Therapy in Prostate Cancer through Ultrasound-controlled In Situ Accumulation. Theranostics, 2018, 8, 1665-1677.	4.6	57

#	Article	IF	Citations
974	Quality indicators of clinical cancer care for prostate cancer: a population-based study in southern Switzerland. BMC Cancer, 2018, 18, 733.	1.1	5
975	Resveratrol treatment may preserve the erectile function after radiotherapy by restoring antioxidant defence mechanisms, SIRT1 and NOS protein expressions. International Journal of Impotence Research, 2018, 30, 179-188.	1.0	17
978	Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer and Prostatic Diseases, 2018, 21, 524-532.	2.0	37
979	Risk of infection following semi-invasive ultrasound procedures in Scotland, 2010 to 2016: A retrospective cohort study using linked national datasets. Ultrasound, 2018, 26, 168-177.	0.3	12
980	Decreased expression of bone morphogenetic protein-2 is correlated with biochemical recurrence in prostate cancer: Immunohistochemical analysis. Scientific Reports, 2018, 8, 10748.	1.6	6
981	Adjuvant Therapy in Locally Advanced Prostate Cancer. , 2018, , 51-57.		0
982	Construction of a Preoperative Radiologic-Risk Signature for Predicting the Pathologic Status of Prostate Cancer at Radical Prostatectomy. American Journal of Roentgenology, 2018, 211, 805-811.	1.0	1
983	Pre- and intra-operative predictors of postoperative hospital length of stay in patients undergoing radical prostatectomy for prostate cancer in China: a retrospective observational study. BMC Urology, 2018, 18, 43.	0.6	5
984	Current guidelines for prostate cancer screening: A systematic review and minimal core proposal. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2018, 64, 290-296.	0.3	5
985	Diffusion-Weighted Genitourinary Imaging. Urologic Clinics of North America, 2018, 45, 407-425.	0.8	3
986	Imaging of Prostate Cancer Using 11 C-Choline PET/Computed Tomography. Urologic Clinics of North America, 2018, 45, 481-487.	0.8	12
987	Impact of a web-based prostate cancer treatment decision aid on patient-reported decision process parameters: results from the Prostate Cancer Patient Centered Care trial. Supportive Care in Cancer, 2018, 26, 3739-3748.	1.0	17
988	Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol. Urologia Internationalis, 2018, 101, 56-64.	0.6	17
989	Suprapubic tube versus urethral catheter drainage after robot-assisted radical prostatectomy: a systematic review and meta-analysis. BMC Urology, 2018, 18, 1.	0.6	31
990	Quality of life after low-dose rate-brachytherapy for prostate carcinoma â€“ long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series. Health and Quality of Life Outcomes, 2018, 16, 21.	1.0	10
991	Italian cultural adaptation of the Memorial Anxiety for Prostate Cancer scale for the population of men on active surveillance. Tumori, 2018, 104, 172-178.	0.6	5
992	Body composition, fatigue and exercise in patients with prostate cancer undergoing androgenâ€deprivation therapy. BJU International, 2018, 122, 986-993.	1.3	24
993	Preoperative evaluation of pelvine lymph node metastasis in high risk prostate cancer with intravoxel incoherent motion (IVIM) MRI. European Journal of Radiology, 2018, 107, 1-6.	1.2	10

#	Article	IF	Citations
994	Diffusion Kurtosis Imaging Combined With DWI at 3-T MRI for Detection and Assessment of Aggressiveness of Prostate Cancer. American Journal of Roentgenology, 2018, 211, 797-804.	1.0	23
996	Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker. Biomarkers in Medicine, 2018, 12, 1035-1048.	0.6	60
997	pH-Sensitive Micelles Based on Star Copolymer Ad-(PCL-b-PDEAEMA-b-PPEGMA)4 for Controlled Drug Delivery. Polymers, 2018, 10, 443.	2.0	15
998	Increased Paxillin expression in prostate cancer is associated with advanced pathological features, lymph node metastases and biochemical recurrence. Journal of Cancer, 2018, 9, 959-967.	1.2	11
999	The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis. International Journal of Surgery, 2018, 56, 133-140.	1.1	9
1000	Effectiveness of a transrectal prostate needle biopsy protocol with risk-tailored antimicrobials in a veterans cohort. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 363.e13-363.e20.	0.8	1
1001	Tumor-Suppressive Function of miR-30d-5p in Prostate Cancer Cell Proliferation and Migration by Targeting NT5E. Cancer Biotherapy and Radiopharmaceuticals, 2018, 33, 203-211.	0.7	22
1002	Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. European Urology, 2018, 74, 376-386.	0.9	58
1003	Contrast-Enhanced Ultrasound (CEUS) and Quantitative Perfusion Analysis in Patients with Suspicion for Prostate Cancer. Ultraschall in Der Medizin, 2019, 40, 340-348.	0.8	42
1004	Imaging modalities in synchronous oligometastatic prostate cancer. World Journal of Urology, 2019, 37, 2573-2583.	1.2	16
1005	Interrupted versus Continuous Suturing for Vesicourethral Anastomosis During Radical Prostatectomy: A Systematic Review and Meta-analysis. European Urology Focus, 2019, 5, 980-991.	1.6	8
1006	Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer and Prostatic Diseases, 2019, 22, 24-38.	2.0	215
1007	A riskâ€based approach to identifying oligometastatic disease on imaging. International Journal of Cancer, 2019, 144, 422-430.	2.3	17
1008	First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 148-158.	3.3	78
1009	Sixâ€Transmembrane Epithelial Antigen of the Prostateâ€1 (STEAPâ€1)â€“Targeted Ultrasound Imaging Microbubble Improves Detection of Prostate Cancer In Vivo. Journal of Ultrasound in Medicine, 2019, 38, 299-305.	0.8	6
1010	Uptake and usage of an online prostate cancer treatment decision aid in Dutch clinical practice: A quantitative analysis from the Prostate Cancer Patient Centered Care trial. Health Informatics Journal, 2019, 25, 1498-1510.	1.1	12
1011	PhaseÂII study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer. Strahlentherapie Und Onkologie, 2019, 195, 113-120.	1.0	32
1012	Laparoscopic abdominoperineal resection with lateral lymph node dissection for advanced rectal and prostate cancer with synchronous lateral lymph node metastases. Asian Journal of Endoscopic Surgery, 2019, 12, 118-121.	0.4	1

#	Article	IF	Citations
1013	A machine learningâ€assisted decisionâ€support model to better identify patients with prostate cancer requiring an extended pelvic lymph node dissection. BJU International, 2019, 124, 972-983.	1.3	19
1014	Editorial: early PSA-testing after radical prostatectomyâ€"the truth behind the scenes. Translational Andrology and Urology, 2019, 8, S307-S309.	0.6	0
1015	Comparison of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy With Systematic Biopsy Alone for the Diagnosis of Prostate Cancer. JAMA Network Open, 2019, 2, e198427.	2.8	47
1016	Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival. , 2019, 7, 201.		11
1017	Is it possible to automatically assess pretreatment digital rectal examination documentation using natural language processing? A single-centre retrospective study. BMJ Open, 2019, 9, e027182.	0.8	6
1018	The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy. Journal of Cancer, 2019, 10, 3102-3111.	1.2	27
1019	Random effects models for estimation of the probability and time to progression of a continuous biomarker. Pharmaceutical Statistics, 2019, 18, 671-687.	0.7	0
1020	A comparison of magnetic resonance imaging techniques used to secure biopsies in prostate cancer patients. Expert Review of Anticancer Therapy, 2019, 19, 705-716.	1.1	9
1021	Clinical Impact of Circulating Tumor Cells in Patients with Localized Prostate Cancer. Cells, 2019, 8, 676.	1.8	39
1022	125I lowâ€'doseâ€'rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer. Oncology Letters, 2019, 18, 72-80.	0.8	5
1023	Evidence-based practice: a comparison of International Clinical Practice Guidelines and current research on physical activity for mild to moderate depression. Translational Behavioral Medicine, 2019, 9, 703-710.	1.2	1
1024	Lobaplatin Inhibits Prostate Cancer Proliferation and Migration Through Regulation of BCL2 and BAX. Dose-Response, 2019, 17, 155932581985098.	0.7	6
1025	Development of 3D Lymph Node Mimetic for Studying Prostate Cancer Metastasis. Advanced Biology, 2019, 3, 1900019.	3.0	4
1026	68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Annals of Nuclear Medicine, 2019, 33, 766-775.	1.2	35
1027	Application of various optical and electrochemical aptasensors for detection of human prostate specific antigen: A review. Biosensors and Bioelectronics, 2019, 142, 111484.	5.3	93
1028	Silencing TTK expression inhibits the proliferation and progression of prostate cancer. Experimental Cell Research, 2019, 385, 111669.	1.2	25
1029	Engaging African American Men as Citizen Scientists to Validate a Prostate Cancer Biomarker: Work-in-Progress. Progress in Community Health Partnerships: Research, Education, and Action, 2019, 13, 103-112.	0.2	10
1030	Overexpression of certain transient receptor potential and Orai channels in prostate cancer is associated with decreased risk of systemic recurrence after radical prostatectomy. Prostate, 2019, 79, 1793-1804.	1.2	15

#	Article	IF	Citations
1031	Similarities and differences between Likert and PIRADS v2.1 scores of prostate multiparametric MRI: a pictorial review of histology-validated cases. Clinical Radiology, 2019, 74, 895.e1-895.e15.	0.5	25
1032	Effects of the Training About Prostate Cancer and Screening Methods on Knowledge Level. Nursing Science Quarterly, 2019, 32, 333-339.	0.3	1
1033	Glycosylation products in prostate diseases. Clinica Chimica Acta, 2019, 498, 52-61.	0.5	10
1034	A novel method for pain control: infiltration free local anesthesia technique (INFLATE) for transrectal prostatic biopsy using transcutaneous electrical nerve stimulation (TENS). International Urology and Nephrology, 2019, 51, 2119-2126.	0.6	10
1035	Prediction of prostate cancer aggressiveness with a combination of radiomics and machine learning-based analysis of dynamic contrast-enhanced MRI. Clinical Radiology, 2019, 74, 896.e1-896.e8.	0.5	36
1036	PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels. Annals of Nuclear Medicine, 2019, 33, 891-898.	1.2	17
1037	Understanding of prognosis in non-metastatic prostate cancer: a randomised comparative study of clinician estimates measured against the PREDICT prostate prognostic model. British Journal of Cancer, 2019, 121, 715-718.	2.9	12
1038	Has Robotic Surgery Improved Erectile Function Recovery Rates in Radical Prostatectomy Patients?. Journal of Sexual Medicine, 2019, 16, 1487-1489.	0.3	0
1039	Comparison of bone lesion distribution between prostate cancer and multiple myeloma with whole-body MRI. Diagnostic and Interventional Imaging, 2019, 100, 295-302.	1.8	8
1040	Deep learning for automatic Gleason pattern classification for grade group determination of prostate biopsies. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 77-83.	1.4	94
1041	Prostate cancer screening: guidelines review and laboratory issues. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1474-1487.	1.4	31
1042	Machine learning for differentiating metastatic and completely responded sclerotic bone lesion in prostate cancer: a retrospective radiomics study. British Journal of Radiology, 2019, 92, 20190286.	1.0	39
1043	National practice patterns and direct medical costs for prostate cancer in Korea across a 10â€‰year period: a nationwide population-based study using a national health insurance database. BMC Health Services Research, 2019, 19, 408.	0.9	11
1044	MR-guidance in clinical reality: current treatment challenges and future perspectives. Radiation Oncology, 2019, 14, 92.	1.2	252
1045	Multiparametric MRI Versus Multiparametric US in the Detection of Prostate Cancer. Anticancer Research, 2019, 39, 3101-3110.	0.5	16
1046	An efficient or methodical review of immunotherapy against breast cancer. Journal of Biochemical and Molecular Toxicology, 2019, 33, e22339.	1.4	14
1047	Signature maps for automatic identification of prostate cancer from colorimetric analysis of H&E- and IHC-stained histopathological specimens. Scientific Reports, 2019, 9, 6992.	1.6	8
1048	Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. Prostate, 2019, 79, 1079-1089.	1.2	28

#	Article	IF	Citations
1049	Circulating tumor cells and their role in prostate cancer. Asian Journal of Andrology, 2019, 21, 24.	0.8	13
1050	Oligometastases in prostate cancer: Ablative treatment. World Journal of Clinical Oncology, 2019, 10, 38-51.	0.9	27
1051	A Retrospective Comparison of Transrectal and Transperineal Prostate Biopsies: Experience of a Single Surgeon. Journal of Endourology, 2019, 33, 498-502.	1.1	9
1052	The Evolution of MRI of the Prostate: The Past, the Present, and the Future. American Journal of Roentgenology, 2019, 213, 384-396.	1.0	39
1053	Healthâ€related quality of life in longâ€term survivors with localised prostate cancer by therapyâ€"Results from a populationâ€based study. European Journal of Cancer Care, 2019, 28, e13076.	0.7	19
1054	Clinical Impact of Lower-Limb Imaging in ⁶⁸Ga-PSMA PET/CT for Patients with Prostate Cancer. Journal of Nuclear Medicine Technology, 2019, 47, 233-237.	0.4	6
1055	Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection. Cancer, 2019, 125, 2955-2964.	2.0	21
1056	Novel multifunctional nanocarrier-mediated codelivery for targeting and treatment of prostate cancer. , 2019, , 185-224.		2
1057	Who Can Avoid Systematic Biopsy Without Missing Clinically Significant Prostate Cancer in Men Who Undergo Magnetic Resonance Imaging-Targeted Biopsy?. Clinical Genitourinary Cancer, 2019, 17, e664-e671.	0.9	8
1058	Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada. BMC Urology, 2019, 19, 19.	0.6	50
1059	Effect of External Cooling on ¹⁷⁷Lu-PSMA Uptake by the Parotid Glands. Journal of Nuclear Medicine, 2019, 60, 1388-1393.	2.8	29
1060	Low PI-RADS assessment category excludes extraprostatic extension (â‰¥pT3a) of prostate cancer: a histology-validated study including 301 operated patients. European Radiology, 2019, 29, 5478-5487.	2.3	20
1061	Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer. Physics and Imaging in Radiation Oncology, 2019, 9, 69-76.	1.2	128
1062	Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer. Clinical Cancer Research, 2019, 25, 3016-3025.	3.2	87
1063	Detrusorrhaphy during Robot-Assisted Radical Prostatectomy: Early Recovery of Urinary Continence and Surgical Technique. BioMed Research International, 2019, 2019, 1-8.	0.9	5
1064	The Tumor Immune Contexture of Prostate Cancer. Frontiers in Immunology, 2019, 10, 603.	2.2	143
1065	Editorial Comment. Urology, 2019, 125, 160-161.	0.5	0
1066	A Dual-Modality Linker Enables Site-Specific Conjugation of Antibody Fragments for ¹⁸F-Immuno-PET and Fluorescence Imaging. Journal of Nuclear Medicine, 2019, 60, 1467-1473.	2.8	24

#	Article	IF	Citations
1067	A randomized controlled comparison between periprostatic nerve block and pelvic plexus block at the base and apex of 14-core prostate biopsies. World Journal of Urology, 2019, 37, 2663-2669.	1.2	7
1068	The clinical utility of prostate cancer heterogeneity using texture analysis of multiparametric MRI. International Urology and Nephrology, 2019, 51, 817-824.	0.6	11
1069	Lycopene exerts anti-inflammatory effect to inhibit prostate cancer progression. Asian Journal of Andrology, 2019, 21, 80.	0.8	33
1070	68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer: diagnostic sensitivity and interobserver agreement. Abdominal Radiology, 2019, 44, 2545-2556.	1.0	30
1071	Predictive Factors and Oncologic Outcome of Downgrade to Pathologic Gleason Score 6â€“7 after Radical Prostatectomy in Patients with Biopsy Gleason Score 8â€“10. Journal of Clinical Medicine, 2019, 8, 438.	1.0	6
1072	Deep neural maps for unsupervised visualization of high-grade cancer in prostate biopsies. International Journal of Computer Assisted Radiology and Surgery, 2019, 14, 1009-1016.	1.7	17
1074	Metabolomics Biomarkers of Prostate Cancer: A Systematic Review. Diagnostics, 2019, 9, 21.	1.3	52
1076	Making Active Surveillance a path towards health promotion: A qualitative study on prostate cancer patientsâ€™ perceptions of health promotion during Active Surveillance. European Journal of Cancer Care, 2019, 28, e13014.	0.7	5
1077	Quantification of PSMA expression in prostate cancer by pharmacokinetic modeling of targeted ultrasound nanobubbles. , 2019, , .		1
1078	Salvage Hemiablation High Intensity Focused Ultrasound for unilateral radio-recurrent prostate cancer. Progres En Urologie, 2019, 29, 627-633.	0.3	3
1079	Outcomes of pathologically localized high-grade prostate cancer treated with radical prostatectomy. Medicine (United States), 2019, 98, e17627.	0.4	5
1080	Fifteenâ€year analysis of prostate biopsies in Western Australia including recent impact of multiparametric magnetic resonance imaging. ANZ Journal of Surgery, 2019, 89, 1605-1609.	0.3	1
1081	Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer. Clinical Nuclear Medicine, 2019, 44, e629-e633.	0.7	20
1082	Impact of the 2014 International Society of Urological Pathology Grading System on Concept of High-Risk Prostate Cancer: Comparison of Long-Term Oncological Outcomes in Patients Undergoing Radical Prostatectomy. Frontiers in Oncology, 2019, 9, 1272.	1.3	9
1083	Incidentalomas of the prostate detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography. Canadian Urological Association Journal, 2019, 14, E180-E184.	0.3	5
1084	Stratification based on adverse laboratory/pathological features for predicting overall survival in patients undergoing radical prostatectomy. Medicine (United States), 2019, 98, e17931.	0.4	2
1085	Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer. Clinical Nuclear Medicine, 2019, 44, 365-376.	0.7	16
1086	Role of surgery in oligometastatic prostate cancer. Prostate International, 2019, 7, 125-130.	1.2	15

#	Article	IF	Citations
1087	Comparison of bone scintigraphy and Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography in the detection of bone metastases of prostate carcinoma. Nuclear Medicine Communications, 2019, 40, 1243-1249.	0.5	7
1088	Magnetic Resonanceâ€“Guided Prostate Ablation. Seminars in Interventional Radiology, 2019, 36, 351-366.	0.3	4
1089	Antimicrobial Lubricant Did Not Reduce Infection Rate in Transrectal Biopsy Patients in a Large Randomized Trial Due to Low Complication Rates. European Urology Focus, 2019, 5, 992-997.	1.6	4
1090	Efficacy of early imaging with 68Ga-PSMA I&T in the discrimination of pelvic lesions in prostate cancer patients. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2019, 38, 100-105.	0.1	0
1091	[68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer. Molecular Imaging and Biology, 2019, 21, 574-581.	1.3	36
1092	Downregulation of miR-139-5p promotes prostate cancer progression through regulation of SOX5. Biomedicine and Pharmacotherapy, 2019, 109, 2128-2135.	2.5	42
1093	Imaging gastrin-releasing peptide receptors (GRPRs) in prostate cancer. Clinical and Translational Imaging, 2019, 7, 39-44.	1.1	5
1094	Optimization of prostate cancer cell detection using multiplex tyramide signal amplification. Journal of Cellular Biochemistry, 2019, 120, 4804-4812.	1.2	14
1095	Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men â‰¥75Âyears with localized prostate cancer. Strahlentherapie Und Onkologie, 2019, 195, 374-382.	1.0	9
1096	Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naÃ¯ve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. European Urology, 2019, 75, 570-578.	0.9	521
1097	Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned. Nature Reviews Clinical Oncology, 2019, 16, 168-184.	12.5	41
1098	Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences. European Radiology, 2019, 29, 4503-4513.	2.3	43
1099	Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration. International Journal of Clinical Oncology, 2019, 24, 546-553.	1.0	8
1100	Comparison of PIRADS 3 lesions with histopathological findings after MRI-fusion targeted biopsy of the prostate in a real world-setting. Clinical Hemorheology and Microcirculation, 2019, 71, 165-170.	0.9	14
1101	Fabrication of a novel and ultrasensitive label-free electrochemical aptasensor for detection of biomarker prostate specific antigen. International Journal of Biological Macromolecules, 2019, 126, 1065-1073.	3.6	53
1102	Eficacia de la imagen precoz con 68Ga-PSMA-I&T para la discriminaciÃ³n de lesiones en los pacientes con cÃ¡ncer de prÃ³stata. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2019, 38, 100-105.	0.0	1
1103	11C-choline PET/CT predicts survival in prostate cancer patients with PSAâ€‰<â€‰1 NG/ml. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 921-929.	3.3	14
1104	Peptide-Based Therapeutics for Oncology. Pharmaceutical Medicine, 2019, 33, 9-20.	1.0	17

#	Article	IF	Citations
1105	Postoperative Radiation Therapy in Localized Prostate Cancer: When, How Much, and How Fast?. International Journal of Radiation Oncology Biology Physics, 2019, 103, 289-292.	0.4	2
1106	MRI-TRUS fusion biopsy of the prostate: Quality of image fusion in a clinical setting. Clinical Hemorheology and Microcirculation, 2019, 70, 433-440.	0.9	13
1107	Non-palliative radiotherapy in ab initio oligometastatic prostate cancer: an Italian national survey. Radiologia Medica, 2019, 124, 211-217.	4.7	5
1108	Hybrid Imaging (PET-Computed Tomography/PET-MR Imaging) of Bone Metastases. PET Clinics, 2019, 14, 121-133.	1.5	7
1109	Pathologically Node-Positive Prostate Carcinoma â€“ Prevalence, Pattern of Care and Outcome From a Population-Based Study. Clinical Oncology, 2019, 31, 91-98.	0.6	5
1110	3D versus 2D laparoscopic radical prostatectomy for organ confined prostate cancer: Our experience. Journal of Clinical Urology, 2019, 12, 186-191.	0.1	3
1111	Permanent 125 I prostate brachytherapy for castrationâ€resistant prostate cancer. International Journal of Urology, 2019, 26, 278-283.	0.5	4
1112	Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology. American Journal of Roentgenology, 2019, 212, 351-356.	1.0	46
1113	Stateâ€ofâ€theâ€art imaging techniques in the management of preoperative staging and reâ€staging of prostate cancer. International Journal of Urology, 2019, 26, 18-30.	0.5	16
1114	Use of vitamin K antagonists and risk of prostate cancer: Metaâ€“analysis and nationwide caseâ€“control study. International Journal of Cancer, 2019, 144, 1522-1529.	2.3	7
1115	Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results. Hormones and Cancer, 2019, 10, 36-44.	4.9	23
1116	Suprapubic tube compared with urethral catheter drainage after robot-assisted radical prostatectomy: A systematic review and meta-analysis. Asian Journal of Surgery, 2019, 42, 71-80.	0.2	7
1117	Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres. European Urology Focus, 2019, 5, 186-191.	1.6	3
1118	A global, incremental development method for a web-based prostate cancer treatment decision aid and usability testing in a Dutch clinical setting. Health Informatics Journal, 2019, 25, 701-714.	1.1	18
1119	Online Interactive Case-Based Instruction in Prostate Magnetic Resonance Imaging Interpretation Using Prostate Imaging and Reporting Data System Version 2: Effect for Novice Readers. Current Problems in Diagnostic Radiology, 2019, 48, 132-141.	0.6	14
1120	Forecasting, uncertainty and risk; perspectives on clinical decision-making in preventive and curative medicine. International Journal of Forecasting, 2019, 35, 659-666.	3.9	12
1121	Initial outcomes of local anaesthetic freehand transperineal prostate biopsies in the outpatient setting. BJU International, 2020, 125, 244-252.	1.3	60
1122	Exercise medicine for the management of androgen deprivation therapy-related side effects in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 62-70.	0.8	32

#	Article	IF	Citations
1123	Effects of the addition of quantitative apparent diffusion coefficient data on the diagnostic performance of the PI-RADS v2 scoring system to detect clinically significant prostate cancer. World Journal of Urology, 2020, 38, 981-991.	1.2	10
1124	Efficacy and safety of periprostatic nerve block combined with perineal subcutaneous anaesthesia and intrarectal lidocaine gel in transrectal ultrasound guided transperineal prostate biopsy: A Prospective Randomised Controlled Trial. Prostate Cancer and Prostatic Diseases, 2020, 23, 74-80.	2.0	13
1125	Implementation of a decision aid for localized prostate cancer in routine care: A successful implementation strategy. Health Informatics Journal, 2020, 26, 1194-1207.	1.1	9
1126	Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysis. European Urology Oncology, 2020, 3, 10-20.	2.6	63
1127	The effects of L-NAME on DU145 human prostate cancer cell line: A cytotoxicity-based study. Human and Experimental Toxicology, 2020, 39, 182-193.	1.1	12
1128	Inflammatory serum markers and risk and severity of prostate cancer: The PROCAâ€life study. International Journal of Cancer, 2020, 147, 84-92.	2.3	26
1129	Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer. Clinical Chemistry, 2020, 66, 161-168.	1.5	21
1130	Radical prostatectomy and simultaneous penile prosthesis implantation: a narrative review. International Journal of Impotence Research, 2020, 32, 274-280.	1.0	4
1131	PI-RADS Version 2 Is an Excellent Screening Tool for Clinically Significant Prostate Cancer as Designated by the Validated International Society of Urological Pathology Criteria: A Retrospective Analysis. Current Problems in Diagnostic Radiology, 2020, 49, 407-411.	0.6	5
1132	Introducing Decision Aids into Routine Prostate Cancer Care in The Netherlands: Implementation and Patient Evaluations from the Multi-regional JIPPA Initiative. Journal of Cancer Education, 2020, 35, 1141-1148.	0.6	7
1133	Detection and monitoring prostate specific antigen using nanotechnology approaches to biosensing. Frontiers of Chemical Science and Engineering, 2020, 14, 4-18.	2.3	20
1134	Clinical Value of the Elastographic Qâ€Analysis Score in Assisting Realâ€Time Elastographyâ€Guided Prostate Biopsy: A Retrospective Study of 125 Patients. Journal of Ultrasound in Medicine, 2020, 39, 83-87.	0.8	5
1135	A single-center, retrospective review of robot-assisted laparoscopic prostatectomy with and without cryopreserved umbilical cord allograft in improving continence recovery. Journal of Robotic Surgery, 2020, 14, 283-289.	1.0	8
1136	Regular vs. selective use of closed suction drains following robot-assisted radical prostatectomy: results from a regional quality improvement collaborative. Prostate Cancer and Prostatic Diseases, 2020, 23, 151-159.	2.0	5
1137	Activated Wnt/Î²-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer. Life Sciences, 2020, 254, 116816.	2.0	10
1138	Rationalising bone scan usage in prostate cancer staging â€“ A UK nationwide audit of the BAUS Radical Prostatectomy (RP) database. Journal of Clinical Urology, 2020, 13, 210-216.	0.1	0
1139	A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 401-409.	0.8	10
1140	Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers. Radiation Oncology, 2020, 15, 1.	1.2	31

#	Article	IF	Citations
1141	A Novel Prediction Tool Based on Multiparametric Magnetic Resonance Imaging to Determine the Biopsy Strategy for Clinically Significant Prostate Cancer in Patients with PSA Levels Less than 50Âng/ml. Annals of Surgical Oncology, 2020, 27, 1284-1295.	0.7	7
1142	Primary Radical Prostatectomy or Ablative Radiotherapy as Protective Factors for Patients With mCRPC Treated With Radium-223 Dichloride: An Italian Multicenter Study. Clinical Genitourinary Cancer, 2020, 18, 185-191.	0.9	8
1143	Laparoscopic radical prostatectomy versus robot-assisted radical prostatectomy: comparison of oncological outcomes at a single center. Prostate International, 2020, 8, 16-21.	1.2	11
1144	Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study. Prostate International, 2020, 8, 34-40.	1.2	10
1145	In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?. Nuclear Medicine Communications, 2020, 41, 139-146.	0.5	17
1146	99mTc-MIP-1404 SPECT/CT for Patients With Metastatic Prostate Cancer. Clinical Nuclear Medicine, 2020, 45, 105-112.	0.7	8
1147	Safety and efficacy of guided biopsy. , 2020, , 431-444.		0
1148	Mapping the prevalence of the neglected sexual side effects after prostate cancer treatment and the questionnaires used in their screening: a scoping review protocol. Systematic Reviews, 2020, 9, 214.	2.5	3
1149	Epidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database. Cancer Epidemiology, 2020, 69, 101833.	0.8	14
1150	99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients With Biochemical Recurrence of Prostate Cancer. Clinical Nuclear Medicine, 2020, 45, e349-e357.	0.7	15
1151	Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study. Cancer Imaging, 2020, 20, 72.	1.2	10
1152	YB-1: The key to personalised prostate cancer management?. Cancer Letters, 2020, 490, 66-75.	3.2	13
1153	An evaluation of the timing of surgical complications following radical prostatectomy: Data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). Arab Journal of Urology Arab Association of Urology, 2020, 18, 136-141.	0.7	3
1154	Subcutaneous in situ gel delivered leuprolide acetate's consistent and prolonged drug delivery maintains effective testosterone suppression independent of age and weight in men with prostate cancer. BJUI Compass, 2020, 1, 64-73.	0.7	4
1156	An Efficient Lightweight CNN and Ensemble Machine Learning Classification of Prostate Tissue Using Multilevel Feature Analysis. Applied Sciences (Switzerland), 2020, 10, 8013.	1.3	13
1157	Neuromodulation and the Epidemiology of Magnetic Resonance Utilization for Lung, Breast, Colon, and Prostate Cancer. Neuromodulation, 2020, 23, 912-921.	0.4	3
1158	PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management. Seminars in Oncology Nursing, 2020, 36, 151044.	0.7	0
1159	Association Between Contrast-Enhanced Ultrasound Indicators and Prostate Cancer Biochemical Recurrence After Treatment . Cancer Management and Research, 2020, Volume 12, 4959-4968.	0.9	4

#	Article	IF	Citations
1160	Superior survival benefits of Radical Prostatectomy than External Beam Radiotherapy in aging 75 and older men with high-risk or very high-risk Prostate Cancer: a population-matched study. Journal of Cancer, 2020, 11, 5371-5378.	1.2	2
1161	Clinical Effectiveness of an Adaptive Treatment Planning Algorithm for Intensity Modulated Radiation Therapy Versus 3D Conformal Radiation Therapy for Node-Positive Breast Cancer Patients Undergoing Regional Nodal Irradiation/Postmastectomy Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1159-1171.	0.4	16
1162	Genomic Analysis of Localized High-Risk Prostate Cancer Circulating Tumor Cells at the Single-Cell Level. Cells, 2020, 9, 1863.	1.8	18
1163	Serum ProGRP as a novel biomarker of bone metastasis in prostate cancer. Clinica Chimica Acta, 2020, 510, 437-441.	0.5	4
1164	Elastography Targeted Prostate Biopsy in Patients under Active Surveillance. Urologia Internationalis, 2020, 104, 948-953.	0.6	1
1165	Evaluation of Plasma Circulating Cell Free DNA Concentration and Integrity in Patients with Prostate Cancer in Jamaica: A Preliminary Study. Diseases (Basel, Switzerland), 2020, 8, 34.	1.0	4
1166	Retrotrigonal muscular layer sling associated with total anatomical reconstruction in robot-assisted radical prostatectomy and early continence. World Journal of Urology, 2021, 39, 2475-2481.	1.2	3
1167	Robot-assisted radical prostatectomy with clipless intrafascial neurovascular bundle-sparing approach: surgical technique and one-year functional and oncologic outcomes. Scientific Reports, 2020, 10, 17595.	1.6	3
1168	PSA Based Biomarkers, Imagistic Techniques and Combined Tests for a Better Diagnostic of Localized Prostate Cancer. Diagnostics, 2020, 10, 806.	1.3	9
1170	Aggressive prostate cancer phenotype and genome-wide association studies: where are we now?. Pharmacogenomics, 2020, 21, 487-503.	0.6	4
1171	Factors affecting health-related quality of life among prostate cancer patients: A systematic review. Journal of Oncology Pharmacy Practice, 2020, 26, 1997-2010.	0.5	17
1172	Diagnostic performance of F-18 fluciclovine PET/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level â‰0.5â€‰ng/mL. Nuclear Medicine Communications, 2020, 41, 906-915.	0.5	9
1173	A Clinical Reminder Order Check Intervention to Improve Guideline-concordant Imaging Practices for Men With Prostate Cancer: A Pilot Study. Urology, 2020, 145, 113-119.	0.5	7
1174	Psychosocial consequences of potential overdiagnosis in prostate cancer a qualitative interview study. Scandinavian Journal of Primary Health Care, 2020, 38, 439-446.	0.6	8
1175	The Effect of Exercise on Body Composition and Physical Performance in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy (ADT): A Narrative Synthesis. Seminars in Oncology Nursing, 2020, 36, 151067.	0.7	5
1176	Harnessing the potential of multimodal radiotherapy in prostate cancer. Nature Reviews Urology, 2020, 17, 321-338.	1.9	15
1177	A Radiomics nomogram for predicting bone metastasis in newly diagnosed prostate cancer patients. European Journal of Radiology, 2020, 128, 109020.	1.2	29
1178	Serum Levels of Matrix Metalloproteinase-1 in Brazilian Patients with Benign Prostatic Hyperplasia or Prostate Cancer. Current Gerontology and Geriatrics Research, 2020, 2020, 1-7.	1.6	1

#	Article	IF	Citations
1179	â€œIn-Boreâ€•MRI-Guided Prostate Biopsy for Prostate Cancer Diagnosis: Results from 140 Consecutive Patients. Current Urology, 2020, 14, 22-31.	0.4	12
1180	A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated with radiotherapy. Scientific Reports, 2020, 10, 8191.	1.6	8
1181	Structural basis of prostate-specific membrane antigen recognition by the A9g RNA aptamer. Nucleic Acids Research, 2020, 48, 11130-11145.	6.5	15
1182	MicroRNA-939 Directly Targets HDGF to Inhibit the Aggressiveness of Prostate Cancer via Deactivation of the WNT/Î²-Catenin Pathway . OncoTargets and Therapy, 2020, Volume 13, 4257-4270.	1.0	9
1183	Association of KLK3, VAMP8 and MDM4 Genetic Variants within microRNA Binding Sites with Prostate Cancer: Evidence from Serbian Population. Pathology and Oncology Research, 2020, 26, 2409-2423.	0.9	7
1184	Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe). BMC Medicine, 2020, 18, 139.	2.3	10
1185	Effectiveness of Decision Aid in Men with Localized Prostate Cancer: a Multicenter Randomized Controlled Trial at Tertiary Referral Hospitals in an Asia Pacific Country. Journal of Cancer Education, 2022, 37, 169-178.	0.6	3
1186	Three-dimensional MRI evaluation of the effect of bladder volume on prostate translocation and distortion. Radiology and Oncology, 2020, 54, 48-56.	0.6	5
1187	Diagnostic Value of Transrectal Shear Wave Elastography for Prostate Cancer Detection in Peripheral Zone: Comparison with Magnetic Resonance Imaging. Journal of Endourology, 2020, 34, 558-566.	1.1	12
1188	Solitary prostate cancer liver metastasis: an exceptional indication for liver resection. Acta Chirurgica Belgica, 2020, 121, 1-5.	0.2	2
1189	Retrospective correlation of 68ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy. Annals of Nuclear Medicine, 2020, 34, 388-396.	1.2	8
1190	A feasibility study of a psychoâ€educational support intervention for men with prostate cancer on active surveillance. Cancer Reports, 2020, 3, e1230.	0.6	2
1191	Clinically significant prostate cancer detection and segmentation in low-risk patients using a convolutional neural network on multi-parametric MRI. European Radiology, 2020, 30, 6582-6592.	2.3	61
1192	Comparison of 68Ga-PSMA-617 PET/CT with mpMRI for the detection of PCa in patients with a PSA level of 4â€“20Âng/ml before the initial biopsy. Scientific Reports, 2020, 10, 10963.	1.6	21
1194	Enâ€face optical coherence tomography for the detection of cancer in prostatectomy specimens: Quantitative analysis in 20 patients. Journal of Biophotonics, 2020, 13, e201960105.	1.1	0
1195	Feasibility of freehand MRI/US cognitive fusion transperineal biopsy of the prostate in local anaesthesia as in-office procedureâ€”experience with 400 patients. Prostate Cancer and Prostatic Diseases, 2020, 23, 429-434.	2.0	31
1196	Early Mortality of Prostatectomy vs. Radiotherapy as a Primary Treatment for Prostate Cancer: A Population-Based Study From the United States and East Germany. Frontiers in Oncology, 2019, 9, 1451.	1.3	0
1197	Cancer Detection Rates of Systematic and Targeted Prostate Biopsies after Biparametric MRI. Prostate Cancer, 2020, 2020, 1-6.	0.4	4

#	Article	IF	Citations
1198	Variation of colorectal, breast and prostate cancer screening activity in Switzerland: Influence of insurance, policy and guidelines. PLoS ONE, 2020, 15, e0231409.	1.1	14
1199	The Management of Patients Diagnosed with Incidental Prostate Cancer: Narrative Review . Research and Reports in Urology, 2020, Volume 12, 105-109.	0.6	10
1200	Limitations of abdominopelvic CT and multiparametric MR imaging for detection of lymph node metastases prior to radical prostatectomy. World Journal of Urology, 2021, 39, 779-785.	1.2	6
1201	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Archives of Pathology and Laboratory Medicine, 2021, 145, 461-493.	1.2	143
1202	The prevalence and locations of bone metastases using whole-body MRI in treatment-naÃ¯ve intermediate- and high-risk prostate cancer. European Radiology, 2021, 31, 2747-2753.	2.3	8
1203	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 174-185.	0.4	77
1204	Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)â€”do we still need contrast media?. European Radiology, 2021, 31, 3754-3764.	2.3	10
1205	Life Expectancy and Treatment Patterns in Elderly Patients With Low-Risk Papillary Thyroid Cancer: A Population-Based Analysis. Endocrine Practice, 2021, 27, 228-235.	1.1	7
1206	Optimizing the risk threshold of lymph node involvement for performing extended pelvic lymph node dissection in prostate cancer patients: a cost-effectiveness analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 72.e7-72.e14.	0.8	1
1207	The diagnostic accuracy of multiparametric MRI for detection and localization of prostate cancer depends on the affected region. BJUI Compass, 2021, 2, 178-187.	0.7	3
1208	Diagnosis of prostate cancer in one day: The benefits of cytology in tumour detection. Cytopathology, 2021, 32, 211-216.	0.4	0
1209	The application of virtual reality training for anastomosis during robot-assisted radical prostatectomy. Asian Journal of Urology, 2021, 8, 204-208.	0.5	8
1210	Multiparametric MRI Lesion Classified as Prostate Imaging-Reporting and Data System 5 but Histopathologically Described as Benign: A Case Report and Review of Literature. Urologia Internationalis, 2021, 105, 520-524.	0.6	1
1211	Extracapsular extension on multiparametric magnetic resonance imaging better predicts pT3 disease at radical prostatectomy compared to perineural invasion on biopsy. Canadian Urological Association Journal, 2021, 15, 261-266.	0.3	1
1212	To sling or not to sling? Impact of intraoperative sling procedures during radical prostatectomy on postoperative continence outcomes: A systematic review and metaâ€analysis. BJUI Compass, 2021, 2, 226-237.	0.7	4
1213	Eligibility criteria according to EAU/ESTRO/SIOG guidelines for exclusive iodine-125 brachytherapy for intermediate-risk prostate adenocarcinoma patients: impact on relapse-free survival. Journal of Contemporary Brachytherapy, 2021, 13, 373-386.	0.4	2
1214	Impact of Benign Prostatic Hyperplasia and/or Prostatitis on the Risk of Prostate Cancer in Korean Patients. World Journal of Men?s Health, 2021, 39, 358.	1.7	9
1215	Novel Metabolic Signatures of Prostate Cancer Revealed by 1H-NMR Metabolomics of Urine. Diagnostics, 2021, 11, 149.	1.3	22

#	Article	IF	Citations
1216	Dynamic contrast-enhanced magnetic resonance imaging for risk stratification in patients with prostate cancer. Quantitative Imaging in Medicine and Surgery, 2022, 12, 742-751.	1.1	6
1217	Microvessel density as a prognostic indicator of prostate cancer: A systematic review and meta-analysis. Open Medicine (Poland), 2021, 16, 882-891.	0.6	0
1218	The role of surgery in high risk and advanced prostate cancer: A narrative review. Turkish Journal of Urology, 2021, 47, S56-S64.	1.3	1
1219	Endocrinology of the Aging Prostate: Current Concepts. Frontiers in Endocrinology, 2021, 12, 554078.	1.5	26
1220	Evaluation of 68Ga-PSMA PET/CT with volumetric parameters for staging of prostate cancer patients. Nuclear Medicine Communications, 2021, 42, 503-509.	0.5	10
1221	Rate of clinically significant prostate cancer on repeat saturation biopsy after a diagnosis of atypical small acinar proliferation. Urologia, 2021, 88, 194-199.	0.3	3
1222	Prostate cancer follow-up costs in Germany from 2000 to 2015. Journal of Cancer Survivorship, 2022, 16, 86-94.	1.5	5
1223	MiRNAs and radical prostatectomy: Current data, bioinformatic analysis and utility as predictors of tumour relapse. Andrology, 2021, 9, 1092-1107.	1.9	2
1224	Rigid and flexible ureteroscopy (URS/RIRS) management of paediatric urolithiasis in a not endemic country. Archivio Italiano Di Urologia Andrologia, 2021, 93, 26-30.	0.4	12
1225	[68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients. Archivio Italiano Di Urologia Andrologia, 2021, 93, 21-25.	0.4	3
1226	Comparison between laparoscopic and open prostatectomy: Oncological progression analysis. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2021, 45, 139-145.	0.2	1
1227	ComparaciÃ³n entre prostatectomÃa laparoscÃ³pica y abierta: anÃ¡lisis de la evoluciÃ³n oncolÃ³gica. Actas UrolÃ³gicas EspaÃ±olas, 2021, 45, 139-145.	0.3	3
1229	The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging. Current Oncology, 2021, 28, 1294-1301.	0.9	7
1230	Pulmonary metastasectomy in germ cell tumors and prostate cancer. Journal of Thoracic Disease, 2021, 13, 2661-2668.	0.6	3
1231	Transvesical Versus Posterior Approach to Retzius-Sparing Robot-Assisted Radical Prostatectomy: A Retrospective Comparison With a 12-Month Follow-Up. Frontiers in Oncology, 2021, 11, 641887.	1.3	12
1232	ENHANCED ANTICANCER POTENCY OF GEMCITABINE IN COMBINATION WITH PROPOFOL IN PROSTATE CANCER. Hacettepe Journal of Biology and Chemistry, 0, , .	0.3	0
1233	Stage and Grade Migration in Prostate Cancer Treated With Radical Prostatectomy in a Large German Multicenter Cohort. Clinical Genitourinary Cancer, 2021, 19, 162-166.e1.	0.9	11
1234	Still Unanswered: The Role of Extended Pelvic Lymphadenectomy in Improving Oncological Outcomes in Prostate Cancer. European Urology, 2021, 79, 605-606.	0.9	5

#	Article	IF	Citations
1235	Modeling-Based Decision Support System for Radical Prostatectomy Versus External Beam Radiotherapy for Prostate Cancer Incorporating an In Silico Clinical Trial and a Costâ€“Utility Study. Cancers, 2021, 13, 2687.	1.7	1
1236	Identification of a serum biomarker signature associated with metastatic prostate cancer. Proteomics - Clinical Applications, 2021, 15, 2000025.	0.8	3
1237	Impact of MRI/US fusionâ€guided prostate biopsy on biopsyâ€naÃ¯ve patients: A single urologistâ€™s experience. BJUI Compass, 2022, 3, 19-25.	0.7	2
1238	Application-specific nuclear medical in vivo imaging devices. Physics in Medicine and Biology, 2021, 66, 10TR01.	1.6	3
1239	Past, present and future magnetic resonance diagnosis of prostate cancer. Onkourologiya, 2021, 17, 142-152.	0.1	0
1240	OR Practiceâ€“Data Analytics for Optimal Detection of Metastatic Prostate Cancer. Operations Research, 2021, 69, 774-794.	1.2	5
1241	Target-Specific Magnetic Resonance Imaging of Human Prostate Adenocarcinoma Using NaDyF4â€“NaGdF4 Coreâ€“Shell Nanoparticles. ACS Applied Materials & Interfaces, 2021, 13, 24345-24355.	4.0	6
1242	Validation of the new STAR-CAP prognostic group staging system in prostate cancer patients treated with radiation therapy. World Journal of Urology, 2021, 39, 4127-4133.	1.2	3
1243	Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naÃ¯ve men. Prostate Cancer and Prostatic Diseases, 2021, 24, 1110-1119.	2.0	40
1244	Modern aspects of targeted prostate biopsy. Onkourologiya, 2021, 17, 153-158.	0.1	0
1245	Untargeted metabolomics of prostate cancer zwitterionic and positively charged compounds in urine. Analytica Chimica Acta, 2021, 1158, 338381.	2.6	24
1246	The role of pre-biopsy mpMRI in lymph node staging for prostate cancer. Urologia, 2022, 89, 64-69.	0.3	0
1247	Using single-vesicle technologies to unravel the heterogeneity of extracellular vesicles. Nature Protocols, 2021, 16, 3163-3185.	5.5	118
1248	Lower Urinary Tract Symptoms in Prostate Cancer Patients Treated With Radiation Therapy: Past and Present. International Neurourology Journal, 2021, 25, 119-127.	0.5	9
1249	Transperineal versus transrectal multi-parametric magnetic resonance imaging fusion targeted prostate biopsy. Journal of King Abdulaziz University, Islamic Economics, 2021, 42, 649-654.	0.5	2
1250	Highâ€doseâ€rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome. Cancer Reports, 2022, 5, e1450.	0.6	9
1251	Bi-parametric magnetic resonance imaging based radiomics for the identification of benign and malignant prostate lesions: cross-vendor validation. Physical and Engineering Sciences in Medicine, 2021, 44, 745-754.	1.3	12
1252	Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study. Radiology and Oncology, 2021, 55, 474-481.	0.6	1

#	Article	IF	Citations
1253	Assessing the accuracy of 68 Gaâ€PSMA PET/CT compared with MRI in the initial diagnosis of prostate malignancy: A cohort analysis of 114 consecutive patients. Journal of Medical Imaging and Radiation Oncology, 2021, , .	0.9	1
1254	Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience. Nuclear Medicine Communications, 2021, 42, 1254-1260.	0.5	7
1255	Differences in treatment choices between prostate cancer patients using a decision aid and patients receiving care as usual: results from a randomized controlled trial. World Journal of Urology, 2021, 39, 4327-4333.	1.2	4
1256	PROSPECT guidelines update for evidence-based pain management after prostatectomy for cancer. Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100922.	0.6	14
1257	The Prognosis of Radical Prostatectomy, External Beam Radiotherapy plus Brachytherapy, and External Beam Radiotherapy Alone for Patients above 70 Years with Very High-Risk Prostate Cancer: A Population-Matched Study. Urologia Internationalis, 2022, 106, 11-19.	0.6	2
1258	Evaluation of lymphovascular invasion as a prognostic predictor of overall survival after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 495.e1-495.e6.	0.8	5
1260	Optimal biopsy approach for detection of clinically significant prostate cancer. British Journal of Radiology, 2022, 95, 20210413.	1.0	11
1261	Prospective comparison of simultaneous [68Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer. European Radiology, 2022, 32, 901-911.	2.3	11
1262	Therapeutic Multidose Preparation of a Ready-to-Use 177Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy. Cancer Biotherapy and Radiopharmaceuticals, 2021, 36, 682-692.	0.7	2
1264	Clinical Evaluation of FOXO1 as a Tumor Suppressor in Prostate Cancer. Computational and Mathematical Methods in Medicine, 2021, 2021, 1-8.	0.7	3
1265	Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management. Biomedicines, 2021, 9, 1179.	1.4	17
1266	Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase. Urology, 2021, 155, 144-151.	0.5	2
1267	Interreader agreement in evaluation of 68Ga-PSMA PET/CT at the time of initial staging: comparison of the three evaluation criteria in the pretreatment risk groups. Nuclear Medicine Communications, 2022, 43, 86-91.	0.5	1
1268	Clinical Impact of the Predict Prostate Risk Communication Tool in Men Newly Diagnosed with Nonmetastatic Prostate Cancer: A Multicentre Randomised Controlled Trial. European Urology, 2021, 80, 661-669.	0.9	7
1269	Ibrutinib conjugated surface-functionalized multiwalled carbon nanotubes and its biopolymer composites for targeting prostate carcinoma. Journal of Materials Science, 2021, 56, 18684.	1.7	2
1270	Comparison of the metabolome in urine prior and eight weeks after radical prostatectomy uncovers pathologic and molecular features of prostate cancer. Journal of Pharmaceutical and Biomedical Analysis, 2021, 205, 114288.	1.4	3
1271	Impact of Decipher on use of postâ€operative radiotherapy: Individual patient analysis of two prospective registries. BJUI Compass, 2021, 2, 267-274.	0.7	7
1272	Navigate: a study protocol for a randomised controlled trial of an online treatment decision aid for men with low-risk prostate cancer and their partners. Trials, 2021, 22, 49.	0.7	6

#	Article	IF	Citations
1273	Detection rate of prostate cancer following 12-core extended biopsy in a Semi-urban Nigerian Tertiary Hospital. Urology Annals, 2021, 13, 150.	0.3	0
1274	PET/CT with ¹⁸F-PSMA in Patients with Prostate Cancer, Review of the Initial Experience. Open Journal of Urology, 2021, 11, 158-175.	0.0	0
1275	External validation of genomic classifier-based risk-stratification tool to identify candidates for adjuvant radiation therapy in patients with prostate cancer. World Journal of Urology, 2021, 39, 3217-3222.	1.2	2
1277	Introduction for sexuality after prostate cancer. International Journal of Impotence Research, 2021, 33, 389-390.	1.0	2
1278	A comparison of perioperative outcomes between extraperitoneal robotic single-port and multiport radical prostatectomy with the da Vinci Si Surgical System. Asian Journal of Andrology, 2021, 23, 640.	0.8	13
1279	Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronieâ€™s Disease. , 2020, , 357-392.		1
1281	Prostate Cryotherapy. , 2017, , 273-285.		1
1282	Radical Prostatectomy Through the Posterior Technique. , 2018, , 401-410.		1
1283	Intensity-Modulated Radiation Therapy for Locally Advanced Prostate Cancer. , 2015, , 379-402.		1
1284	Biomedical application of VIMP: screening of malignant cells in the prostate. Journal of Solid State Electrochemistry, 2020, 24, 2853-2860.	1.2	2
1285	68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy. Academic Radiology, 2019, 26, 450-460.	1.3	16
1288	Control Strategies and Daily Affect. GeroPsych: the Journal of Gerontopsychology and Geriatric Psychiatry, 2020, 33, 155-169.	0.2	5
1289	Transitioning to whole-body SPECT/CT in prostate cancer staging: aÂnew concept for a better imaging workflow. Nuklearmedizin - NuclearMedicine, 2019, 58, 451-459.	0.3	1
1290	Detection and Characterization of Musculoskeletal Cancer Using Whole-Body Magnetic Resonance Imaging. Seminars in Musculoskeletal Radiology, 2020, 24, 726-750.	0.4	7
1291	Full Neurovascular Preservation in Radical Prostatectomy: Technical Note. Videourology (New) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 182	0.1	1
1292	Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomized controlled feasibility trial. BJU International, 2017, 120, E8-E20.	1.3	33
1293	Needle-based optical coherence tomography for the detection of prostate cancer: a visual and quantitative analysis in 20 patients. Journal of Biomedical Optics, 2018, 23, 1.	1.4	17
1294	A real-time 4-bit imaging electrical impedance sensing biopsy needle for prostate cancer detection. , 2018, , .		4

#	Article	IF	Citations
1295	Progress in applications of F-fluciclovine in diagnosis of prostate cancer. Journal of Central South University (Medical Sciences), 2020, 45, 187-192.	0.1	2
1296	Promoter Methylation of Protocadherin8 is an Independent Prognostic Factor for Biochemical Recurrence of Early-Stage Prostate Cancer. Medical Science Monitor, 2014, 20, 2584-2589.	0.5	14
1297	Photoacoustic tomography for imaging the prostate: a transurethral illumination probe design and application. Biomedical Optics Express, 2019, 10, 2588.	1.5	16
1298	â€˜Act on Oncologyâ€™ as a New Comprehensive Approach to Assess Prostate Cancer Centres â€“ Method Description and Results of a Pilot Study. PLoS ONE, 2014, 9, e106743.	1.1	4
1299	DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer. PLoS ONE, 2015, 10, e0130651.	1.1	30
1300	Fat Intake Is Not Linked to Prostate Cancer: A Systematic Review and Dose-Response Meta-Analysis. PLoS ONE, 2015, 10, e0131747.	1.1	34
1301	Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence. PLoS ONE, 2016, 11, e0152391.	1.1	13
1302	Preoperative Multiparametric Magnetic Resonance Imaging Predicts Biochemical Recurrence in Prostate Cancer after Radical Prostatectomy. PLoS ONE, 2016, 11, e0157313.	1.1	32
1303	Standardized Reporting of Prostate MRI: Comparison of the Prostate Imaging Reporting and Data System (PI-RADS) Version 1 and Version 2. PLoS ONE, 2016, 11, e0162879.	1.1	41
1304	Rectal Culture-Guided Targeted Antimicrobial Prophylaxis Reduces the Incidence of Post-Operative Infectious Complications in Men at High Risk for Infections Submitted to Transrectal Ultrasound Prostate Biopsy â€“ Results of a Cross-Sectional Study. PLoS ONE, 2017, 12, e0170319.	1.1	15
1305	Dietary patterns and risk of prostate cancer: a factor analysis study in a sample of Iranian men. Health Promotion Perspectives, 2018, 8, 133-138.	0.8	11
1306	Ziarniniakowe zapalenie stercza po immunoterapii dopÄ™cherzowej imitujÄ…ce raka stercza. Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ‚-SzopiÅ„ska, 2016, 16, 404-410.	0.7	3
1308	Analysis of association of potentially functional genetic variants within genes encoding miR-34b/c, miR-378 and miR-143/145 with prostate cancer in Serbian population. EXCLI Journal, 2019, 18, 515-529.	0.5	9
1310	Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers. Oncotarget, 2016, 7, 51965-51980.	0.8	35
1311	Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget, 2016, 7, 64447-64470.	0.8	130
1312	An imaging-based approach predicts clinical outcomes in prostate cancer through a novel support vector machine classification. Oncotarget, 2016, 7, 78140-78151.	0.8	40
1313	Development and comparison of a Chinese nomogram adding multi-parametric MRI information for predicting extracapsular extension of prostate cancer. Oncotarget, 2017, 8, 22095-22103.	0.8	15
1314	Photosensitizers in prostate cancer therapy. Oncotarget, 2017, 8, 30524-30538.	0.8	67

#	Article	IF	Citations
1315	Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death. Oncotarget, 2017, 8, 31765-31774.	0.8	15
1316	The combination of prostate imaging reporting and data system version 2 (PI-RADS v2) and periprostatic fat thickness on multi-parametric MRI to predict the presence of prostate cancer. Oncotarget, 2017, 8, 44040-44049.	0.8	15
1317	Genetic risk score to predict biochemical recurrence after radical prostatectomy in prostate cancer: prospective cohort study. Oncotarget, 2017, 8, 75979-75988.	0.8	6
1318	Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer. Oncotarget, 2017, 8, 63703-63714.	0.8	55
1319	Mitochondrial genome variation and prostate cancer: a review of the mutational landscape and application to clinical management. Oncotarget, 2017, 8, 71342-71357.	0.8	28
1320	Comparison on efficacy of radical prostatectomy versus external beam radiotherapy for the treatment of localized prostate cancer. Oncotarget, 2017, 8, 79854-79863.	0.8	20
1321	ThemicroRNA-23b/27b/24-1cluster is a disease progression marker and tumor suppressor in prostate cancer. Oncotarget, 2014, 5, 7748-7759.	0.8	115
1322	DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance. Oncotarget, 2015, 6, 2134-2147.	0.8	38
1323	Influence of age on predictiveness of genetic risk score for prostate cancer in a Chinese hospital-based biopsy cohort. Oncotarget, 2015, 6, 22978-22984.	0.8	9
1324	Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. Oncotarget, 2015, 6, 35542-35555.	0.8	60
1325	Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions. Current Cancer Drug Targets, 2019, 19, 368-381.	0.8	9
1326	Comparison of Bone Uptake in Bone Scan and Ga-68 PSMA PET/CT Images in Patients with Prostate Cancer. Current Medical Imaging, 2019, 15, 589-594.	0.4	5
1327	Multiparametric-Magnetic Resonance/Ultrasound Fusion Targeted Prostate Biopsy Improves Agreement Between Biopsy and Radical Prostatectomy Gleason Score. Anticancer Research, 2016, 36, 4833-4840.	0.5	42
1328	Role of Holmium laser enucleation of the prostate to increase cancer detection rate in patients with gray-zone PSA level. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 72-78.	3.9	7
1329	Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 7-18.	0.4	19
1330	MRI and 11C acetate PET/CT for prediction of regional lymph node metastasis in newly diagnosed prostate cancer. Radiology and Oncology, 2018, 52, 90-97.	0.6	3
1331	Assessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening. Iranian Biomedical Journal, 2018, 22, 331-337.	0.4	10
1332	Cancer de la prostate : communiquer dans le cadre dâ€™une recherche clinique avec des patients fragilisÃ©s par une prostatectomie radicale. Psycho-oncologie, 2018, 12, 62-66.	0.0	2

#	Article	IF	Citations
1333	The Treatment of Localized Prostate Cancer in Everyday Practice in Germany. Deutsches Ärzteblatt International, 2016, 113, 329-36.	0.6	21
1334	Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?. Radiation Oncology Journal, 2014, 32, 247.	0.7	2
1335	Endocrinotherapy resistance of prostate and breast cancer: Importance of the NFâ€ÎºB pathway (Review). International Journal of Oncology, 2020, 56, 1064-1074.	1.4	11
1336	Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients. Reviews in Urology, 2018, 20, 63-68.	0.9	7
1337	PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 65-71.	0.7	22
1338	Surgery and hormonal treatment for prostate cancer and sexual function. Translational Andrology and Urology, 2015, 4, 103-9.	0.6	6
1339	The current and future role of magnetic resonance imaging in prostate cancer detection and management. Translational Andrology and Urology, 2015, 4, 326-41.	0.6	29
1340	Extended lymph node dissection in robotic radical prostatectomy: Current status. Indian Journal of Urology, 2016, 32, 109.	0.2	1
1341	Analysis of expanded criteria to select candidates for active surveillance of low-risk prostate cancer. Asian Journal of Andrology, 2015, 17, 248.	0.8	2
1342	Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia. Asian Journal of Andrology, 2015, 17, 475.	0.8	47
1343	The prognostic value of lymphovascular invasion in radical prostatectomy: a systematic review and meta-analysis. Asian Journal of Andrology, 2016, 18, 780.	0.8	20
1344	Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy. Asian Journal of Andrology, 2016, 18, 639.	0.8	18
1345	Clinically available RNA profiling tests of prostate tumors: utility and comparison. Asian Journal of Andrology, 2016, 18, 575.	0.8	14
1346	Level of education and mortality after radical prostatectomy. Asian Journal of Andrology, 2017, 19, 173.	0.8	5
1347	Peripheral monocyte count: an independent diagnostic and prognostic biomarker for prostate cancer - a large Chinese cohort study. Asian Journal of Andrology, 2017, 19, 579.	0.8	21
1348	A comparative study of 68Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: An initial experience. World Journal of Nuclear Medicine, 2017, 16, 186-191.	0.3	61
1349	A prospective randomized comparative study of targeted versus empirical prophylactic antibiotics in the prevention of infective complications following transrectal ultrasound-guided prostate biopsy. Annals of African Medicine, 2019, 18, 132.	0.2	10
1350	Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients. Asian Journal of Andrology, 2018, 20, 56.	0.8	6

#	Article	IF	Citations
1351	Battle of the sexes: contrasting roles of testis-specific protein Y-encoded (TSPY) and TSPX in human oncogenesis. Asian Journal of Andrology, 2019, 21, 260.	0.8	9
1352	Initial experience with a novel method for cognitive transperineal magnetic resonance imaging-targeted prostate biopsy. Asian Journal of Andrology, 2020, 22, 432.	0.8	5
1353	Can Early Dynamic Positron Emission Tomography/Computed Tomography Obviate the Need for Postdiuresis Image in Ga-PSMA-HBED-CC Scan for Evaluation of Prostate Adenocarcinoma?. Indian Journal of Nuclear Medicine, 2018, 33, 202-208.	0.1	4
1354	Localization and restaging of carcinoma prostate by ⁶⁸Gallium prostate-specific membrane antigen positron emission tomography computed tomography in patients with biochemical recurrence. Indian Journal of Urology, 2020, 36, 191.	0.2	4
1355	Role of transrectal ultrasound elastography in the diagnosis of prostate carcinoma. Journal of Medical Ultrasound, 2020, 28, 173.	0.2	10
1356	A comparison of pain control and complications using three different ways of anesthesia in patients undergoing transrectal ultrasound-guided prostate biopsy. Journal of Research in Medical Sciences, 2018, 23, 17.	0.4	3
1357	Initial risk stratification and staging in prostate cancer with prostatic-specific membrane antigen positron emission tomography/computed tomography: A first-stop-shop. World Journal of Nuclear Medicine, 2018, 17, 261-269.	0.3	12
1358	Selection Criteria for Active Surveillance of Patients with Prostate Cancer in Korea: A Multicenter Analysis of Pathology after Radical Prostatectomy. Cancer Research and Treatment, 2018, 50, 265-274.	1.3	10
1359	Re-stratification of Patients with High-Risk Prostate Cancer According to the NCCN Guidelines among Patients Who Underwent Radical Prostatectomy: An Analysis Based on the K-CaP Registry. Cancer Research and Treatment, 2018, 50, 88-94.	1.3	4
1360	Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses. Cancer Research and Treatment, 2018, 50, 129-137.	1.3	15
1361	Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management. Bioanalysis, 2016, 8, 439-455.	0.6	11
1362	Correlation of SUV_{max} and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study. Molecular Imaging and Radionuclide Therapy, 2019, 28, 104-111.	0.3	9
1363	Frequency of IL-10+CD19+ B cells in patients with prostate cancer compared to patients with benign prostatic hyperplasia. African Health Sciences, 2020, 20, 1264-1272.	0.3	15
1364	Significance of atypical small acinar proliferation and extensive high-grade prostatic interaepithelial neoplasm in clinical practice. Central European Journal of Urology, 2014, 67, 136-41.	0.2	14
1365	Should active surveillance in prostate cancer patients be based on a single histological assessment?. Central European Journal of Urology, 2014, 67, 242-6.	0.2	1
1366	The comparison of the influence between two different bowel preparation methods on sepsis after prostate biopsies. Central European Journal of Urology, 2015, 68, 91-4.	0.2	7
1367	Transrectal-ultrasound prostatic biopsy preparati rectal enema vs. mechanical bowel preparation. Central European Journal of Urology, 2015, 68, 223-8.	0.2	10
1368	Age and aggressiveness of prostate cancer: analysis of clinical and pathological characteristics after radical prostatectomy for men with localized prostate cancer. Central European Journal of Urology, 2019, 72, 240-246.	0.2	2

#	Article	IF	Citations
1369	Prostatic surgery associated acute kidney injury. World Journal of Nephrology, 2014, 3, 98.	0.8	12
1371	Predictors of Positive Bone Metastasis in Newly Diagnosed Prostate Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2016, 17, 1187-1191.	0.5	8
1372	An examination of clinical differences between carriers and non-carriers of chromosome 8q24 risk alleles in a New Zealand Caucasian population with prostate cancer. PeerJ, 2016, 4, e1731.	0.9	2
1374	Single-Center Comparison of [64Cu]-DOTAGA-PSMA and [18F]-PSMA PETâ€“CT for Imaging Prostate Cancer. Current Oncology, 2021, 28, 4167-4173.	0.9	2
1375	Long-term consequences of bilateral cavernous crush injury in normal and diabetic rats: a functional study. International Journal of Impotence Research, 2022, 34, 781-785.	1.0	3
1376	Comparison of PET/CT and MRI in the Diagnosis of Bone Metastasis in Prostate Cancer Patients: A Network Analysis of Diagnostic Studies. Frontiers in Oncology, 2021, 11, 736654.	1.3	10
1377	Prevention and Early Detection of Urologic Cancers: A Mini-Review. , 2014, S, .		0
1378	Prostate Biopsy in the Elderly: Histologic Findings and Treatment Necessity. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8937-8939.	0.5	1
1379	Minimally Invasive Therapies for Pelvic Urological Cancer. , 2015, , 93-102.		0
1381	Future Uro-technologies: Hope or Hell for Prostate Cancer Patients?. , 2015, , 135-142.		0
1383	Gasless Single-Port RoboSurgeon Retroperitoneoscopic Radical Prostatectomy. , 2015, , 105-126.		0
1384	Does anterior prostatic fat tissue removed during robotic radical prostatectomy contain any lymph nodes?. Central European Journal of Urology, 2015, 68, 410-4.	0.2	5
1385	Gasless Single-Port RoboSurgeon Retroperitoneoscopic Pelvic Lymph Node Dissection and Inguinal Hernia Prevention. , 2015, , 159-173.		0
1386	The Cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 5-9.	0.7	3
1387	Prostatos vÄ—Å¾io rizikos skaiÄiuoklÄ—s galimybiÅ³ vertinimas planuojant prostatos biopsijÄ…. Medicinos Teorija Ir Praktika, 2015, 21, 277-279.	0.0	0
1388	Diagnosis and treatment of prostate cancer in elderly men. Pediatria I Medycyna Rodzinna, 2015, 11, 39-47.	2.3	0
1389	Extended pelvic lymphadenectomy in prostate cancer: Practice makes perfect. Canadian Urological Association Journal, 2015, 9, 232.	0.3	2
1390	SIGNIFICANCE OF DOPPLER-GRAPHIC RESEARCHES FOR DIAGNOSTICS OF PROSTATE CANCER. Vestnik Khirurgii Imeni I I Grekova, 2015, 174, 45-49.	0.0	0

#	Article	IF	Citations
1391	Frequency of Unnecessarily Biopsies among Patients with Suspicion of Prostate Cancer in Syrian Men. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5967-5970.	0.5	0
1392	PRIEÅOPERACINÄ–S MAGNETINIO REZONANSO TOMOGRAFIJOS REIKÅMÄ– PROSTATOS NAVIKO T DYDÅ½IUI NUSTATYTI. Medicinos Teorija Ir Praktika, 2015, 21, 612-617.	0.0	0
1393	Threshold-based parametric analysis of diffusion-weighted magnetic resonance imaging at 3.0 Tesla to identify men with prostate cancer. Advances in Modern Oncology Research, 2015, 1, .	0.1	0
1394	Alternative Verfahren bei Prostatakrebs. , 2016, , 1-63.		0
1395	Urologische Tumoren. , 2016, , 247-325.		0
1396	Prostate Carcinoma. , 2016, , 534-539.		0
1397	The limitations of multiparametric magnetic resonance imaging also must be borne in mind. Central European Journal of Urology, 2016, 69, 22-3.	0.2	5
1398	Does the molecular classification of breast cancer point the way for biomarker identification in prostate cancer?. World Journal of Clinical Urology, 2016, 5, 80.	0.0	0
1399	Pelvic Lymph Node Dissection: Open Benchmarks with Lymphoscintigraphy. , 2016, , 131-142.		0
1400	Adequate Diagnostic Performance of Combined [¹⁸F]-Fluormethylcholine PET-CT with Diffusion-Weighted MRI in Primary Staging of High Risk Prostate Cancer. Advances in Molecular Imaging, 2016, 06, 1-9.	0.3	0
1401	AB190. Could magnetic resonance imaging help identify the presence of prostate cancer before initial biopsy? The development of nomogram predicting the outcomes of prostate biopsy in the Chinese population. Translational Andrology and Urology, 2016, 5, AB190-AB190.	0.6	0
1402	Dual-timing PSA as a biomarker for patients with salvage intensity modulated radiation therapy for biochemical failure after radical prostatectomy. Oncotarget, 2016, 7, 44224-44235.	0.8	2
1403	The Cuban Institute of Oncology and Radiobiology experience on the beliefs and opinions about digital rectal exam in urological patients. Medwave, 2016, 16, e6501-e6501.	0.2	1
1404	Oligometastatic Disease in Prostate Cancer: Advances in Diagnosis and Treatment. , 0, , .		0
1405	Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA. Oncotarget, 2017, 8, 9935-9946.	0.8	2
1406	Chapter 2 Global Epidemiology of Prostate Cancer. Traditional Herbal Medicines for Modern Times, 2016, , 17-28.	0.1	0
1407	Comparison of Localized High Volume Tumor and Locally Advanced Low Volume Tumor after Radical Prostatectomy according to Risk Classification. The Korean Journal of Urological Oncology, 2016, 14, 165-171.	0.1	0
1408	Biopsie und Targeting. , 2017, , 91-110.		0

#	Article	IF	Citations
1409	Follow-Up After Radical Treatments and Relapse. , 2017, , 303-311.		0
1410	Re-irradiation in Prostate Cancer. , 2017, , 387-398.		0
1411	Combination of Androgen Deprivation Therapy and Radiation Therapy for Locally Advanced and Localized Prostate Cancer. , 2017, , 217-230.		0
1412	Focal Therapy and Active Surveillance in Europe. Current Clinical Urology, 2017, , 57-74.	0.0	0
1413	Advanced Radiotherapy Techniques in Prostate Cancer. , 2017, , 273-291.		0
1414	PrimÃrstaging des Prostatakarzinoms. , 2017, , 111-137.		0
1415	In-Bore Magnetic Resonance Imaging-Targeted Prostate Biopsy. Current Clinical Urology, 2017, , 205-218.	0.0	1
1416	Open Radical Prostatectomy. , 2017, , 171-180.		0
1417	10-Year Experience in Performing Saturation Prostate Biopsy. Revista Universitas Medica, 2017, 57, 430-437.	0.0	0
1418	Assessment of prostate cancer with integrated CT-perfusion using a sector-wise approach. Turkish Journal of Urology, 2017, 43, 152-157.	1.3	1
1419	Population Trends in Aging and Cancer. , 2018, , 1-8.		0
1420	PSMA-Based Therapy of Metastasized Castrate-Resistant Prostate Cancer. , 2018, , 451-464.		0
1421	Comparison of Perioperative and Functional Outcomes between Standard Laparoscopic and Robotic-Assisted Radical Prostatectomy: A Systemic Review and Meta-Analysis. Asian Case Reports in Surgery, 2018, 07, 17-30.	0.0	0
1422	Prostate Cancer Survivorship Programmes. , 2018, , 249-252.		0
1423	Effects of a Six-month Supervised Physical Exercise Program on Physical and Cardio-Metabolic Profile and Quality of Life in Patients with Prostate Cancer on Androgen Deprivation Therapy: a Pilot and Feasibility Study.. Central European Journal of Urology, 2018, 71, 234-241.	0.2	1
1424	Evaluation of safety and advisability of salvage lymph node dissection in patients with lymphogenic metastases of prostate cancer after radical treatment. Onkourologiya, 2018, 13, 64-69.	0.1	1
1425	Post Treatment Monitoring for Recurrence: The â€˜Usual Pathwayâ€™. , 2018, , 25-25.		0
1426	Systematic Review 1: Prostate Cancer Survivorship Care. , 2018, , 211-218.		0

#	Article	IF	Citations
1427	Prostate Carcinoma. , 2018, , 324-329.		0
1428	Current Follow-Up Care Pathway vs. a New â€˜Psychosexualâ€™ Pathway. , 2018, , 29-29.		0
1429	Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) as a Diagnostic Method for Prostate Cancer. Nephro-Urology Monthly, 2018, In Press, .	0.0	0
1431	Current status and new approaches in prostate cancer diagnosis. Zdrowie Publiczne, 2018, 128, 166-169.	0.2	0
1434	Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer. World Journal of Nuclear Medicine, 2019, 18, 143.	0.3	4
1435	Does the prostate volume always effect cancer detection rate in prostate biopsy? Additional role of prostate-specific antigen levels: A retrospective analysis of 2079 patients. Turkish Journal of Urology, 2019, 45, 103-107.	1.3	4
1436	DIAGNOSTIC INFORMATIVITY OF IMMUNOHISTOCHEMICAL BIOMARKERS IN CONDUCTING PRIVATIC PATHOLOGICAL AND ANATOMICAL RESEARCH OF PROSTATE CANCER. , 2019, 69, 55-58.		1
1437	Cancer de la prostate : souffrir de sa guÃ©rison. Psycho-oncologie, 2019, 13, 34-38.	0.0	1
1438	DIAGNOSTIC UTILITY OF AMACR EXPRESSION TO DIFFERENTIATE PROSTATE CARCINOMA FROM BENIGN HYPERPLASIA OF PROSTATE- A HOSPITAL BASED CROSS-SECTIONAL STUDY. Journal of Evolution of Medical and Dental Sciences, 2019, 8, 1435-1438.	0.1	2
1439	miRâ€‘589â€‘5p is downregulated in prostate cancer and regulates tumor cell viability and metastasis by targeting CCLâ€‘5. Molecular Medicine Reports, 2019, 20, 1373-1382.	1.1	6
1440	Is Serum Prostate-Specific Antigen a Reliable Prostate Cancer Marker in Liver Transplant Candidates. Experimental and Clinical Transplantation, 2019, 17, 536-539.	0.2	0
1441	Benign Prostatic Hyperplasia and Prostate Cancer Laser Ablation. , 2020, , 117-134.		0
1442	LUTS Assessment. , 2020, , 75-129.		1
1443	Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer. Molecular and Clinical Oncology, 2020, 12, 104-110.	0.4	4
1444	Population Trends in Aging and Cancer. , 2020, , 3-10.		0
1445	Wide-field optical spectroscopy system integrating reflectance and spatial frequency domain imaging to measure attenuation-corrected intrinsic tissue fluorescence in radical prostatectomy specimens. Biomedical Optics Express, 2020, 11, 2052.	1.5	4
1446	Impact of Multiple Prostate Biopsies: Risk of Perioperative Complications and Biochemical Recurrence After Radical Prostatectomy. The Korean Journal of Urological Oncology, 2020, 18, 24-31.	0.1	0
1447	Raccomandazioni per la gestione di variabili preanalitiche legate al paziente nella determinazione del PSA in fase di screening e follow-up di cancro prostatico. Rivista Italiana Della Medicina Di Laboratorio, 2020, 16, .	0.2	0

#	Article	IF	Citations
1448	Metabolic changes in patients with prostate cancer with androgen deprivation therapy. Diabetes Mellitus, 2020, 23, 192-200.	0.5	2
1449	Radical Prostatectomy: from Open Surgery towards Robotic Laparoscopy. KreativnaÃ¢ HirurgiÃ¢ I OnkologiÃ¢, 2020, 10, 87-93.	0.1	1
1450	Implementation of repeat biopsy and detection of cancer after a diagnosis of atypical small acinar proliferation of the prostate. Molecular and Clinical Oncology, 2020, 13, 1-1.	0.4	3
1451	Effect of obesity on the prognosis and recurrence of prostate cancer after radical prostatectomy: a meta-analysis. Translational Andrology and Urology, 2020, 9, 2713-2722.	0.6	6
1452	Health-related quality of life and rates of toxicity after high-dose-rate brachytherapy in combination with external beam radiation therapy for high-risk prostate cancer. Investigative and Clinical Urology, 2020, 61, 250.	1.0	1
1453	A new nomogram allows doctors to identify high-risk patients with fever after prostate biopsy in advance. Medical Science Monitor, 2020, 26, e921350.	0.5	2
1454	Safety and Efficacy of Using Tranexamic Acid at the Beginning of Robotic-Assisted Radical Prostatectomy in a Double-Blind Prospective Randomized Pilot Study. Acta Medica (Hradec Kralove), 2020, 63, 176-182.	0.2	4
1455	Transurethral resection of the prostate is an independent risk factor for biochemical recurrence after radical prostatectomy for prostate cancer. Asian Journal of Andrology, 2020, 22, 217.	0.8	2
1456	Erectile function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment. Asian Journal of Andrology, 2020, 22, 454.	0.8	5
1457	Comparison of Traditional Citation Metrics and Altmetrics Among Dermatology Journals: Content and Correlational Analysis Study. JMIR Dermatology, 2020, 3, e15643.	0.4	3
1458	Some ways of improvement of detection of hormone-naive non-metastatic high-risk prostate cancer. Urology, 2020, 24, .	0.1	0
1459	Oligometastatic prostate cancer: diagnosis and preliminary results of radiation therapy. Urology Herald, 2020, 8, 55-66.	0.1	1
1462	Health literacy in patients with oncological diseases: a literature review. Onkologie (Czech Republic), 2020, 14, 246-250.	0.0	0
1463	Implication of Prophetic Variables and their Impulsive Interplay in CA Prostate Patients Experiencing Osteo-Metastasis. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 2106-2113.	0.9	2
1464	Active surveillance for prostate cancer: a legal perspective. American Journal of Clinical and Experimental Urology, 2014, 2, 323-31.	0.4	0
1465	Parameters of prostate cancer at contrast-enhanced ultrasound: correlation with prostate cancer risk. International Journal of Clinical and Experimental Medicine, 2015, 8, 2562-9.	1.3	6
1466	Associations between ABO blood groups and biochemical recurrence after radical prostatectomy. International Journal of Clinical and Experimental Medicine, 2015, 8, 2642-8.	1.3	3
1467	Perineural invasion is an independent predictor of biochemical recurrence of prostate cancer after local treatment: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 13267-74.	1.3	12

#	Article	IF	Citations
1468	Do tumor volume, percent tumor volume predict biochemical recurrence after radical prostatectomy? A meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 22319-27.	1.3	7
1469	68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?. Central European Journal of Urology, 2017, 70, 37-43.	0.2	7
1470	Synthesis and evaluation of [Cu]PSMA-617 targeted for prostate-specific membrane antigen in prostate cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 40-52.	1.0	13
1471	Diagnostic test accuracy study of F-sodium fluoride PET/CT, Tc-labelled diphosphonate SPECT/CT, and planar bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 218-227.	1.0	31
1473	The loss of CD44 and HSP70 overexpression is related to aggressive clinicopathologic factors in prostate cancer. International Journal of Clinical and Experimental Pathology, 2018, 11, 5466-5472.	0.5	1
1474	Associations of LIM kinase1 (LIMK1) gene single nucleotide polymorphisms with prostate cancer susceptibility in Chinese population. International Journal of Clinical and Experimental Pathology, 2017, 10, 9725-9734.	0.5	1
1475	Different clinical significance of ASAP/HGPIN pattern in systematic vs. MRI-US fusion guided prostate biopsy. Experimental and Therapeutic Medicine, 2020, 20, 195.	0.8	1
1476	Comparison of whole-body bone scintigraphy with axial skeleton magnetic resonance imaging in the skeletal evaluation of carcinoma prostate. Indian Journal of Urology, 2021, 37, 72-78.	0.2	0
1477	Transrectal povidone-iodine efficiency in reducing infections occurring after transrectal ultrasound guided biopsy of the prostate. Medicine (United States), 2021, 100, e27539.	0.4	0
1478	Transrectal povidone-iodine efficiency in reducing infections occurring after transrectal ultrasound guided biopsy of the prostate. Medicine (United States), 2021, 100, e27539.	0.4	1
1479	The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer. JAMA Network Open, 2021, 4, e2133388.	2.8	3
1480	Prevalence and outcomes of focal ablation versus prostatectomy for elderly patients with prostate cancer: a population-based study. Journal of the National Cancer Center, 2021, , .	3.0	3
1481	Noninvasive urine metabolomics of prostate cancer and its therapeutic approaches: a current scenario and future perspective. Expert Review of Proteomics, 2021, 18, 995-1008.	1.3	9
1482	The Use of High-Intensity Focused Ultrasound (HIFU) Plus 150mg Bicalutamide as First Line Salvage Therapy for Local Recurrent Prostate Cancer. Frontiers in Oncology, 2021, 11, 705025.	1.3	0
1484	Near-infrared fluorescence imaging with intraoperative administration of indocyanine green for laparoscopic radical prostatectomy: Is it a useful weapon for pelvic lymph node dissection?. Journal of Surgical Case Reports, 2022, 2022, rjab614.	0.2	3
1485	Different clinical significance of ASAP/HGPIN pattern in systematic vs. MRIâ€‘US fusion guided prostate biopsy. Experimental and Therapeutic Medicine, 2020, 20, 1-1.	0.8	2
1486	STAT3-regulated LncRNA LINC00160 mediates cell proliferation and cell metabolism of prostate cancer cells by repressing RCAN1 expression. Molecular and Cellular Biochemistry, 2022, 477, 865-875.	1.4	4
1488	Cost-Effectiveness of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy Versus Systematic Transrectal Ultrasound-Guided Biopsy for Prostate Cancer Diagnosis: A Systematic Review. Value in Health Regional Issues, 2022, 30, 31-38.	0.5	3

#	Article	IF	Citations
1489	Impact of Gleason score of the tumor at the positive surgical margin as a prognostic factor. Molecular and Clinical Oncology, 2022, 16, 82.	0.4	0
1490	Comparison of Different Machine Learning Models in Prediction of Postirradiation Recurrence in Prostate Carcinoma Patients. BioMed Research International, 2022, 2022, 1-13.	0.9	0
1492	Potential of nuclear magnetic resonance metabolomics in the study of prostate cancer. Indian Journal of Urology, 2022, 38, 99.	0.2	1
1493	Relationship between Apparent Diffusion Coefficient Distribution and Cancer Grade in Prostate Cancer and Benign Prostatic Hyperplasia. Diagnostics, 2022, 12, 525.	1.3	4
1494	Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers. Cancers, 2022, 14, 1004.	1.7	3
1495	Safety and Diagnostic Yield of ⁶⁸Ga Prostate-specific Membrane Antigen PET/CT-guided Robotic-assisted Transgluteal Prostatic Biopsy. Radiology, 2022, 303, 392-398.	3.6	14
1496	Expression of miR-24-1-5p in Tumor Tissue Influences Prostate Cancer Recurrence: The PROCA-life Study. Cancers, 2022, 14, 1142.	1.7	4
1497	Comparison of Multiparametric and Fast <scp>MRI</scp> Protocols in Detecting Clinically Significant Prostate Cancer and a Detailed Cost Analysis. Journal of Magnetic Resonance Imaging, 2022, 56, 1437-1447.	1.9	1
1498	The Effectiveness of Pelvic Floor Muscle Training in Men after Radical Prostatectomy Measured with the Insert Test. International Journal of Environmental Research and Public Health, 2022, 19, 2890.	1.2	6
1499	Curative effect of pelvic floor muscle exercise on urinary incontinence after radical prostatectomyâ€"Comparisons of different approaches at different time point. Andrologia, 2022, 54, e14373.	1.0	6
1500	Robot-assisted radical prostatectomy in the treatment of patients with clinically high-risk localized and locally advanced prostate cancer: single surgeons functional and oncologic outcomes. BMC Urology, 2022, 22, 49.	0.6	6
1502	Review of the application of photoselective vaporization in benign hyperplasia of the prostate. Revista Mexicana De Urologia, 2021, 81, 1-13.	0.0	0
1503	Iodine-125 brachytherapy and robotic stereotactic radiotherapy â€" treatment options for patients with localized prostate cancer. Urology Herald, 2021, 9, 40-50.	0.1	0
1504	Classification of Clinically Significant Prostate Cancer on Multi-Parametric MRI: A Validation Study Comparing Deep Learning and Radiomics. Cancers, 2022, 14, 12.	1.7	21
1505	Effect of Glison index on survival of patients with localized prostate cancer in Samara region. Vestnik Medicinskogo Instituta REAVIZ ReabilitaciÃ¢, VraÄ•I ZdorovÊ¹e, 2022, 12, 90-97.	0.1	1
1506	Multiparametric transrectal ultrasound for the diagnosis of peripheral zone prostate cancer and clinically significant prostate cancer: novel scoring systems. BMC Urology, 2022, 22, 64.	0.6	4
1507	Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3917-3928.	3.3	10
1511	Transperineal ultrasound-guided prostate biopsy: what the radiologist needs to know. Insights Into Imaging, 2022, 13, 77.	1.6	5

#	Article	IF	Citations
1512	A review of clinical evidence to assess differences in efficacy and safety of luteinizing hormoneâ€“releasing hormone (LHRH) agonist (goserelin) and LHRH antagonist (degarelix). Indian Journal of Cancer, 2022, 59, 160.	0.2	2
1513	Comparison of whole-body bone scintigraphy with axial skeleton magnetic resonance imaging in the skeletal evaluation of carcinoma prostate. Indian Journal of Urology, 2021, 37, 72.	0.2	1
1515	Performance of multi-parametric magnetic resonance imaging through PIRADS scoring system in biopsy naÃ¯ve patients with suspicious prostate cancer. Arab Journal of Urology Arab Association of Urology, 0, , 1-5.	0.7	1
1516	Optimized grade group for reporting prostate cancer grade in systematic and MRIâ€targeted biopsies. Prostate, 2022, 82, 1125-1132.	1.2	3
1517	The Correlation Between Platelet Count and Survival in Prostate Cancer. Research and Reports in Urology, 2022, Volume 14, 193-202.	0.6	2
1518	Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends. Journal of Clinical Medicine, 2022, 11, 2738.	1.0	12
1519	Screening of peptide selectively recognizing prostate-specific antigen and its application in detecting total prostate-specific antigen. Sensors and Actuators B: Chemical, 2022, 367, 132009.	4.0	19
1521	A systematic review of supervised comprehensive functional physiotherapy after radical prostatectomy. Progres En Urologie, 2022, , .	0.3	1
1522	Prostate Cancer Detection Rate of Manually Operated and Robot-assisted In-bore Magnetic Resonance Imaging Targeted Biopsy. European Urology Open Science, 2022, 41, 88-94.	0.2	3
1523	Can the prophylactic administration of tranexamic acid reduce the blood loss after robotic-assisted radical prostatectomy? Robotic Assisted Radical Prostatectomy with tranEXamic acid (RARPEX): study protocol for a randomized controlled trial. Trials, 2022, 23, .	0.7	0
1524	Suboptimal use of hormonal therapy among German men with localized high-risk prostate Cancer during 2005 to 2015: analysis of registry data. BMC Cancer, 2022, 22, .	1.1	0
1525	Relevance of emerging metabolomics-based biomarkers of prostate cancer: a systematic review. Expert Reviews in Molecular Medicine, 2022, 24, .	1.6	2
1526	Biomarker sensing using luminescent metal nanoclusters. , 2022, , 435-464.		0
1527	Applying Sequence Clustering Methods to Characterize Healthcare Pathways of Patients at Different Prostate Cancer Stages in the French Nationwide Healthcare Database. SSRN Electronic Journal, 0, , .	0.4	0
1528	Mesenchymal stem cells and prostate cancer: A concise review of therapeutic potentials and biological aspects. Stem Cell Research, 2022, 63, 102864.	0.3	4
1529	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. ESMO Open, 2022, 7, 100518.	2.0	10
1530	Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer. Scientific Reports, 2022, 12, .	1.6	2
1531	The role of prophylactic prostatectomy as a primary prevention strategy in high-risk germline mutation carriers. Current Opinion in Urology, 0, Publish Ahead of Print, .	0.9	1

#	Article	IF	Citations
1532	Malignancies in HIV. , 2021, , 313-354.		0
1533	Dictionary learning compressed sensing reconstruction: pilot validation of accelerated echo planar J-resolved spectroscopic imaging in prostate cancer. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 667-682.	1.1	1
1534	Pelvic lymphadenectomy for radical prostatectomy: perioperative and oncological results. Onkourologiya, 2022, 18, 76-87.	0.1	0
1535	Can Urine Sarcosine Predict the Prostate Biopsy Necessity in Patients with Total PSA Value Ranging Between 2.5-10 ng/mL?. Journal of Academic Research in Medicine, 2022, 12, 42-48.	0.1	0
1536	Detection of lymph node metastases in patients with prostate cancer: Comparing conventional and digital [¹⁸ F]â€fluorocholine PETâ€CT using histopathology as a reference. Clinical Physiology and Functional Imaging, 0, , .	0.5	4
1537	Prostate Cancer Detection with mpMRI According to PI-RADS v2 Compared with Systematic MRI/TRUS-Fusion Biopsy: A Prospective Study. Tomography, 2022, 8, 2020-2029.	0.8	2
1538	WWC1, a target of miR-138-5p, facilitates the progression of prostate cancer. American Journal of the Medical Sciences, 2022, , .	0.4	0
1539	Ki-67, topoisomerase IIÎ± and miR-221 have a limited prostate cancer risk stratification ability on a medium-term follow-up: results of a high-risk radical prostatectomy cohort. Translational Andrology and Urology, 2022, 11, 1271-1281.	0.6	0
1540	Usefulness of PSA in prostate cancer screening in the perspective of personalized medicine. Revista De Medicina De Laboratorio, 2022, , .	0.0	0
1542	Assessment of the Utility of Multiparametric Magnetic Resonance Imaging for Initial Detection of Prostate Cancer. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 1840-1845.	0.1	1
1543	Pharmacokinetic modeling of PSMAâ€targeted nanobubbles for quantification of extravasation and binding in mice models of prostate cancer. Medical Physics, 2022, 49, 6547-6559.	1.6	4
1544	Combining targeted and systematic prostate biopsy improves prostate cancer detection and correlation with the whole mount histopathology in biopsy naÃ¯ve and previous negative biopsy patients. Frontiers in Surgery, 0, 9, .	0.6	3
1545	Impact of Androgen Deprivation Therapy on Cardiovascular Outcomes in Prostate Cancer. SociÃ©tÃ© Internationale D'urologie Journal, 2022, 3, 259-275.	0.2	1
1546	Hospital-based prostate cancer screening in vietnamese men with lower urinary tract symptoms: a classification and regression tree model. BMC Urology, 2022, 22, .	0.6	0
1547	Robot Based Transurethral Bladder Tumor Resection with automatic detection of Tumor Cells. Measurement: Journal of the International Measurement Confederation, 2022, , 112079.	2.5	1
1548	A Pilot Study of⁶⁸Ga-PSMA11 and⁶⁸Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High-Intensity Focused Ultrasound Therapy. Journal of Nuclear Medicine, 2023, 64, 592-597.	2.8	5
1549	Menâ€™s perceptions and preferences regarding prostate cancer radiation therapy: A systematic scoping review. Clinical and Translational Radiation Oncology, 2023, 38, 28-42.	0.9	0
1550	Evaluation of serum osteopontin as a potential novel diagnostic marker of prostate cancer in Iraqi patients. AIP Conference Proceedings, 2022, , .	0.3	0

#	Article	IF	Citations
1551	A Pilot Study of⁶⁸Ga-PSMA11 and⁶⁸Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. Journal of Nuclear Medicine, 2023, 64, 744-750.	2.8	6
1552	Tugcu Bakirkoy Technique. , 2022, , 265-270.		0
1553	Does transrectal prostate biopsy cause sexual dysfunction? Cross - sectional evaluation of 252 patients. Middle Black Sea Journal of Health Science, 0, , .	0.2	0
1554	A Randomized Study of Transrectal Prostate Biopsy in Left Lateral Versus Lithotomy Positions on Pain, Anxiety, and Erectile Function. Indian Journal of Surgery, 0, , .	0.2	0
1555	SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?. BMC Cancer, 2022, 22, .	1.1	4
1556	Diagnostic performance of 99mTc-HYNIC-PSMA SPECT/CT for biochemically recurrent prostate cancer after radical prostatectomy. Frontiers in Oncology, 0, 12, .	1.3	5
1557	Is Upgrade in Gleason Score After Radical Prostatectomy Predictable with Preoperative Multiparametric Prostate MRI?: Comparison of ADC, K-trans, Tumor size and PI-RADS Score. Ìİzmir Democracy University Health Sciences Journal, 0, , .	0.4	0
1558	MR-based simplified extraprostatic extension evaluation: comparison of performances of different predictive models. European Radiology, 2023, 33, 2975-2984.	2.3	1
1559	Examining the effectiveness and implementation of patient treatment decisionâ€aid tools for men with localised prostate cancer: A systematic review. Psycho-Oncology, 2023, 32, 469-491.	1.0	4
1560	Variability of radiotherapy volume delineation: PSMA PET/MRI and MRI based clinical target volume and lymph node target volume for high-risk prostate cancer. Cancer Imaging, 2023, 23, .	1.2	2
1561	Prostate cancer bioinformatics analysis: emerging genomic profiling techniques. Translational Cancer Research, 2023, 12, 4-7.	0.4	0
1562	(18F)-PSMA-1007PET/CT in patients with biochemical recurrence after radical prostatectomy: Diagnostic performance and impact on treatment management. , 2023, 5, 100021.		1
1563	Tumor-Infiltrating Lymphocytes in Localized Prostate Cancer: Do They Play an Important Role?. Cureus, 2023, , .	0.2	0
1564	Clustering of prostate cancer healthcare pathways in the French National Healthcare database. , 2023, 2, 52-64.		1
1565	Evaluating the clinical application of PAMD score in the assessment of TRUS-biopsy positive outcomes in patients with PSA 4-10 ng/ml treated in Serbia. , 2023, 56, 15-20.		0
1566	Low risk is low risk, regardless of race or ethnicity: Outcomes of prostate cancer active surveillance and factors associated with reclassification in a racially diverse cohort. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 204.e7-204.e15.	0.8	1
1567	Seneszenz und Altershypogonadismus. Springer Reference Medizin, 2023, , 1-23.	0.0	0
1568	Erectile Disfunction after Radical Prostatectomy. , 2020, 1, 29-34.		0

#	Article	IF	Citations
1569	Predictive Factors for Gleason Score Upgrading in Patients with Prostate Cancer after Radical Prostatectomy: A Systematic Review and Meta-Analysis. Urologia Internationalis, 2023, 107, 460-479.	0.6	1
1570	Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer. Journal of Personalized Medicine, 2023, 13, 608.	1.1	1
1571	Hormonal Therapies for Patients with Advanced Prostate Cancer. European Medical Journal (Chelmsford, England), 0, , 39-51.	3.0	0
1572	Robotic-assisted versus laparoscopic radical prostatectomy for prostate cancer: the first separate systematic review and meta-analysis of randomised controlled trials and non-randomised studies. International Journal of Surgery, 2023, 109, 1350-1359.	1.1	2
1573	Long non-coding RNAs in bone metastasis: progresses and perspectives as potential diagnostic and prognostic biomarkers. Frontiers in Endocrinology, 0, 14, .	1.5	0
1575	Seneszenz und Altershypogonadismus. Springer Reference Medizin, 2023, , 339-361.	0.0	0
1596	Senescence and Late-Onset Hypogonadism. , 2023, , 329-349.		0
1606	Cryoablation for Prostate Cancer. , 2023, , 1-12.		0
1609	In Vivo Clinical Biochemistry. , 2023, , 533-551.		0